PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 33924567-2 2021 Fabry disease (FD) is a lysosomal storage disorder caused by deficient alpha-galactosidase A activity in the lysosome due to mutations in the GLA gene, resulting in gradual accumulation of globotriaosylceramide and other derivatives in different tissues. globotriaosylceramide 189-210 galactosidase alpha Homo sapiens 71-92 33924567-2 2021 Fabry disease (FD) is a lysosomal storage disorder caused by deficient alpha-galactosidase A activity in the lysosome due to mutations in the GLA gene, resulting in gradual accumulation of globotriaosylceramide and other derivatives in different tissues. globotriaosylceramide 189-210 galactosidase alpha Homo sapiens 142-145 33555391-2 2021 Our previous work identified the interaction between the bacterial lectin LecA and its host cell glycosphingolipid receptor globotriaosylceramide (Gb3) as a crucial step for the engulfment of P. aeruginosa via the lipid zipper mechanism. globotriaosylceramide 124-145 PA-I galactophilic lectin Pseudomonas aeruginosa PAO1 74-78 33968642-2 2021 Tissue and organ changes are caused by widespread progressive accumulation of globotriaosylceramide (Gb3) and globotriaosylsphingosine (lysoGb3). globotriaosylceramide 78-99 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 101-104 33968643-2 2021 The deposition of globotriaosylceramide (Gb3) may cause damage to all organs, particularly brain, heart and kidney. globotriaosylceramide 18-39 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 41-44 33725118-1 2021 AIMS: Fabry disease (FD) is an X-linked lysosomal storage disorder caused by a deficiency of the lysosomal enzyme alpha-galactosidase A (GLA/AGAL) resulting in lysosomal accumulation of globotriaosylceramide (Gb3). globotriaosylceramide 186-207 galactosidase alpha Homo sapiens 114-135 33910691-1 2021 Fabry disease is due to mutations in the GLA gene that cause a deficiency of the activity of the lysosomal enzyme alpha-galactosidase A (alpha-gal A) resulting in intra-tissue accumulation of globotriaosylceramide. globotriaosylceramide 192-213 galactosidase alpha Homo sapiens 41-44 33910691-1 2021 Fabry disease is due to mutations in the GLA gene that cause a deficiency of the activity of the lysosomal enzyme alpha-galactosidase A (alpha-gal A) resulting in intra-tissue accumulation of globotriaosylceramide. globotriaosylceramide 192-213 galactosidase alpha Homo sapiens 114-135 33910691-1 2021 Fabry disease is due to mutations in the GLA gene that cause a deficiency of the activity of the lysosomal enzyme alpha-galactosidase A (alpha-gal A) resulting in intra-tissue accumulation of globotriaosylceramide. globotriaosylceramide 192-213 galactosidase alpha Homo sapiens 137-148 33910691-3 2021 It binds, in a specific and reversible manner, to the catalytic site of alpha-gal A mutants, to prevent their degradation by the quality control system of the endoplasmic reticulum and allow them to catabolize globotriaosylceramide in the lysosomes. globotriaosylceramide 210-231 galactosidase alpha Homo sapiens 72-83 33765701-1 2021 Fabry disease is a rare X-linked genetic lysosomal storage disorder caused by mutations in the GLA gene, which results of reduced or absent activity of alpha-galactosidase A, accumulation of metabolic substrates globotriaosylceramide (GL-3) and derivatives deacylated derivative globotriaosylsphingosine (Lyso-GL-3) in multiple tissues, and multi-organ diseases and even life-threatening complications. globotriaosylceramide 212-233 galactosidase alpha Homo sapiens 95-98 33661535-2 2021 Deficiency of the lysosomal enzyme alpha-galactosidase (GLA) leads to accumulation of potentially toxic globotriaosylceramide (Gb3) on a multisystem level. globotriaosylceramide 104-125 galactosidase alpha Homo sapiens 56-59 33661535-2 2021 Deficiency of the lysosomal enzyme alpha-galactosidase (GLA) leads to accumulation of potentially toxic globotriaosylceramide (Gb3) on a multisystem level. globotriaosylceramide 104-125 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 127-130 33477028-1 2021 Identification of 19 molecular species of globotriaosylceramides (Gb3) in extracts from a Fabry"s plasma patient and a healthy control was performed by High-Performance Thin-Layer Chromatography (HPTLC)-densitometry and online coupling to Mass Spectrometry (MS). globotriaosylceramide 42-64 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 66-69 33531072-1 2021 BACKGROUND: Fabry disease (FD) is a rare X-linked disease caused by mutations in GLA gene with consequent lysosomal accumulation of globotriaosylceramide (Gb3). globotriaosylceramide 132-153 galactosidase alpha Homo sapiens 81-84 33531072-1 2021 BACKGROUND: Fabry disease (FD) is a rare X-linked disease caused by mutations in GLA gene with consequent lysosomal accumulation of globotriaosylceramide (Gb3). globotriaosylceramide 132-153 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 155-158 32948848-1 2021 Fabry is an X-linked disorder of glycosphingolipid metabolism that is caused by variants of the GLA gene that codes for alpha-galactosidase A, leading to lysosomal accumulation of globotriaosylceramide in many cell types. globotriaosylceramide 180-201 galactosidase alpha Homo sapiens 96-99 32948848-1 2021 Fabry is an X-linked disorder of glycosphingolipid metabolism that is caused by variants of the GLA gene that codes for alpha-galactosidase A, leading to lysosomal accumulation of globotriaosylceramide in many cell types. globotriaosylceramide 180-201 galactosidase alpha Homo sapiens 120-141 33572752-5 2021 Indeed, mutations of the galactosidase alpha gene (GLA) cause a reduction or lack of GAL activity leading to globotriaosylceramide (Gb3) accumulation in several organs. globotriaosylceramide 109-130 galactosidase alpha Homo sapiens 25-44 33572752-5 2021 Indeed, mutations of the galactosidase alpha gene (GLA) cause a reduction or lack of GAL activity leading to globotriaosylceramide (Gb3) accumulation in several organs. globotriaosylceramide 109-130 galactosidase alpha Homo sapiens 51-54 33572752-5 2021 Indeed, mutations of the galactosidase alpha gene (GLA) cause a reduction or lack of GAL activity leading to globotriaosylceramide (Gb3) accumulation in several organs. globotriaosylceramide 109-130 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 132-135 33495303-1 2022 BACKGROUND: Fabry disease (FD) is a rare X-linked lysosomal storage disease caused by mutations in the alpha-galactosidase A gene (GLA) leading to deficiency of alpha-galactosidase A and ultimately in progressive glycosphingolipid accumulation, especially globotriaosylceramide (Gb3) and its deacylated derivative globotriaosylsphingosine (Lyso-Gb3). globotriaosylceramide 256-277 galactosidase alpha Homo sapiens 131-134 33721270-2 2021 The lysosomal accumulation of glycosphingolipids, especially globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3, deacylated form), leads to a multisystemic disease with progressive renal failure, cardiomyopathy with potentially malignant cardiac arrhythmias, and strokes, which considerably limits the life expectancy of affected patients. globotriaosylceramide 61-82 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 84-87 33592213-6 2021 RESULTS: Total and subspecies of serum SMs and globotriaosyl ceramides (Gb3s) were positively related to GIR30, free FAs (FFA 16:1, FFA20:4), some long chain GM3 and complex ceramide GluCers showed strong negative correlations with GIR30. globotriaosylceramide 47-70 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 72-76 33738082-7 2021 Moreover, a single intravenous administration of EV-GLA was able to reduce globotriaosylceramide (Gb3) substrate levels in clinically relevant tissues, such kidneys and brain. globotriaosylceramide 75-96 galactosidase alpha Homo sapiens 52-55 33738082-7 2021 Moreover, a single intravenous administration of EV-GLA was able to reduce globotriaosylceramide (Gb3) substrate levels in clinically relevant tissues, such kidneys and brain. globotriaosylceramide 75-96 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 98-101 33673160-1 2021 Fabry disease (FD) is a lysosomal storage disorder (LSD) characterized by the deficiency of alpha-galactosidase A (alpha-GalA) and the consequent accumulation of toxic metabolites such as globotriaosylceramide (Gb3) and globotriaosylsphingosine (lysoGb3). globotriaosylceramide 188-209 galactosidase alpha Homo sapiens 115-125 33725118-1 2021 AIMS: Fabry disease (FD) is an X-linked lysosomal storage disorder caused by a deficiency of the lysosomal enzyme alpha-galactosidase A (GLA/AGAL) resulting in lysosomal accumulation of globotriaosylceramide (Gb3). globotriaosylceramide 186-207 galactosidase alpha Homo sapiens 137-140 33577039-2 2021 This is caused by pathogenic variants in the GLA gene, coding for the lysosomal enzyme called alpha-galactosidase A (aGLA), responsible for the cleavage of globotriaosylceramide (Gb3). globotriaosylceramide 156-177 galactosidase alpha Homo sapiens 45-48 33156427-1 2021 Fabry disease (FD) is a rare X-linked glycosphingolipidosis caused by mutations in GLA, a gene responsible for encoding alpha-galactosidase A, an enzyme required for degradation of glycosphingolipids, mainly globotriaosylceramide (Gb3) in all cells of the body. globotriaosylceramide 208-229 galactosidase alpha Homo sapiens 83-86 33156427-1 2021 Fabry disease (FD) is a rare X-linked glycosphingolipidosis caused by mutations in GLA, a gene responsible for encoding alpha-galactosidase A, an enzyme required for degradation of glycosphingolipids, mainly globotriaosylceramide (Gb3) in all cells of the body. globotriaosylceramide 208-229 galactosidase alpha Homo sapiens 120-141 33577039-2 2021 This is caused by pathogenic variants in the GLA gene, coding for the lysosomal enzyme called alpha-galactosidase A (aGLA), responsible for the cleavage of globotriaosylceramide (Gb3). globotriaosylceramide 156-177 galactosidase alpha Homo sapiens 94-115 33577039-2 2021 This is caused by pathogenic variants in the GLA gene, coding for the lysosomal enzyme called alpha-galactosidase A (aGLA), responsible for the cleavage of globotriaosylceramide (Gb3). globotriaosylceramide 156-177 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 179-182 32994552-4 2021 The relationship between changes in lyso-Gb3 and kidney interstitial capillary (KIC) globotriaosylceramide (Gb3) inclusions was assessed in treatment-naive patients. globotriaosylceramide 85-106 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 41-44 33460651-2 2021 It synthesizes the Galalpha1 4Gal linkage on two different glycosphingolipids (GSLs), producing globotriaosylceramide (Gb3, CD77, Pk) and the P1 antigen. globotriaosylceramide 96-117 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 119-122 32868283-1 2020 Fabry disease is caused by deficient activity of alpha-galactosidase A-an enzyme that hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins--and subsequent accumulation of glycosphingolipids, mainly globotriaosylceramide (Gb3), globotriaosylsphingosine (lyso-Gb3) and galabiosylceramide. globotriaosylceramide 230-251 galactosidase, alpha Mus musculus 49-70 33460651-2 2021 It synthesizes the Galalpha1 4Gal linkage on two different glycosphingolipids (GSLs), producing globotriaosylceramide (Gb3, CD77, Pk) and the P1 antigen. globotriaosylceramide 96-117 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 124-128 32772454-5 2020 Macrophage-like differentiated THP-1 cells treated with Stxs secreted Stx-associated exosomes (Stx-Exo) of 90-130 nm in diameter, which induced cytotoxicity in recipient cells in a toxin receptor globotriaosylceramide (Gb3 )-dependent manner. globotriaosylceramide 196-217 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2 Homo sapiens 56-59 32772454-5 2020 Macrophage-like differentiated THP-1 cells treated with Stxs secreted Stx-associated exosomes (Stx-Exo) of 90-130 nm in diameter, which induced cytotoxicity in recipient cells in a toxin receptor globotriaosylceramide (Gb3 )-dependent manner. globotriaosylceramide 196-217 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2 Homo sapiens 70-73 32661622-1 2020 Fabry disease (FD) is a multisystemic X-linked disorder characterized by the accumulation of lysosomal globotriaosylceramide (Gb3) secondary to decreased activity of alpha-galactosidase in cells. globotriaosylceramide 103-124 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 126-129 32854306-2 2020 This enzyme cleaves the last sugar unit of glycosphingolipids, including globotriaosylceramide (Gb3), globotriaosylsphingosine (lyso-Gb3), and galabiosylceramide (Ga2). globotriaosylceramide 73-94 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 96-99 32738442-1 2020 Fabry disease is an X-linked lysosomal storage disorder caused by the deficiency of the enzyme, alpha-galactosidase A that induces the accumulation of the substrate globotriaosylceramide. globotriaosylceramide 165-186 galactosidase alpha Homo sapiens 96-117 32248228-2 2020 Silurus asotus egg lectin (SAL) has been reported to enhance the incorporation of propidium iodide as well as doxorubicin into Burkitt"s lymphoma Raji cells through binding to globotriaosylceramide (Gb3) on the cell surface. globotriaosylceramide 176-197 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 199-202 32963035-1 2021 INTRODUCTION: Recent studies showed the usefulness of globotriaosylsphingosine (lyso-Gb3) and related analogues, deacylated forms of globotriaosylceramide (Gb3), for high-risk screening, treatment monitoring and follow-up for patients with Fabry disease. globotriaosylceramide 133-154 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 85-88 33205006-5 2020 We report herewith that globotriaosylceramide (Gb3) is associated with cSrc kinase in GEMs and plays a crucial role in modulating expression of p53 R273H mutant and drug resistance. globotriaosylceramide 24-45 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 47-50 33205006-5 2020 We report herewith that globotriaosylceramide (Gb3) is associated with cSrc kinase in GEMs and plays a crucial role in modulating expression of p53 R273H mutant and drug resistance. globotriaosylceramide 24-45 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 71-75 33205006-5 2020 We report herewith that globotriaosylceramide (Gb3) is associated with cSrc kinase in GEMs and plays a crucial role in modulating expression of p53 R273H mutant and drug resistance. globotriaosylceramide 24-45 tumor protein p53 Homo sapiens 144-147 32699723-2 2020 This deficiency results in a progressive, multiorgan accumulation of glycolipids, most notably globotriaosylceramide (Gb3), leading to multiorgan failure and subsequently premature death. globotriaosylceramide 95-116 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 118-121 32198894-1 2020 Fabry disease (FD) is an X-linked lysosomal storage disorder caused by the deficient activity of the lysosomal enzyme alpha-galactosidase A (alpha-Gal A) leading to intracellular accumulation of globotriaosylceramide (Gb3). globotriaosylceramide 195-216 galactosidase alpha Homo sapiens 118-139 32198894-1 2020 Fabry disease (FD) is an X-linked lysosomal storage disorder caused by the deficient activity of the lysosomal enzyme alpha-galactosidase A (alpha-Gal A) leading to intracellular accumulation of globotriaosylceramide (Gb3). globotriaosylceramide 195-216 galactosidase alpha Homo sapiens 141-152 32198894-1 2020 Fabry disease (FD) is an X-linked lysosomal storage disorder caused by the deficient activity of the lysosomal enzyme alpha-galactosidase A (alpha-Gal A) leading to intracellular accumulation of globotriaosylceramide (Gb3). globotriaosylceramide 195-216 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 218-221 32673369-7 2020 We used the portable real-time optical sensing system to detect Alexa Fluor 488-tagged Stx2B-subunits bound to monocytic THP-1 cells expressing the toxin receptor globotriaosylceramide (Gb3). globotriaosylceramide 163-184 syntaxin 2 Homo sapiens 87-92 32673369-7 2020 We used the portable real-time optical sensing system to detect Alexa Fluor 488-tagged Stx2B-subunits bound to monocytic THP-1 cells expressing the toxin receptor globotriaosylceramide (Gb3). globotriaosylceramide 163-184 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 186-189 32189245-1 2020 Fabry disease is an X-linked inherited lysosomal storage disorder caused by a deficiency of alpha-galactosidase A activity, resulting in the intracellular accumulation of globotriaosylceramide and related glycosphingolipids. globotriaosylceramide 171-192 galactosidase alpha Homo sapiens 92-113 32606714-1 2020 Fabry disease (FD) is an X-linked lysosomal storage disorder caused by absence or deficient activity of alpha-galactosidase A (alpha-Gal A) due to mutations in the alpha-galactosidase A gene (GLA), leading to progressive accumulation of globotriaosylceramide (Gb3) in tissues and organs including heart, kidney, the eyes, vascular endothelium, the nervous system and the skin. globotriaosylceramide 237-258 galactosidase alpha Homo sapiens 104-125 32775495-2 2020 Deficient alpha-Gal A activity results in the progressive, systemic accumulation of its substrates, globotriaosylceramide (Gb3) and globotriaosylsphingosine (Lyso-Gb3), leading to renal, cardiac, and/or cerebrovascular disease and early demise. globotriaosylceramide 100-121 galactosidase alpha Homo sapiens 10-21 32775495-2 2020 Deficient alpha-Gal A activity results in the progressive, systemic accumulation of its substrates, globotriaosylceramide (Gb3) and globotriaosylsphingosine (Lyso-Gb3), leading to renal, cardiac, and/or cerebrovascular disease and early demise. globotriaosylceramide 100-121 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 123-126 32640076-1 2020 Fabry disease (FD) is an X-linked lysosomal storage disorder caused by pathogenic variants in the alpha-galactosidase A gene (GLA) that leads to reduced or undetectable alpha-galactosidase A (AGAL-A) enzyme activity and progressive accumulation of globotriaosylceramide (Gb3 ) and its deacylated form globotriaosylsphingosine (lysoGb3 ) in cells throughout the body. globotriaosylceramide 248-269 galactosidase alpha Homo sapiens 126-129 32640076-1 2020 Fabry disease (FD) is an X-linked lysosomal storage disorder caused by pathogenic variants in the alpha-galactosidase A gene (GLA) that leads to reduced or undetectable alpha-galactosidase A (AGAL-A) enzyme activity and progressive accumulation of globotriaosylceramide (Gb3 ) and its deacylated form globotriaosylsphingosine (lysoGb3 ) in cells throughout the body. globotriaosylceramide 248-269 galactosidase alpha Homo sapiens 98-119 32389574-1 2020 Fabry disease is a rare X-linked lysosomal disease, in which mutations in the gene encoding alpha-galactosidase A result in progressive cellular accumulation of globotriaosylceramide (GL-3) in various organs including the skin, kidney, and heart, often leading to life-threatening conditions. globotriaosylceramide 161-182 galactosidase alpha Homo sapiens 92-113 32606714-1 2020 Fabry disease (FD) is an X-linked lysosomal storage disorder caused by absence or deficient activity of alpha-galactosidase A (alpha-Gal A) due to mutations in the alpha-galactosidase A gene (GLA), leading to progressive accumulation of globotriaosylceramide (Gb3) in tissues and organs including heart, kidney, the eyes, vascular endothelium, the nervous system and the skin. globotriaosylceramide 237-258 galactosidase alpha Homo sapiens 127-138 32606714-1 2020 Fabry disease (FD) is an X-linked lysosomal storage disorder caused by absence or deficient activity of alpha-galactosidase A (alpha-Gal A) due to mutations in the alpha-galactosidase A gene (GLA), leading to progressive accumulation of globotriaosylceramide (Gb3) in tissues and organs including heart, kidney, the eyes, vascular endothelium, the nervous system and the skin. globotriaosylceramide 237-258 galactosidase alpha Homo sapiens 164-185 32606714-1 2020 Fabry disease (FD) is an X-linked lysosomal storage disorder caused by absence or deficient activity of alpha-galactosidase A (alpha-Gal A) due to mutations in the alpha-galactosidase A gene (GLA), leading to progressive accumulation of globotriaosylceramide (Gb3) in tissues and organs including heart, kidney, the eyes, vascular endothelium, the nervous system and the skin. globotriaosylceramide 237-258 galactosidase alpha Homo sapiens 192-195 32532136-2 2020 This disorder leads to intracellular globotriaosylceramide (Gb3) deposition associated with increased Gb3 plasma levels. globotriaosylceramide 37-58 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 60-63 32532136-2 2020 This disorder leads to intracellular globotriaosylceramide (Gb3) deposition associated with increased Gb3 plasma levels. globotriaosylceramide 37-58 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 102-105 32087678-2 2020 BACKGROUND: Fabry disease (FD) is a rare, lysosomal storage disorder caused by the absence or deficiency of the enzyme alpha-galactosidase A (alpha-Gal A) that leads to the abnormal accumulation of the lipid globotriaosylceramide (GB3) in a variety of cell types and tissues throughout the body. globotriaosylceramide 208-229 galactosidase alpha Homo sapiens 119-140 32523894-3 2020 The aim of this study was to examine if recipient cells must express the globotriaosylceramide (Gb3) toxin receptor for this to occur, or if Gb3-negative cells are also susceptible after uptake of Gb3-positive and toxin-positive microvesicles. globotriaosylceramide 73-94 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 96-99 32296648-2 2020 This AB5 subunit toxin family bind target cell globotriaosyl ceramide (Gb3), a glycosphingolipid (GSL) (aka CD77, pk blood group antigen) of the globoseries of neutral GSLs, initiating lipid raft-dependent plasma membrane Gb3 clustering, membrane curvature, invagination, scission, endosomal trafficking, and retrograde traffic via the TGN to the Golgi, and ER. globotriaosylceramide 47-69 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 108-112 32183018-3 2020 Globotriaosylsphingosine (LysoGb3), the deacylated form of globotriaosylceramide (Gb3), is described as a highly sensitive biomarker for another lysosomal storage disease-Fabry disease. globotriaosylceramide 59-80 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 30-33 32127409-2 2020 Defects in the gene encoding alpha-galactosidase A lead to accumulation of globotriaosylceramide (GL3) in various cell types. globotriaosylceramide 75-96 galactosidase, alpha Mus musculus 29-50 32292674-2 2020 This leads to intracellular accumulation of glycosphingolipids, mainly globotriaosylceramide (Gb3), throughout the body. globotriaosylceramide 71-92 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 94-97 32087678-2 2020 BACKGROUND: Fabry disease (FD) is a rare, lysosomal storage disorder caused by the absence or deficiency of the enzyme alpha-galactosidase A (alpha-Gal A) that leads to the abnormal accumulation of the lipid globotriaosylceramide (GB3) in a variety of cell types and tissues throughout the body. globotriaosylceramide 208-229 galactosidase alpha Homo sapiens 142-153 31778673-7 2020 Globotriaosylceramide (Gb3) was analyzed in dried urine spots by liquid chromatography/tandem mass spectrometry followed by globotriaosylsphingosine (lyso-Gb3) on the repeat analysis. globotriaosylceramide 0-21 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 23-26 31566927-2 2019 The GLA gene variant c.352C>T/p.Arg118Cys was considered with uncertain pathogenicity because of the finding of high residual alpha-galactosidase A (alpha-Gal A) enzyme activity, the absence of Mendelian segregation with an FD phenotype with many individuals remaining asymptomatic at old ages and the lack of globotriaosylceramide (Gb3) deposits in tissues. globotriaosylceramide 310-331 galactosidase alpha Homo sapiens 4-7 31778662-0 2020 Globotriaosylceramide-induced reduction of KCa1.1 channel activity and activation of the Notch1 signaling pathway in skin fibroblasts of male Fabry patients with pain. globotriaosylceramide 0-21 potassium calcium-activated channel subfamily M alpha 1 Homo sapiens 43-49 31778662-0 2020 Globotriaosylceramide-induced reduction of KCa1.1 channel activity and activation of the Notch1 signaling pathway in skin fibroblasts of male Fabry patients with pain. globotriaosylceramide 0-21 notch receptor 1 Homo sapiens 89-95 31939530-3 2020 Mutations in the GLA gene lead to the progressive accumulation of globotriaosylceramide (Gb3). globotriaosylceramide 66-87 galactosidase alpha Homo sapiens 17-20 31939530-3 2020 Mutations in the GLA gene lead to the progressive accumulation of globotriaosylceramide (Gb3). globotriaosylceramide 66-87 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 89-92 32306353-3 2020 The StxB pentamer specifically recognizes a glycosphingolipid, globotriaosylceramide (Gb3), as a receptor; therefore, it can be used as a probe to detect Gb3. globotriaosylceramide 63-84 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 86-89 32306353-3 2020 The StxB pentamer specifically recognizes a glycosphingolipid, globotriaosylceramide (Gb3), as a receptor; therefore, it can be used as a probe to detect Gb3. globotriaosylceramide 63-84 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 154-157 31630715-1 2019 Anderson-Fabry Disease (AFD) is a rare, X-linked inborn error of glycosphingolipid catabolism caused by a deficient or absent activity of the lysosomal enzyme, alpha-galactosidase A, resulting in the progressive multisystem lysosomal accumulation of glycosphingolipids, mainly globotriaosylceramide (Gb3). globotriaosylceramide 277-298 galactosidase alpha Homo sapiens 160-181 31101366-0 2019 Renal globotriaosylceramide facilitates tubular albumin absorption and its inhibition protects against acute kidney injury. globotriaosylceramide 6-27 albumin Mus musculus 48-55 30413389-4 2018 As previously observed with siRNA knockdown of GLA, globotriaosylceramide (Gb3) accumulated in EA.hy926 cells. globotriaosylceramide 52-73 galactosidase alpha Homo sapiens 47-50 31291414-1 2019 BACKGROUND: Fabry disease (FD) is an X-linked lysosomal storage disorder caused by mutations in the alpha galactosidase A gene (GLA) that lead to the enzymatic deficiency of alpha galactosidase (alpha-Gal A), resulting in the accumulation of globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3), causing multiple organ dysfunctions. globotriaosylceramide 242-263 galactosidase alpha Homo sapiens 100-121 31291414-1 2019 BACKGROUND: Fabry disease (FD) is an X-linked lysosomal storage disorder caused by mutations in the alpha galactosidase A gene (GLA) that lead to the enzymatic deficiency of alpha galactosidase (alpha-Gal A), resulting in the accumulation of globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3), causing multiple organ dysfunctions. globotriaosylceramide 242-263 galactosidase alpha Homo sapiens 128-131 31291414-1 2019 BACKGROUND: Fabry disease (FD) is an X-linked lysosomal storage disorder caused by mutations in the alpha galactosidase A gene (GLA) that lead to the enzymatic deficiency of alpha galactosidase (alpha-Gal A), resulting in the accumulation of globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3), causing multiple organ dysfunctions. globotriaosylceramide 242-263 galactosidase alpha Homo sapiens 195-206 31123589-2 2019 This enzymatic deficit results in the cellular accumulation of globotriaosylceramide (GL-3 or Gb3) and related glycosphingolipids in practically all organs and tissues in the body. globotriaosylceramide 63-84 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 94-97 30972193-2 2019 The mutations lead to lack of or faulty enzyme causing accumulation of globotriaosylceramide (Gb3) and related glycosphingolipids including globotriaosylsphingosine (lyso-Gb3). globotriaosylceramide 71-92 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 94-97 30972193-2 2019 The mutations lead to lack of or faulty enzyme causing accumulation of globotriaosylceramide (Gb3) and related glycosphingolipids including globotriaosylsphingosine (lyso-Gb3). globotriaosylceramide 71-92 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 171-174 30853972-1 2019 Fabry disease (FD) is a rare X-linked alpha-galactosidase A (GLA) deficiency, resulting in progressive lysosomal accumulation of globotriaosylceramide (Gb3) in a variety of cell types. globotriaosylceramide 129-150 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 152-155 30578766-5 2019 Furthermore, glycosphingolipids (particularly globotriaosylceramide) generated from serial ceramide glycosylation were seen to activate cSrc and beta-catenin signaling so as to upregulate METTL3 expression, in turn promoting expression of p53 R273H mutant protein, with consequent drug resistance. globotriaosylceramide 46-67 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 136-140 30578766-5 2019 Furthermore, glycosphingolipids (particularly globotriaosylceramide) generated from serial ceramide glycosylation were seen to activate cSrc and beta-catenin signaling so as to upregulate METTL3 expression, in turn promoting expression of p53 R273H mutant protein, with consequent drug resistance. globotriaosylceramide 46-67 catenin beta 1 Homo sapiens 145-157 30578766-5 2019 Furthermore, glycosphingolipids (particularly globotriaosylceramide) generated from serial ceramide glycosylation were seen to activate cSrc and beta-catenin signaling so as to upregulate METTL3 expression, in turn promoting expression of p53 R273H mutant protein, with consequent drug resistance. globotriaosylceramide 46-67 methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit Homo sapiens 188-194 30578766-5 2019 Furthermore, glycosphingolipids (particularly globotriaosylceramide) generated from serial ceramide glycosylation were seen to activate cSrc and beta-catenin signaling so as to upregulate METTL3 expression, in turn promoting expression of p53 R273H mutant protein, with consequent drug resistance. globotriaosylceramide 46-67 tumor protein p53 Homo sapiens 239-242 30660999-2 2019 To address this knowledge disparity, we focused on biosynthesis of globotriaosylceramide (Gb3), the Shiga toxin (STx) receptor, and performed a genome-wide CRISPR/CAS9 knockout screen in HeLa cells using STx1-mediated cytotoxicity. globotriaosylceramide 67-88 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 90-93 29979634-8 2019 With respect to the kidney and heart, we found that both organs accumulate alpha-Gal A substrates, including the established biomarkers, globotriaosylceramide and globotriaosylsphingosine. globotriaosylceramide 137-158 galactosidase, alpha Rattus norvegicus 75-86 29875425-0 2019 Identification of lysosomal and extralysosomal globotriaosylceramide (Gb3) accumulations before the occurrence of typical pathological changes in the endomyocardial biopsies of Fabry disease patients. globotriaosylceramide 47-68 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 70-73 29875425-3 2019 We aimed to examine globotriaosylceramide (Gb3) deposits in patients" endomyocardial biopsies to understand the early pathogenesis of FD cardiomyopathy. globotriaosylceramide 20-41 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 43-46 30117110-2 2019 Mutations in the gene coding for alpha-galactosidase A lead to globotriaosylceramide (Gb-3) accumulation in lysosomes and in placenta and umbilical cord. globotriaosylceramide 63-84 galactosidase alpha Homo sapiens 33-54 30117110-2 2019 Mutations in the gene coding for alpha-galactosidase A lead to globotriaosylceramide (Gb-3) accumulation in lysosomes and in placenta and umbilical cord. globotriaosylceramide 86-90 galactosidase alpha Homo sapiens 33-54 31242288-1 2019 Purpose: Fabry disease (FD) is a multiorgan X-linked condition characterized by a deficiency of the lysosomal enzyme alpha-galactosidase A, resulting in a progressive intralysosomal deposit of globotriaosylceramide. globotriaosylceramide 193-214 galactosidase alpha Homo sapiens 117-138 30965672-3 2019 It is well documented that alpha-galactosidase A (GLA) enzyme activity deficiency causes globotriaosylceramide (Gb3) accumulation, which plays a crucial role in the etiology of FD. globotriaosylceramide 89-110 galactosidase alpha Homo sapiens 27-48 30965672-3 2019 It is well documented that alpha-galactosidase A (GLA) enzyme activity deficiency causes globotriaosylceramide (Gb3) accumulation, which plays a crucial role in the etiology of FD. globotriaosylceramide 89-110 galactosidase alpha Homo sapiens 50-53 30632067-4 2019 We could show that the presence of tumor-derived mHsp70 in TNTs with a diameter ranging from 120 to 140 nm predominantly originates from cholesterol-rich-microdomains containing the lipid compound globoyltriaosylceramide (Gb3). globotriaosylceramide 222-225 heat shock protein 1B Mus musculus 49-55 30413389-4 2018 As previously observed with siRNA knockdown of GLA, globotriaosylceramide (Gb3) accumulated in EA.hy926 cells. globotriaosylceramide 52-73 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 75-78 31020209-11 2018 Discussion: Fabry disease is a rare X-linked disease caused by mutations on the GLA gene, which leads to low levels of AGAL and accumulation of globotriaosylceramide in the lysosomes of most tissues. globotriaosylceramide 144-165 galactosidase alpha Homo sapiens 80-83 30328411-3 2018 alpha-GAL deficient mice (GLA KO) age-dependently accumulate globotriaosylceramide (Gb3) in dorsal root ganglion (DRG) neurons paralleled by endoplasmic stress and apoptosis as contributors to skin denervation. globotriaosylceramide 61-82 galactosidase, alpha Mus musculus 0-9 30400144-1 2018 Fabry disease is an X-linked lysosomal storage disease caused by mutations in the GLA gene that lead to a reduction or an absence of the enzyme alpha-galactosidase A, resulting in the progressive and multisystemic accumulation of globotriaosylceramide. globotriaosylceramide 230-251 galactosidase alpha Homo sapiens 82-85 30400144-1 2018 Fabry disease is an X-linked lysosomal storage disease caused by mutations in the GLA gene that lead to a reduction or an absence of the enzyme alpha-galactosidase A, resulting in the progressive and multisystemic accumulation of globotriaosylceramide. globotriaosylceramide 230-251 galactosidase alpha Homo sapiens 144-165 30481169-3 2018 Here, we carried out Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9-mediated genome-wide loss-of-function screens using two related bacterial toxins, Shiga-like toxins (Stxs) 1 and 2, which use a specific glycolipid, globotriaosylceramide (Gb3), as receptors, and the plant toxin ricin, which recognizes a broad range of glycans. globotriaosylceramide 242-263 syntaxin 1A Homo sapiens 175-207 30282881-1 2018 BACKGROUND: Fabry disease is an X-linked lysosomal storage disorder and shows globotriosylceramide (Gb3) accumulation in multiple organs, resulting from a deficiency of alpha-galactosidase. globotriaosylceramide 78-98 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 100-103 30328411-3 2018 alpha-GAL deficient mice (GLA KO) age-dependently accumulate globotriaosylceramide (Gb3) in dorsal root ganglion (DRG) neurons paralleled by endoplasmic stress and apoptosis as contributors to skin denervation. globotriaosylceramide 84-87 galactosidase, alpha Mus musculus 0-9 30328411-7 2018 We show that in vitro alpha-GAL silencing increases intracellular Gb3 accumulation paralleled by loss of Nav1.7 currents, which is reversed by incubation with agalsidase-alpha and lucerastat. globotriaosylceramide 66-69 galactosidase, alpha Mus musculus 22-31 29983334-5 2018 Here, we show that primary human monocytes stimulated with Shiga toxin 1a (Stx1a) through the glycolipid receptor globotriaosylceramide released larger amounts of proinflammatory molecules (IL-1beta, TNFalpha, IL-6, G-CSF, CXCL8, CCL2, CCL4) than Stx1a-treated neutrophils. globotriaosylceramide 114-135 syntaxin 1A Homo sapiens 75-80 29974530-1 2018 BACKGROUND: The X-linked Fabry disease (FD) is a multiorgan disorder due to alpha-galactosidase A (alpha-GAL) deficiency with consequent lysosomal accumulation of globotriaosylceramide (Gb3). globotriaosylceramide 163-184 galactosidase alpha Homo sapiens 99-108 29974530-1 2018 BACKGROUND: The X-linked Fabry disease (FD) is a multiorgan disorder due to alpha-galactosidase A (alpha-GAL) deficiency with consequent lysosomal accumulation of globotriaosylceramide (Gb3). globotriaosylceramide 163-184 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 186-189 29982630-0 2018 Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types. globotriaosylceramide 60-81 UDP-glucose ceramide glucosyltransferase Homo sapiens 0-25 29982630-2 2018 The deleterious mutations lead to accumulation of alpha-GalA substrates, including globotriaosylceramide (Gb3) and globotriaosylsphingosine. globotriaosylceramide 83-104 galactosidase alpha Homo sapiens 50-60 29982630-2 2018 The deleterious mutations lead to accumulation of alpha-GalA substrates, including globotriaosylceramide (Gb3) and globotriaosylsphingosine. globotriaosylceramide 83-104 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 106-109 29927462-2 2018 Reduced alpha-GAL activity leads to progressive accumulation of globotriaosylceramide (Gb3), also known as CD77. globotriaosylceramide 64-85 galactosidase alpha Homo sapiens 8-17 29927462-2 2018 Reduced alpha-GAL activity leads to progressive accumulation of globotriaosylceramide (Gb3), also known as CD77. globotriaosylceramide 64-85 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 87-90 29927462-2 2018 Reduced alpha-GAL activity leads to progressive accumulation of globotriaosylceramide (Gb3), also known as CD77. globotriaosylceramide 64-85 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 107-111 29983334-5 2018 Here, we show that primary human monocytes stimulated with Shiga toxin 1a (Stx1a) through the glycolipid receptor globotriaosylceramide released larger amounts of proinflammatory molecules (IL-1beta, TNFalpha, IL-6, G-CSF, CXCL8, CCL2, CCL4) than Stx1a-treated neutrophils. globotriaosylceramide 114-135 interleukin 1 beta Homo sapiens 190-198 29983334-5 2018 Here, we show that primary human monocytes stimulated with Shiga toxin 1a (Stx1a) through the glycolipid receptor globotriaosylceramide released larger amounts of proinflammatory molecules (IL-1beta, TNFalpha, IL-6, G-CSF, CXCL8, CCL2, CCL4) than Stx1a-treated neutrophils. globotriaosylceramide 114-135 tumor necrosis factor Homo sapiens 200-208 29983334-5 2018 Here, we show that primary human monocytes stimulated with Shiga toxin 1a (Stx1a) through the glycolipid receptor globotriaosylceramide released larger amounts of proinflammatory molecules (IL-1beta, TNFalpha, IL-6, G-CSF, CXCL8, CCL2, CCL4) than Stx1a-treated neutrophils. globotriaosylceramide 114-135 interleukin 6 Homo sapiens 210-214 29983334-5 2018 Here, we show that primary human monocytes stimulated with Shiga toxin 1a (Stx1a) through the glycolipid receptor globotriaosylceramide released larger amounts of proinflammatory molecules (IL-1beta, TNFalpha, IL-6, G-CSF, CXCL8, CCL2, CCL4) than Stx1a-treated neutrophils. globotriaosylceramide 114-135 colony stimulating factor 3 Homo sapiens 216-221 29983334-5 2018 Here, we show that primary human monocytes stimulated with Shiga toxin 1a (Stx1a) through the glycolipid receptor globotriaosylceramide released larger amounts of proinflammatory molecules (IL-1beta, TNFalpha, IL-6, G-CSF, CXCL8, CCL2, CCL4) than Stx1a-treated neutrophils. globotriaosylceramide 114-135 C-X-C motif chemokine ligand 8 Homo sapiens 223-228 29983334-5 2018 Here, we show that primary human monocytes stimulated with Shiga toxin 1a (Stx1a) through the glycolipid receptor globotriaosylceramide released larger amounts of proinflammatory molecules (IL-1beta, TNFalpha, IL-6, G-CSF, CXCL8, CCL2, CCL4) than Stx1a-treated neutrophils. globotriaosylceramide 114-135 C-C motif chemokine ligand 2 Homo sapiens 230-234 29983334-5 2018 Here, we show that primary human monocytes stimulated with Shiga toxin 1a (Stx1a) through the glycolipid receptor globotriaosylceramide released larger amounts of proinflammatory molecules (IL-1beta, TNFalpha, IL-6, G-CSF, CXCL8, CCL2, CCL4) than Stx1a-treated neutrophils. globotriaosylceramide 114-135 C-C motif chemokine ligand 4 Homo sapiens 236-240 29983334-5 2018 Here, we show that primary human monocytes stimulated with Shiga toxin 1a (Stx1a) through the glycolipid receptor globotriaosylceramide released larger amounts of proinflammatory molecules (IL-1beta, TNFalpha, IL-6, G-CSF, CXCL8, CCL2, CCL4) than Stx1a-treated neutrophils. globotriaosylceramide 114-135 syntaxin 1A Homo sapiens 247-252 29866658-3 2018 Globotriaosylceramide and globotetraosylceramide, known as receptors for Stx1a, Stx2a, and Stx2e, and Forssman GSL as a specific receptor for Stx2e, were found to cooccur with SM and cholesterol in DRMs of MDCK II cells, which was shown using TLC overlay assay detection combined with mass spectrometry. globotriaosylceramide 0-21 STX1A Canis lupus familiaris 73-78 29549423-6 2018 These cellular effects seem to be mediated by an altered composition of glycosphingolipid-enriched microdomains (GEMs), especially an accumulation of globotriaosylceramide (Gb3) and glucosylceramide (GlcCer), which leads to an activation of Akt and ERK1/2. globotriaosylceramide 150-171 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 173-176 30211005-2 2018 Fabry disease is a genetic disorder characterized by the accumulation of globotriaosylceramide in cell lysosomes resulting from an X-linked deficiency of alpha-galactosidase A activity. globotriaosylceramide 73-94 galactosidase alpha Homo sapiens 154-175 30054149-2 2018 It is caused by deficiency of the enzyme alpha-galactosidase A (alpha-Gal A), which leads to excessive deposition of neutral glycosphingolipids, especially globotriaosylceramide (GL-3), in cells throughout the body. globotriaosylceramide 156-177 galactosidase, alpha Mus musculus 41-62 30054149-2 2018 It is caused by deficiency of the enzyme alpha-galactosidase A (alpha-Gal A), which leads to excessive deposition of neutral glycosphingolipids, especially globotriaosylceramide (GL-3), in cells throughout the body. globotriaosylceramide 156-177 galactosidase, alpha Mus musculus 64-75 29909504-3 2018 Deficiency in alpha-galactosidase A causes an accumulation of neutral glycosphingolipids such as globotriaosylceramide (Gb3) in lysosomes within various tissues including the vascular endothelium, kidneys, heart, eyes, skin and nervous system. globotriaosylceramide 97-118 galactosidase alpha Homo sapiens 14-35 29909504-3 2018 Deficiency in alpha-galactosidase A causes an accumulation of neutral glycosphingolipids such as globotriaosylceramide (Gb3) in lysosomes within various tissues including the vascular endothelium, kidneys, heart, eyes, skin and nervous system. globotriaosylceramide 97-118 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 120-123 29801874-1 2018 INTRODUCTION: Hypohidrosis and heat intolerance, frequently reported by men and women with Fabry disease (FD), is thought to be related not only to the deposition of globotriaosylceramide (Gb3) in eccrine sweat glands, but also to reduced sweat gland sympathetic innervation. globotriaosylceramide 166-187 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 189-192 29530250-0 2018 Analysis of globotriaosylceramide (Gb3) isoforms/analogs in unfractionated leukocytes, B lymphocytes and monocytes from Fabry patients using ultra-high performance liquid chromatography/tandem mass spectrometry. globotriaosylceramide 12-33 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 35-38 29713479-1 2018 Introduction: Anderson-Fabry disease (AFD) is an X-linked lysosomal storage disorder caused by mutations of GLA gene leading to reduced alpha-galactosidase activity and resulting in a progressive accumulation of globotriaosylceramide (Gb3) and its deacylated derivative, globotriaosyl-sphingosine (Lyso-Gb3). globotriaosylceramide 212-233 galactosidase alpha Homo sapiens 108-111 30013462-1 2018 Fabry disease is an X-chromosome linked hereditary disease that is caused by loss of function mutations in the alpha-galactosidase A (alpha-Gal A) gene, resulting in defective glycolipid degradation and subsequent accumulation of globotriaosylceramide (Gb3) in different tissues, including vascular endothelial cells and neurons in the peripheral and central nervous system. globotriaosylceramide 230-251 galactosidase, alpha Mus musculus 111-132 30013462-1 2018 Fabry disease is an X-chromosome linked hereditary disease that is caused by loss of function mutations in the alpha-galactosidase A (alpha-Gal A) gene, resulting in defective glycolipid degradation and subsequent accumulation of globotriaosylceramide (Gb3) in different tissues, including vascular endothelial cells and neurons in the peripheral and central nervous system. globotriaosylceramide 230-251 galactosidase, alpha Mus musculus 134-145 30013462-1 2018 Fabry disease is an X-chromosome linked hereditary disease that is caused by loss of function mutations in the alpha-galactosidase A (alpha-Gal A) gene, resulting in defective glycolipid degradation and subsequent accumulation of globotriaosylceramide (Gb3) in different tissues, including vascular endothelial cells and neurons in the peripheral and central nervous system. globotriaosylceramide 253-256 galactosidase, alpha Mus musculus 111-132 30013462-1 2018 Fabry disease is an X-chromosome linked hereditary disease that is caused by loss of function mutations in the alpha-galactosidase A (alpha-Gal A) gene, resulting in defective glycolipid degradation and subsequent accumulation of globotriaosylceramide (Gb3) in different tissues, including vascular endothelial cells and neurons in the peripheral and central nervous system. globotriaosylceramide 253-256 galactosidase, alpha Mus musculus 134-145 29674318-3 2018 Deficiency of human alpha-galactosidase A (alpha-Gal A) causes Fabry disease (FD), a heritable, X-linked lysosomal storage disorder, characterized by accumulation of globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3). globotriaosylceramide 166-187 galactosidase alpha Homo sapiens 20-41 29674318-3 2018 Deficiency of human alpha-galactosidase A (alpha-Gal A) causes Fabry disease (FD), a heritable, X-linked lysosomal storage disorder, characterized by accumulation of globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3). globotriaosylceramide 166-187 galactosidase alpha Homo sapiens 43-54 29674318-3 2018 Deficiency of human alpha-galactosidase A (alpha-Gal A) causes Fabry disease (FD), a heritable, X-linked lysosomal storage disorder, characterized by accumulation of globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3). globotriaosylceramide 166-187 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 189-192 29713479-1 2018 Introduction: Anderson-Fabry disease (AFD) is an X-linked lysosomal storage disorder caused by mutations of GLA gene leading to reduced alpha-galactosidase activity and resulting in a progressive accumulation of globotriaosylceramide (Gb3) and its deacylated derivative, globotriaosyl-sphingosine (Lyso-Gb3). globotriaosylceramide 212-233 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 235-238 29274327-0 2018 Investigation of correlation of urinary globotriaosylceramide (Gb3) levels with markers of renal function in patients with Fabry disease. globotriaosylceramide 40-61 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 63-66 29274327-2 2018 The enzymatic defect leads to accumulation of globotriaosylceramide (Gb3) in the kidney. globotriaosylceramide 46-67 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 69-72 29215092-9 2018 Ten patients received endomyocardial biopsy and all were found to have significant globotriaosylceramide (Gb3) accumulation in their cardiomyocytes. globotriaosylceramide 83-104 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 106-109 28618999-1 2018 BACKGROUND: Fabry disease is an X-linked lysosomal storage disorder caused by deficient activity of alpha -galactosidase A which leads to progressive intracellular accumulation of globotriaosylceramide in tissues and organs including heart, kidney, vascular endothelium, the nervous system, the eyes and the skin. globotriaosylceramide 180-201 galactosidase alpha Homo sapiens 100-122 29582965-1 2018 Background: Fabry disease is a rare genetic lysosomal storage disease, inherited in an X-linked manner, characterized by lysosomal deposition of globotriaosylceramide due to deficient activity of the enzyme alpha-galactosidase A. globotriaosylceramide 145-166 galactosidase alpha Homo sapiens 207-228 29558749-2 2018 Complete or partial deficiency in this enzyme leads to intracellular accumulation of globotriaosylceramide (Gb3) and other glycosphingolipids in many cell types throughout the body, including the kidney. globotriaosylceramide 85-106 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 108-111 28835480-1 2017 BACKGROUND: Fabry disease is characterised by the progressive accumulation of globotriaosylceramide (Gb3) and related glycosphingolipids in vascular endothelial cells. globotriaosylceramide 78-99 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 101-104 28728877-1 2018 BACKGROUND: Fabry disease (FD) is a rare X-linked lysosomal storage disease caused by mutations in the alpha-galactosidase A (GLA) gene causing deficiency of alpha-galactosidase A which results in progressive glycosphingolipid accumulation, especially globotriaosylceramide (Gb3), in body liquids and lysosomes. globotriaosylceramide 252-273 galactosidase alpha Homo sapiens 103-124 28728877-1 2018 BACKGROUND: Fabry disease (FD) is a rare X-linked lysosomal storage disease caused by mutations in the alpha-galactosidase A (GLA) gene causing deficiency of alpha-galactosidase A which results in progressive glycosphingolipid accumulation, especially globotriaosylceramide (Gb3), in body liquids and lysosomes. globotriaosylceramide 252-273 galactosidase alpha Homo sapiens 126-129 28728877-1 2018 BACKGROUND: Fabry disease (FD) is a rare X-linked lysosomal storage disease caused by mutations in the alpha-galactosidase A (GLA) gene causing deficiency of alpha-galactosidase A which results in progressive glycosphingolipid accumulation, especially globotriaosylceramide (Gb3), in body liquids and lysosomes. globotriaosylceramide 252-273 galactosidase alpha Homo sapiens 158-179 29099167-2 2017 This enzyme contributes to the cellular recycling of glycosphingolipids such as galabiosylceramide (Ga2), globotriaosylceramide (Gb3), and globotriaosylsphingosine (lyso-Gb3) by hydrolyzing the terminal alpha-galactosyl moiety. globotriaosylceramide 106-127 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 129-132 28756410-1 2017 OBJECTIVE: Deficiency of alpha-galactosidase A (alphaGal-A) in Fabry disease leads to the accumulation mainly of globotriaosylceramide (GL3) in multiple renal cell types. globotriaosylceramide 113-134 galactosidase, alpha Mus musculus 25-46 28674962-1 2017 Fabry disease resulting from a deficiency of alpha-galactosidase A leads to the accumulation of globotriaosylceramide in various organs. globotriaosylceramide 96-117 galactosidase alpha Homo sapiens 45-66 28593486-1 2017 Fabry disease is an X-linked lysosomal storage disorder caused by a lack of alpha-galactosidase A activity, which leads to the accumulation of globotriaosylceramide in various organs. globotriaosylceramide 143-164 galactosidase alpha Homo sapiens 76-97 28877708-1 2017 BACKGROUND: Fabry disease is an X-linked lysosomal storage disorder caused by deficient activity of alpha-galactosidase A and the resulting accumulation of the glycosphingolipid globotriaosylceramide (Gb3) and its derivatives, including globotriaosylsphingosine (Lyso-Gb3). globotriaosylceramide 178-199 galactosidase alpha Homo sapiens 100-121 29068380-3 2017 Only limited data are available regarding precise structures of their Stx receptor glycosphingolipids (GSLs) globotriaosylceramide (Gb3Cer) and globotetraosylceramide (Gb4Cer), and lipid raft association. globotriaosylceramide 109-130 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2 Homo sapiens 70-73 29068380-3 2017 Only limited data are available regarding precise structures of their Stx receptor glycosphingolipids (GSLs) globotriaosylceramide (Gb3Cer) and globotetraosylceramide (Gb4Cer), and lipid raft association. globotriaosylceramide 132-138 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2 Homo sapiens 70-73 28947349-7 2017 Innate immunity is activated by signals originating from dendritic cells via interactions between toll-like receptors and globotriaosylceramide (Gb3) and/or globotriaosylsphingosine (lyso-Gb3). globotriaosylceramide 122-143 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 145-148 28535204-6 2017 Exposure of primary HRGECs to the ceramide analogon d-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP) reduced total Gb3Cer and Gb4Cer content, roughly calculated from two biological replicates, down to half and quarter of its primordial content, respectively, but strengthened their prevalence and cholesterol preponderance in DRMs. globotriaosylceramide 132-138 beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group) Homo sapiens 143-149 28625968-11 2017 Podocyte globotriaosylceramide (Gb3) reduction correlated with cumulative agalsidase dose (r=0.69; P=0.001). globotriaosylceramide 9-30 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 32-35 28877708-1 2017 BACKGROUND: Fabry disease is an X-linked lysosomal storage disorder caused by deficient activity of alpha-galactosidase A and the resulting accumulation of the glycosphingolipid globotriaosylceramide (Gb3) and its derivatives, including globotriaosylsphingosine (Lyso-Gb3). globotriaosylceramide 178-199 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 201-204 28877708-1 2017 BACKGROUND: Fabry disease is an X-linked lysosomal storage disorder caused by deficient activity of alpha-galactosidase A and the resulting accumulation of the glycosphingolipid globotriaosylceramide (Gb3) and its derivatives, including globotriaosylsphingosine (Lyso-Gb3). globotriaosylceramide 178-199 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 268-271 28847675-1 2017 Fabry disease (FD) results from impaired globotriaosylceramide (Gb3) catabolism, due to a deficiency of the lysosomal hydrolase, alpha-galactosidase A (alpha-GalA). globotriaosylceramide 41-62 galactosidase alpha Homo sapiens 129-150 28847675-1 2017 Fabry disease (FD) results from impaired globotriaosylceramide (Gb3) catabolism, due to a deficiency of the lysosomal hydrolase, alpha-galactosidase A (alpha-GalA). globotriaosylceramide 41-62 galactosidase alpha Homo sapiens 152-162 28847675-1 2017 Fabry disease (FD) results from impaired globotriaosylceramide (Gb3) catabolism, due to a deficiency of the lysosomal hydrolase, alpha-galactosidase A (alpha-GalA). globotriaosylceramide 64-67 galactosidase alpha Homo sapiens 129-150 28847675-1 2017 Fabry disease (FD) results from impaired globotriaosylceramide (Gb3) catabolism, due to a deficiency of the lysosomal hydrolase, alpha-galactosidase A (alpha-GalA). globotriaosylceramide 64-67 galactosidase alpha Homo sapiens 152-162 28662189-1 2017 Fabry disease is an X-linked inherited lysosomal storage disorder with intracellular accumulation of globotriaosylceramide (Gb3) due to alpha-galactosidase A (alpha-Gal A) deficiency. globotriaosylceramide 101-122 galactosidase, alpha Mus musculus 136-157 28663131-1 2017 BACKGROUND: Fabry disease (FD), an X-linked lysosomal storage disorder, results from the deficient activity of alpha-galactosidase A (alpha-Gal A) and the accumulation of its substrates, globotriaosylceramide (Gb3) and its deacylated derivative, globotriaosyl-sphingosine (Lyso-Gb3). globotriaosylceramide 187-208 galactosidase alpha Homo sapiens 111-132 28663131-1 2017 BACKGROUND: Fabry disease (FD), an X-linked lysosomal storage disorder, results from the deficient activity of alpha-galactosidase A (alpha-Gal A) and the accumulation of its substrates, globotriaosylceramide (Gb3) and its deacylated derivative, globotriaosyl-sphingosine (Lyso-Gb3). globotriaosylceramide 187-208 galactosidase alpha Homo sapiens 134-145 28662189-1 2017 Fabry disease is an X-linked inherited lysosomal storage disorder with intracellular accumulation of globotriaosylceramide (Gb3) due to alpha-galactosidase A (alpha-Gal A) deficiency. globotriaosylceramide 101-122 galactosidase, alpha Mus musculus 159-170 28161408-2 2017 Fabry disease (FD) is caused by a deficiency of alpha-galactosidase (GLA), which results in the accumulation of globotriaosylceramide (GL-3). globotriaosylceramide 112-133 galactosidase, alpha Mus musculus 69-72 28702361-1 2017 Fabry disease (FD) [OMIM 301500] is an X-linked lysosomal storage disorder caused by a deficiency of the lysosomal enzyme alpha-galactosidase A, resulting in progressive multisystem accumulation of globotriaosylceramide (Gb3). globotriaosylceramide 198-219 galactosidase alpha Homo sapiens 122-143 27938475-2 2017 Progressive intracellular accumulation of globotriaosylceramide (Gb3) is considered to be pathogenically responsible for the phenotype variability of FD that causes cardiovascular dysfunction; however, molecular mechanisms underlying the impairment of FD-associated cardiovascular tissues remain unclear. globotriaosylceramide 42-63 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 65-68 28384397-0 2017 High-Risk Screening for Fabry Disease: Analysis by Tandem Mass Spectrometry of Globotriaosylceramide (Gb3 ) in Urine Collected on Filter Paper. globotriaosylceramide 79-100 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 102-105 28384397-7 2017 The purpose of this protocol is to focus on the high-risk screening of patients who might have Fabry disease using a simple, rapid, non-invasive high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method for urinary globotriaosylceramide (Gb3 ) analysis. globotriaosylceramide 241-262 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 264-267 28165371-1 2017 Shiga toxins consist of an A-moiety and five B-moieties able to bind the neutral glycosphingolipid globotriaosylceramide (Gb3) on the cell surface. globotriaosylceramide 99-120 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 122-125 27943675-1 2017 The bacterial Shiga toxin interacts with its cellular receptor, the glycosphingolipid globotriaosylceramide (Gb3 or CD77), as a first step to entering target cells. globotriaosylceramide 86-107 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 109-112 27943675-1 2017 The bacterial Shiga toxin interacts with its cellular receptor, the glycosphingolipid globotriaosylceramide (Gb3 or CD77), as a first step to entering target cells. globotriaosylceramide 86-107 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 116-120 28075357-1 2017 We retrospectively evaluated correlations between cardiac manifestations and globotriaosylceramide (Gb3) accumulation in cardiomyocytes from Taiwanese patients with Fabry disease and the IVS4+919G>A (IVS4) mutation who underwent endomyocardial biopsy (Shire; Fabry Outcome Survey data; extracted January 2015). globotriaosylceramide 77-98 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 100-103 28601129-2 2017 Consequently, there is very low, or even absent, activity of the lysosomal enzyme alpha-galactosidase A (alpha-Gal A), resulting in the progressive accumulation of glycosphingolipids (predominantly, globotriaosylceramide (GL-3)) in various cells of different organs. globotriaosylceramide 199-220 galactosidase, alpha Mus musculus 82-103 28049500-2 2017 Clinical onset of Fabry disease is preceded by significant storage of globotriaosylceramide (Gb3) and related glycosphingolipids, but the extent of the metabolic progression before symptoms is unknown. globotriaosylceramide 70-91 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 93-96 28601129-2 2017 Consequently, there is very low, or even absent, activity of the lysosomal enzyme alpha-galactosidase A (alpha-Gal A), resulting in the progressive accumulation of glycosphingolipids (predominantly, globotriaosylceramide (GL-3)) in various cells of different organs. globotriaosylceramide 199-220 galactosidase, alpha Mus musculus 105-116 27558838-2 2017 Stxs are AB5 toxins and the B-pentamers of the two major Stx subtypes Stx1a and Stx2a preferentially bind to the glycosphingolipid (GSL) globotriaosylceramide (Gb3Cer) expressed by human endothelial cells. globotriaosylceramide 137-158 syntaxin 1A Homo sapiens 70-75 27558838-2 2017 Stxs are AB5 toxins and the B-pentamers of the two major Stx subtypes Stx1a and Stx2a preferentially bind to the glycosphingolipid (GSL) globotriaosylceramide (Gb3Cer) expressed by human endothelial cells. globotriaosylceramide 137-158 syntaxin 2 Homo sapiens 80-85 27558838-2 2017 Stxs are AB5 toxins and the B-pentamers of the two major Stx subtypes Stx1a and Stx2a preferentially bind to the glycosphingolipid (GSL) globotriaosylceramide (Gb3Cer) expressed by human endothelial cells. globotriaosylceramide 160-166 syntaxin 1A Homo sapiens 70-75 27558838-2 2017 Stxs are AB5 toxins and the B-pentamers of the two major Stx subtypes Stx1a and Stx2a preferentially bind to the glycosphingolipid (GSL) globotriaosylceramide (Gb3Cer) expressed by human endothelial cells. globotriaosylceramide 160-166 syntaxin 2 Homo sapiens 80-85 27458128-2 2016 Its substrates, mainly globotriaosylceramide (Gb3), accumulate and seem to induce other pathophysiological findings of FD. globotriaosylceramide 23-44 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 46-49 29098097-1 2017 Fabry disease is an X-linked lysosomal storage disorder resulting from the deficiency or absence of the enzyme alpha galactosidase A; this defect leads to the systemic accumulation of globotriaosylceramide and its metabolites. globotriaosylceramide 184-205 galactosidase alpha Homo sapiens 111-132 27756537-1 2017 In Fabry disease, large amounts of globotriaosylceramide (Gb3) and related glycosphingolipids accumulate in organs due to a deficiency of alpha-galactosidase A (GLA) activity. globotriaosylceramide 35-56 galactosidase, alpha Mus musculus 138-159 27756537-1 2017 In Fabry disease, large amounts of globotriaosylceramide (Gb3) and related glycosphingolipids accumulate in organs due to a deficiency of alpha-galactosidase A (GLA) activity. globotriaosylceramide 35-56 galactosidase, alpha Mus musculus 161-164 27773586-2 2017 As a result, the major glycosphingolipid substrates, globotriaosylceramide (Gb3) and globotriaosylsphingosine (LysoGb3) accumulate in plasma, urine and tissue lysosomes. globotriaosylceramide 53-74 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 76-79 28933415-1 2016 Fabry disease (FD) is a rare X-linked recessive genetic disorder caused by a deficient activity of the lysosomal enzyme alpha-galactosidase A (GLA) and is characterised by intra-lysosomal accumulation of globotriaosylceramide (Gb3). globotriaosylceramide 204-225 galactosidase alpha Homo sapiens 120-141 28933415-1 2016 Fabry disease (FD) is a rare X-linked recessive genetic disorder caused by a deficient activity of the lysosomal enzyme alpha-galactosidase A (GLA) and is characterised by intra-lysosomal accumulation of globotriaosylceramide (Gb3). globotriaosylceramide 204-225 galactosidase alpha Homo sapiens 143-146 27195818-4 2016 Here, we review the various types of GLA variants and recommend that pathogenicity be considered only when associated with elevated globotriaosylceramide in disease-relevant organs and tissues as analyzed by mass spectrometry. globotriaosylceramide 132-153 galactosidase alpha Homo sapiens 37-40 27112153-2 2016 Human alpha-galactosidase A (halphaGAL) hydrolyses the terminal alpha-galactosyl moiety from glycosphingolipids, predominantly globotriaosylceramide (Gb3). globotriaosylceramide 127-148 galactosidase alpha Homo sapiens 6-27 27225543-1 2016 OPINION STATEMENT: Fabry disease is an X-linked, lysosomal storage disorder caused by a mutation in the GLA gene leading to a deficiency in alpha-galactosidase A enzyme (alpha-Gal A) activity, which in turn results in accumulation of globotriaosylceramide in the vascular endothelium and smooth muscle cells of different organs, including kidney and heart, finally leading to impairment or failure of organ function. globotriaosylceramide 234-255 galactosidase alpha Homo sapiens 104-107 27083555-1 2016 BACKGROUND: Fabry disease (FD) is an X-linked lysosomal storage disorder caused by a deficiency of alpha-galactosidase A enzyme, which leads to the accumulation of its substrate, the globotriaosylceramide or Gb3, in many organs and tissues. globotriaosylceramide 183-204 galactosidase alpha Homo sapiens 99-120 27070906-2 2016 Upon STxB-mediated binding to the glycolipid globotriaosylceramide (Gb3) at the plasma membrane of target cells, Shiga toxin is internalized by clathrin-dependent and independent endocytosis. globotriaosylceramide 45-66 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 68-71 28649509-1 2017 Fabry disease (FD) is an X-linked lysosomal storage disorder caused by loss of function mutations in the GLA gene at Xq22 with subsequent functional deficiency of alpha-galactosidase A, resulting in the accumulation of globotriaosylceramide (GL-3 or Gb3) in multiple cells types throughout the body. globotriaosylceramide 219-240 galactosidase, alpha Mus musculus 105-108 28649509-1 2017 Fabry disease (FD) is an X-linked lysosomal storage disorder caused by loss of function mutations in the GLA gene at Xq22 with subsequent functional deficiency of alpha-galactosidase A, resulting in the accumulation of globotriaosylceramide (GL-3 or Gb3) in multiple cells types throughout the body. globotriaosylceramide 219-240 galactosidase, alpha Mus musculus 163-184 27531673-2 2016 alpha-GalA deficiency leads to multisystemic clinical manifestations caused by the preferential accumulation of globotriaosylceramide (Gb3) in the endothelium and vascular smooth muscles. globotriaosylceramide 112-133 galactosidase, alpha Mus musculus 0-10 27225543-1 2016 OPINION STATEMENT: Fabry disease is an X-linked, lysosomal storage disorder caused by a mutation in the GLA gene leading to a deficiency in alpha-galactosidase A enzyme (alpha-Gal A) activity, which in turn results in accumulation of globotriaosylceramide in the vascular endothelium and smooth muscle cells of different organs, including kidney and heart, finally leading to impairment or failure of organ function. globotriaosylceramide 234-255 galactosidase alpha Homo sapiens 140-168 27225543-1 2016 OPINION STATEMENT: Fabry disease is an X-linked, lysosomal storage disorder caused by a mutation in the GLA gene leading to a deficiency in alpha-galactosidase A enzyme (alpha-Gal A) activity, which in turn results in accumulation of globotriaosylceramide in the vascular endothelium and smooth muscle cells of different organs, including kidney and heart, finally leading to impairment or failure of organ function. globotriaosylceramide 234-255 galactosidase alpha Homo sapiens 170-181 27367162-2 2016 Currently, globotriaosylsphingosine (lyso-Gb3 ) and globotriaosylceramide (Gb3 ) are used as biomarkers to diagnose and monitor Fabry patients. globotriaosylceramide 52-73 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 75-78 27367163-1 2016 Fabry disease is an X-linked lysosomal storage disorder, caused by a deficit in alpha-galactosidase A enzyme activity, leading to the storage of sphingolipids such as globotriaosylsphingosine (lyso-Gb3 ), globotriaosylceramide (Gb3 ), and galabiosylceramide (Ga2 ) in organs, tissues and biological fluids. globotriaosylceramide 205-226 galactosidase alpha Homo sapiens 80-101 27438980-1 2016 Every cell in the human body has globotriaosylceramide accumulation (Gb3) in Fabry disease due to the mutation in gene of the enzyme alpha-galactosidase A. globotriaosylceramide 33-54 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 69-72 27438980-1 2016 Every cell in the human body has globotriaosylceramide accumulation (Gb3) in Fabry disease due to the mutation in gene of the enzyme alpha-galactosidase A. globotriaosylceramide 33-54 galactosidase alpha Homo sapiens 133-154 27112153-2 2016 Human alpha-galactosidase A (halphaGAL) hydrolyses the terminal alpha-galactosyl moiety from glycosphingolipids, predominantly globotriaosylceramide (Gb3). globotriaosylceramide 127-148 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 150-153 27398254-1 2016 Fabry"s disease is an X-linked lysosomal storage disorder caused by a deficiency of alpha-galactosidase A enzyme with the progressive accumulation of globotriaosylceramide in vascular endothelial cells leading to cardiovascular, renal, gastrointestinal, neuropathic, lenticular, and dermatological manifestations. globotriaosylceramide 150-171 galactosidase alpha Homo sapiens 84-105 27145802-1 2016 BACKGROUND: Fabry disease is an X-linked lysosomal storage disorder due to impaired activity of alpha-galactosidase A with intracellular accumulation of globotriaosylceramide. globotriaosylceramide 153-174 galactosidase, alpha Mus musculus 96-117 26470913-2 2016 This study investigated the localization of globotriaosylceramide (Gb3) in human brain and kidney tissues removed from forensic autopsy cases in Japan. globotriaosylceramide 44-65 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 67-70 27061865-1 2016 Fabry disease is an inherited, X-linked lysosomal storage disorder caused by deficiency of the enzyme alpha galactosidase A (alpha-GLA A), which leads to glycosphingolipid accumulation, mainly globotriaosylceramide, in tissues. globotriaosylceramide 193-214 galactosidase alpha Homo sapiens 102-123 27061865-1 2016 Fabry disease is an inherited, X-linked lysosomal storage disorder caused by deficiency of the enzyme alpha galactosidase A (alpha-GLA A), which leads to glycosphingolipid accumulation, mainly globotriaosylceramide, in tissues. globotriaosylceramide 193-214 galactosidase alpha Homo sapiens 125-136 26826119-2 2016 Here, we tested whether human gastric cancers, which are among the most aggressive tumor entities, express the cellular receptor of Shiga toxin, the glycosphingolipid globotriaosylceramide (Gb3/CD77). globotriaosylceramide 167-188 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 190-193 26826119-2 2016 Here, we tested whether human gastric cancers, which are among the most aggressive tumor entities, express the cellular receptor of Shiga toxin, the glycosphingolipid globotriaosylceramide (Gb3/CD77). globotriaosylceramide 167-188 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 194-198 27123349-2 2016 It is characterized by progressive lysosomal accumulation of globotriaosylceramide (Gb3) and multisystem pathology, affecting the skin, nervous and cerebrovascular systems, kidneys, and heart. globotriaosylceramide 61-82 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 84-87 26773500-1 2016 Human Gb3/CD77 synthase (alpha1,4-galactosyltransferase, P(k) synthase), encoded by A4GALT gene, is known for synthesis of Gal(alpha1-4)Gal moiety in globotriaosylceramide (Gb3Cer, CD77, P(k) blood group antigen), a glycosphingolipid of the globo series. globotriaosylceramide 150-171 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 6-9 26773500-1 2016 Human Gb3/CD77 synthase (alpha1,4-galactosyltransferase, P(k) synthase), encoded by A4GALT gene, is known for synthesis of Gal(alpha1-4)Gal moiety in globotriaosylceramide (Gb3Cer, CD77, P(k) blood group antigen), a glycosphingolipid of the globo series. globotriaosylceramide 150-171 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 10-23 26773500-1 2016 Human Gb3/CD77 synthase (alpha1,4-galactosyltransferase, P(k) synthase), encoded by A4GALT gene, is known for synthesis of Gal(alpha1-4)Gal moiety in globotriaosylceramide (Gb3Cer, CD77, P(k) blood group antigen), a glycosphingolipid of the globo series. globotriaosylceramide 150-171 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 25-55 26773500-1 2016 Human Gb3/CD77 synthase (alpha1,4-galactosyltransferase, P(k) synthase), encoded by A4GALT gene, is known for synthesis of Gal(alpha1-4)Gal moiety in globotriaosylceramide (Gb3Cer, CD77, P(k) blood group antigen), a glycosphingolipid of the globo series. globotriaosylceramide 150-171 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 84-90 26773500-1 2016 Human Gb3/CD77 synthase (alpha1,4-galactosyltransferase, P(k) synthase), encoded by A4GALT gene, is known for synthesis of Gal(alpha1-4)Gal moiety in globotriaosylceramide (Gb3Cer, CD77, P(k) blood group antigen), a glycosphingolipid of the globo series. globotriaosylceramide 150-171 adrenoceptor alpha 1D Homo sapiens 127-135 26773500-1 2016 Human Gb3/CD77 synthase (alpha1,4-galactosyltransferase, P(k) synthase), encoded by A4GALT gene, is known for synthesis of Gal(alpha1-4)Gal moiety in globotriaosylceramide (Gb3Cer, CD77, P(k) blood group antigen), a glycosphingolipid of the globo series. globotriaosylceramide 150-171 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 10-14 26773500-1 2016 Human Gb3/CD77 synthase (alpha1,4-galactosyltransferase, P(k) synthase), encoded by A4GALT gene, is known for synthesis of Gal(alpha1-4)Gal moiety in globotriaosylceramide (Gb3Cer, CD77, P(k) blood group antigen), a glycosphingolipid of the globo series. globotriaosylceramide 173-179 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 6-9 26773500-1 2016 Human Gb3/CD77 synthase (alpha1,4-galactosyltransferase, P(k) synthase), encoded by A4GALT gene, is known for synthesis of Gal(alpha1-4)Gal moiety in globotriaosylceramide (Gb3Cer, CD77, P(k) blood group antigen), a glycosphingolipid of the globo series. globotriaosylceramide 173-179 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 10-23 26773500-1 2016 Human Gb3/CD77 synthase (alpha1,4-galactosyltransferase, P(k) synthase), encoded by A4GALT gene, is known for synthesis of Gal(alpha1-4)Gal moiety in globotriaosylceramide (Gb3Cer, CD77, P(k) blood group antigen), a glycosphingolipid of the globo series. globotriaosylceramide 173-179 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 25-55 26773500-1 2016 Human Gb3/CD77 synthase (alpha1,4-galactosyltransferase, P(k) synthase), encoded by A4GALT gene, is known for synthesis of Gal(alpha1-4)Gal moiety in globotriaosylceramide (Gb3Cer, CD77, P(k) blood group antigen), a glycosphingolipid of the globo series. globotriaosylceramide 173-179 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 84-90 26773500-1 2016 Human Gb3/CD77 synthase (alpha1,4-galactosyltransferase, P(k) synthase), encoded by A4GALT gene, is known for synthesis of Gal(alpha1-4)Gal moiety in globotriaosylceramide (Gb3Cer, CD77, P(k) blood group antigen), a glycosphingolipid of the globo series. globotriaosylceramide 173-179 adrenoceptor alpha 1D Homo sapiens 127-135 26773500-1 2016 Human Gb3/CD77 synthase (alpha1,4-galactosyltransferase, P(k) synthase), encoded by A4GALT gene, is known for synthesis of Gal(alpha1-4)Gal moiety in globotriaosylceramide (Gb3Cer, CD77, P(k) blood group antigen), a glycosphingolipid of the globo series. globotriaosylceramide 173-179 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 10-14 26593248-2 2016 Globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3) are currently used for Fabry screening and diagnosis. globotriaosylceramide 0-21 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 23-26 26797827-2 2016 Globotriaosylceramide (Gb3) and its isoforms and analogues have been identified and quantified as biomarkers of disease severity and treatment efficacy. globotriaosylceramide 0-21 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 23-26 27047943-1 2016 Fabry disease is an X-chromosome-linked lysosomal storage disease characterized by a deficient activity or, in most males, absence of the enzyme alpha-galactosidase A (a-Gal A) leading to systemic, primary lysosomal accumulation of globotriaosylceramide (Gb3) (1). globotriaosylceramide 232-253 galactosidase alpha Homo sapiens 145-166 27047943-1 2016 Fabry disease is an X-chromosome-linked lysosomal storage disease characterized by a deficient activity or, in most males, absence of the enzyme alpha-galactosidase A (a-Gal A) leading to systemic, primary lysosomal accumulation of globotriaosylceramide (Gb3) (1). globotriaosylceramide 232-253 galactosidase alpha Homo sapiens 168-175 26454753-1 2016 UNLABELLED: Fabry disease is an X-linked glycosphingolipidosis caused by deficient synthesis of the enzyme alpha-galactosidase A, which results in accumulations of globotriaosylceramide (GL-3) in systemic tissues. globotriaosylceramide 164-185 galactosidase alpha Homo sapiens 107-128 26928672-5 2016 Using Annexin V (AV) and Shiga toxin B subunit (ST) with affinities for phosphatidylserine and globotriaosylceramide, respectively, AV- and a ST-binding EV were identified. globotriaosylceramide 95-116 annexin A5 Homo sapiens 6-15 26683465-0 2016 A Short Synthetic Peptide Mimetic of Apolipoprotein A1 Mediates Cholesterol and Globotriaosylceramide Efflux from Fabry Fibroblasts. globotriaosylceramide 80-101 apolipoprotein A1 Homo sapiens 37-54 26333625-2 2016 Fabry disease is an X-linked metabolic storage disorder due to the deficiency of lysosomal alpha-galactosidase A which causes accumulation of glycosphingolipids, primarily globotriaosylceramide, throughout the body. globotriaosylceramide 172-193 galactosidase alpha Homo sapiens 91-112 26426881-0 2016 Globotriaosylceramide inhibits iNKT-cell activation in a CD1d-dependent manner. globotriaosylceramide 0-21 CD1d molecule Homo sapiens 57-61 26426881-1 2016 Globotriaosylceramide (Gb3) is a glycosphingolipid present in cellular membranes that progressively accumulates in Fabry disease. globotriaosylceramide 0-21 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 23-26 26683465-1 2016 Fabry disease is an X-linked sphingolipid storage disorder caused by a deficiency of the lysosomal enzyme alpha-galactosidase A (AGA, EC 3.2.1.22) resulting in the intracellular accumulation of globotriaosylceramide (Gb3). globotriaosylceramide 194-215 galactosidase alpha Homo sapiens 106-127 26683465-1 2016 Fabry disease is an X-linked sphingolipid storage disorder caused by a deficiency of the lysosomal enzyme alpha-galactosidase A (AGA, EC 3.2.1.22) resulting in the intracellular accumulation of globotriaosylceramide (Gb3). globotriaosylceramide 194-215 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 217-220 25857295-0 2015 Interfering parameters in the determination of urinary globotriaosylceramide (Gb3) in patients with chronic kidney disease. globotriaosylceramide 55-76 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 78-81 26835405-2 2016 Mutations of the GLA gene result in deficiency of the lysosomal enzyme, alpha-galactosidase A (alpha-Gal A) with accumulation of glycosphingolipids, particularly globotriaosylceramide (GL3) in the vascular endothelium of various tissues. globotriaosylceramide 162-183 galactosidase alpha Homo sapiens 17-20 26835405-2 2016 Mutations of the GLA gene result in deficiency of the lysosomal enzyme, alpha-galactosidase A (alpha-Gal A) with accumulation of glycosphingolipids, particularly globotriaosylceramide (GL3) in the vascular endothelium of various tissues. globotriaosylceramide 162-183 galactosidase alpha Homo sapiens 95-106 27735906-2 2016 Fabry disease (Anderson-Fabry disease) is an X-linked recessive lysosomal storage disorder resulting from deficient activity of lysosomal hydrolase, alpha-galactosidase A (alpha-Gal A), which leads to progressive accumulation of globotriaosylceramide (Gb3) in various cells, predominantly endothelial and vascular smooth muscle cells, with clinical manifestations affecting major organs including the central nervous system. globotriaosylceramide 229-250 galactosidase alpha Homo sapiens 149-170 27735906-2 2016 Fabry disease (Anderson-Fabry disease) is an X-linked recessive lysosomal storage disorder resulting from deficient activity of lysosomal hydrolase, alpha-galactosidase A (alpha-Gal A), which leads to progressive accumulation of globotriaosylceramide (Gb3) in various cells, predominantly endothelial and vascular smooth muscle cells, with clinical manifestations affecting major organs including the central nervous system. globotriaosylceramide 229-250 galactosidase alpha Homo sapiens 172-183 26592662-2 2015 The disease ultimately manifests as multiple organ dysfunctions owing to excessive accumulation of globotriaosylceramide (Gb3). globotriaosylceramide 99-120 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 122-125 25857295-1 2015 INTRODUCTION: Globotriaosylceramide (Gb3, CD77) represents a pivotal part of the cell membrane. globotriaosylceramide 14-35 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 37-40 25857295-1 2015 INTRODUCTION: Globotriaosylceramide (Gb3, CD77) represents a pivotal part of the cell membrane. globotriaosylceramide 14-35 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 42-46 25697597-2 2015 Globotriaosylsphingosine (lyso-Gb3), a deacylated form of globotriaosylceramide (Gb3), has emerged as a marker of Fabry disease. globotriaosylceramide 58-79 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 31-34 26464281-5 2015 We identified globotriaosylceramide (Gb3Cer) and globotetraosylceramide (Gb4Cer) as the GSL receptors for Stx1a, Stx2a, and Stx2e subtypes using TLC overlay detection combined with MS. globotriaosylceramide 14-35 syntaxin-1A Chlorocebus sabaeus 106-111 26464281-5 2015 We identified globotriaosylceramide (Gb3Cer) and globotetraosylceramide (Gb4Cer) as the GSL receptors for Stx1a, Stx2a, and Stx2e subtypes using TLC overlay detection combined with MS. globotriaosylceramide 14-35 syntaxin-2 Chlorocebus sabaeus 113-117 26464281-5 2015 We identified globotriaosylceramide (Gb3Cer) and globotetraosylceramide (Gb4Cer) as the GSL receptors for Stx1a, Stx2a, and Stx2e subtypes using TLC overlay detection combined with MS. globotriaosylceramide 37-43 syntaxin-1A Chlorocebus sabaeus 106-111 26502906-4 2016 The treatment of cells with a chemical inhibitor of glycosphingolipid biosynthesis, which suppresses the expression of the Stx receptor globotriaosylceramide and subsequent endocytosis of the toxin, substantially blocked activation of the NLRP3 inflammasome and processing of caspase-1 and IL-1beta. globotriaosylceramide 136-157 NLR family pyrin domain containing 3 Homo sapiens 239-244 26055721-2 2015 Globoside or P antigen is synthesized by UDP-N-acetylgalactosamine:globotriaosyl-ceramide 3-beta-N-acetylgalactosaminyltransferase encoded by B3GALNT1. globotriaosylceramide 67-89 beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group) Homo sapiens 142-150 26070511-0 2015 Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma. globotriaosylceramide 42-63 galactosidase alpha Homo sapiens 18-21 26070511-1 2015 Recent data have shown that lyso-Gb3, the deacylated derivative of globotriaosylceramide (Gb3), is possibly involved in the pathogenesis of Fabry disease (FD) and might be a clinically useful biomarker of its metabolic load. globotriaosylceramide 67-88 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 33-36 26070511-1 2015 Recent data have shown that lyso-Gb3, the deacylated derivative of globotriaosylceramide (Gb3), is possibly involved in the pathogenesis of Fabry disease (FD) and might be a clinically useful biomarker of its metabolic load. globotriaosylceramide 67-88 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 90-93 25666440-1 2015 Fabry disease (FD) is an X-linked lysosomal storage disorder caused by a deficiency of the lysosomal hydrolase alpha-galactosidase A (alpha-GalA) that leads to the intra-lysosomal accumulation of globotriaosylceramide (Gb3) in various organ systems. globotriaosylceramide 196-217 galactosidase alpha Homo sapiens 111-132 25666440-1 2015 Fabry disease (FD) is an X-linked lysosomal storage disorder caused by a deficiency of the lysosomal hydrolase alpha-galactosidase A (alpha-GalA) that leads to the intra-lysosomal accumulation of globotriaosylceramide (Gb3) in various organ systems. globotriaosylceramide 196-217 galactosidase alpha Homo sapiens 134-144 26464281-5 2015 We identified globotriaosylceramide (Gb3Cer) and globotetraosylceramide (Gb4Cer) as the GSL receptors for Stx1a, Stx2a, and Stx2e subtypes using TLC overlay detection combined with MS. globotriaosylceramide 37-43 syntaxin-2 Chlorocebus sabaeus 113-117 26135632-1 2015 Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the gene encoding the alpha-galactosidase A (alpha-Gal A) lysosomal enzyme, which results in globotriaosylceramide (Gb3) storage in vascular endothelial cells and different cell types throughout the body. globotriaosylceramide 172-193 galactosidase alpha Homo sapiens 101-122 26135632-1 2015 Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the gene encoding the alpha-galactosidase A (alpha-Gal A) lysosomal enzyme, which results in globotriaosylceramide (Gb3) storage in vascular endothelial cells and different cell types throughout the body. globotriaosylceramide 172-193 galactosidase alpha Homo sapiens 124-135 26135632-1 2015 Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the gene encoding the alpha-galactosidase A (alpha-Gal A) lysosomal enzyme, which results in globotriaosylceramide (Gb3) storage in vascular endothelial cells and different cell types throughout the body. globotriaosylceramide 172-193 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 195-198 26291612-1 2015 Fabry disease is a lysosomal storage disorder caused by deficiency of alpha-galactosidase A (alpha-gal A), which results in the deposition of globotriaosylceramide (Gb3) in the vascular endothelium. globotriaosylceramide 142-163 galactosidase alpha Homo sapiens 70-91 26291612-1 2015 Fabry disease is a lysosomal storage disorder caused by deficiency of alpha-galactosidase A (alpha-gal A), which results in the deposition of globotriaosylceramide (Gb3) in the vascular endothelium. globotriaosylceramide 142-163 galactosidase alpha Homo sapiens 93-104 26291612-1 2015 Fabry disease is a lysosomal storage disorder caused by deficiency of alpha-galactosidase A (alpha-gal A), which results in the deposition of globotriaosylceramide (Gb3) in the vascular endothelium. globotriaosylceramide 142-163 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 165-168 26004871-0 2015 Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells. globotriaosylceramide 62-83 UDP-glucose ceramide glucosyltransferase Homo sapiens 10-35 26004871-0 2015 Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells. globotriaosylceramide 62-83 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 85-88 26004871-3 2015 However, a tumour stress activation of glucosylceramide synthase (GCS) follows to eliminate ceramide by formation of glycosphingolipids (GSLs) such as globotriaosylceramide (Gb3), the functional receptor of verotoxin-1. globotriaosylceramide 151-172 UDP-glucose ceramide glucosyltransferase Homo sapiens 39-64 26004871-3 2015 However, a tumour stress activation of glucosylceramide synthase (GCS) follows to eliminate ceramide by formation of glycosphingolipids (GSLs) such as globotriaosylceramide (Gb3), the functional receptor of verotoxin-1. globotriaosylceramide 151-172 UDP-glucose ceramide glucosyltransferase Homo sapiens 66-69 25915924-1 2015 Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the gene that encodes alpha-galactosidase A and is characterized by pathological accumulation of globotriaosylceramide and globotriaosylsphingosine. globotriaosylceramide 176-197 galactosidase alpha Homo sapiens 101-122 25697597-2 2015 Globotriaosylsphingosine (lyso-Gb3), a deacylated form of globotriaosylceramide (Gb3), has emerged as a marker of Fabry disease. globotriaosylceramide 58-79 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 81-84 25030479-1 2015 Anderson-Fabry disease (AFD) is a lysosomal storage disease caused by the inappropriate accumulation of globotriaosylceramide in tissues due to a deficiency in the enzyme alpha-galactosidase A (alpha-Gal A). globotriaosylceramide 104-125 galactosidase alpha Homo sapiens 171-192 25030479-1 2015 Anderson-Fabry disease (AFD) is a lysosomal storage disease caused by the inappropriate accumulation of globotriaosylceramide in tissues due to a deficiency in the enzyme alpha-galactosidase A (alpha-Gal A). globotriaosylceramide 104-125 galactosidase alpha Homo sapiens 194-205 25156739-6 2014 Since the glycosphingolipids (GSLs) globotriaosylceramide (Gb3Cer) and globotetraosylceramide (Gb4Cer) are well-known receptors for Stx but also for P fimbriae, a major virulence factor of extraintestinal pathogenic E. coli (ExPEC), the expression of Gb3Cer and Gb4Cer by T24 cells and in murine urinary bladder tissue was examined by thin-layer chromatography and mass spectrometry. globotriaosylceramide 36-57 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 59-62 25690728-2 2015 This defect results in an accumulation of glycosphingolipids, primarily globotriaosylceramide (Gb3) which causes a multisystemic vasculopathy. globotriaosylceramide 72-93 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 95-98 25701267-2 2015 Reduced or missing alpha-gal A enzyme results in the storage of globotriaosylceramide (GL3) and related glycosphingolipids in the cellular lysosomes throughout the body. globotriaosylceramide 64-85 galactosidase alpha Homo sapiens 19-30 25386848-2 2014 an X-linked deficiency of alpha-galactosidase A coded by the GLA gene, leads to intracellular globotriaosylceramide (GL-3) accumulation. globotriaosylceramide 94-115 galactosidase alpha Homo sapiens 26-47 25386848-2 2014 an X-linked deficiency of alpha-galactosidase A coded by the GLA gene, leads to intracellular globotriaosylceramide (GL-3) accumulation. globotriaosylceramide 94-115 galactosidase alpha Homo sapiens 61-64 25637016-5 2015 Stx2 bound to P1 (k) and P2 (k) phenotype RBCs, expressing high levels of the P(k) Ag (globotriaosylceramide), the known Stx receptor. globotriaosylceramide 87-108 syntaxin 2 Homo sapiens 0-4 25575293-1 2015 Globotriaosylceramide (Gb3) is a glycosphingolipid present in the plasma membrane that is the natural receptor of the bacterial Shiga toxin. globotriaosylceramide 0-21 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 23-26 25156739-6 2014 Since the glycosphingolipids (GSLs) globotriaosylceramide (Gb3Cer) and globotetraosylceramide (Gb4Cer) are well-known receptors for Stx but also for P fimbriae, a major virulence factor of extraintestinal pathogenic E. coli (ExPEC), the expression of Gb3Cer and Gb4Cer by T24 cells and in murine urinary bladder tissue was examined by thin-layer chromatography and mass spectrometry. globotriaosylceramide 36-57 beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group) Homo sapiens 262-268 25185550-1 2014 Globotriaosylceramide (Gb3), a glycosphingolipid found in the plasma membrane of animal cells, is the endocytic receptor of the bacterial Shiga toxin. globotriaosylceramide 0-21 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 23-26 25337704-2 2014 The alpha-GalA deficiency leads to multi-systemic clinical manifestations caused by the preferential accumulation of globotriaosylceramide in the endothelium and vascular smooth muscles. globotriaosylceramide 117-138 galactosidase, alpha Mus musculus 4-14 24645664-1 2014 Fabry disease (FD) is an X-linked disease in which mutations of the GLA gene result in a deficiency of the enzyme alpha-galactosidase A and subsequent progressive, intralysosomal deposition of undegraded glycosphingolipid products, primarily globotriaosylceramide, in multiple organs. globotriaosylceramide 242-263 galactosidase alpha Homo sapiens 68-71 24778057-1 2014 Fabry disease is an inherited (X-linked) lysosomal storage disorder caused by deficiency of alpha-galactosidase A, leading to accumulation of globotriaosylceramide in various tissues. globotriaosylceramide 142-163 galactosidase alpha Homo sapiens 92-113 25345090-1 2014 Fabry disease (FD) is an X-linked disorder caused by deficiency of the enzyme alpha-galactosidase A, required for the degradation of globotriaosylceramide. globotriaosylceramide 133-154 galactosidase alpha Homo sapiens 78-99 24886109-2 2014 Complete or partial deficiency in this enzyme leads to intracellular accumulation of globotriaosylceramide (Gb3) and related glycosphingolipids in many cell types throughout the body, including the kidney. globotriaosylceramide 85-106 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 108-111 25530917-7 2014 The function of the B pentamer is to bind to the cellular receptor, globotriaosylceramide, Gb3, found primarily on endothelial cells. globotriaosylceramide 68-89 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 91-94 24402087-5 2014 Knockdown of alpha-galactosidase A was confirmed using immunoblotting and globotriaosylceramide accumulation. globotriaosylceramide 74-95 galactosidase alpha Homo sapiens 13-34 24980630-4 2014 Except for three patients who had received ERT for more than 3 years, all other patients showed significant pathological change and globotriaosylceramide (Gb3) accumulation in their cardiomyocytes. globotriaosylceramide 132-153 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 155-158 24983355-5 2014 Here, we studied binding of holotoxin and B-subunits of Stx1, Stx2a, Stx2b, Stx2c and Stx2d to glycolipid receptors globotriaosylceramide (Gb3) and globotetraosylceramide (Gb4) in the presence of cell membrane components such as phosphatidylcholine (PC), cholesterol (Ch) and other neutral glycolipids. globotriaosylceramide 116-137 syntaxin 1A Homo sapiens 56-60 24983355-5 2014 Here, we studied binding of holotoxin and B-subunits of Stx1, Stx2a, Stx2b, Stx2c and Stx2d to glycolipid receptors globotriaosylceramide (Gb3) and globotetraosylceramide (Gb4) in the presence of cell membrane components such as phosphatidylcholine (PC), cholesterol (Ch) and other neutral glycolipids. globotriaosylceramide 116-137 syntaxin 2 Homo sapiens 62-67 24983355-5 2014 Here, we studied binding of holotoxin and B-subunits of Stx1, Stx2a, Stx2b, Stx2c and Stx2d to glycolipid receptors globotriaosylceramide (Gb3) and globotetraosylceramide (Gb4) in the presence of cell membrane components such as phosphatidylcholine (PC), cholesterol (Ch) and other neutral glycolipids. globotriaosylceramide 116-137 syntaxin 2 Homo sapiens 69-74 24983355-5 2014 Here, we studied binding of holotoxin and B-subunits of Stx1, Stx2a, Stx2b, Stx2c and Stx2d to glycolipid receptors globotriaosylceramide (Gb3) and globotetraosylceramide (Gb4) in the presence of cell membrane components such as phosphatidylcholine (PC), cholesterol (Ch) and other neutral glycolipids. globotriaosylceramide 116-137 syntaxin 2 Homo sapiens 76-81 26012164-1 2014 Fabry disease (Anderson-Fabry disease) is one of the most common lysosomal storage diseases (after Gaucher disease) caused by deficient activity of the alpha-galactosidase A (alpha-Gal A) enzyme, which leads to progressive accumulation of globotriaosylceramide in various cells, predominantly in endothelium and vascular smooth muscles, with multisystem clinical manifestations. globotriaosylceramide 239-260 galactosidase alpha Homo sapiens 152-173 26012164-1 2014 Fabry disease (Anderson-Fabry disease) is one of the most common lysosomal storage diseases (after Gaucher disease) caused by deficient activity of the alpha-galactosidase A (alpha-Gal A) enzyme, which leads to progressive accumulation of globotriaosylceramide in various cells, predominantly in endothelium and vascular smooth muscles, with multisystem clinical manifestations. globotriaosylceramide 239-260 galactosidase alpha Homo sapiens 175-186 25530762-1 2014 Fabry disease is an X-linked lysosomal storage disorder caused by deficient activity of a-galactosidase A (also known as ceramide trihexosidase) and resultant accumulation of globotriaosylceramide (Gb3) and related glycophospholipids. globotriaosylceramide 175-196 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 198-201 24634980-1 2014 Fabry disease is a multisystemic, X-linked lysosomal storage disorder caused by a deficit in alpha-galactosidase A enzyme activity leading to glycosphingolipid accumulation, mainly globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3). globotriaosylceramide 181-202 galactosidase alpha Homo sapiens 93-114 24634980-1 2014 Fabry disease is a multisystemic, X-linked lysosomal storage disorder caused by a deficit in alpha-galactosidase A enzyme activity leading to glycosphingolipid accumulation, mainly globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3). globotriaosylceramide 181-202 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 204-207 24671194-3 2014 Although Stx1a and Stx2a bind to the same receptor, globotriaosylceramide (Gb3), Stx2a is more potent than Stx1a in mice, whereas Stx1a is more cytotoxic than Stx2a in cell culture. globotriaosylceramide 52-73 syntaxin 1A (brain) Mus musculus 9-14 24215016-2 2014 Deficiency of alpha-galactosidase A (alpha-Gal A) causes intracellular accumulations of globotriaosylceramide (GL-3) and related glycosphingolipids in all organs, including the kidney, often leading to end-stage renal failure. globotriaosylceramide 88-109 galactosidase alpha Homo sapiens 14-35 24215016-2 2014 Deficiency of alpha-galactosidase A (alpha-Gal A) causes intracellular accumulations of globotriaosylceramide (GL-3) and related glycosphingolipids in all organs, including the kidney, often leading to end-stage renal failure. globotriaosylceramide 88-109 galactosidase alpha Homo sapiens 37-48 24626231-8 2014 A myocardial biopsy performed in one during this procedure demonstrated substantial accumulation of globotriaosylceramide (Gb3) in cardiomyocytes. globotriaosylceramide 100-121 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 123-126 24215843-1 2014 Accumulation of globotriaosylceramide (Gb3) and other neutral glycosphingolipids with galactosyl residues is the hallmark of Fabry disease, a lysosomal storage disorder caused by deficiency of the enzyme alpha-galactosidase A (alpha-gal A). globotriaosylceramide 16-37 galactosidase alpha Canis lupus familiaris 204-225 24215843-1 2014 Accumulation of globotriaosylceramide (Gb3) and other neutral glycosphingolipids with galactosyl residues is the hallmark of Fabry disease, a lysosomal storage disorder caused by deficiency of the enzyme alpha-galactosidase A (alpha-gal A). globotriaosylceramide 16-37 galactosidase alpha Canis lupus familiaris 227-238 24215843-1 2014 Accumulation of globotriaosylceramide (Gb3) and other neutral glycosphingolipids with galactosyl residues is the hallmark of Fabry disease, a lysosomal storage disorder caused by deficiency of the enzyme alpha-galactosidase A (alpha-gal A). globotriaosylceramide 39-42 galactosidase alpha Canis lupus familiaris 204-225 24215843-1 2014 Accumulation of globotriaosylceramide (Gb3) and other neutral glycosphingolipids with galactosyl residues is the hallmark of Fabry disease, a lysosomal storage disorder caused by deficiency of the enzyme alpha-galactosidase A (alpha-gal A). globotriaosylceramide 39-42 galactosidase alpha Canis lupus familiaris 227-238 24398019-1 2014 BACKGROUND: Fabry disease is an X-linked inherited metabolic condition where the deficit of the alpha-galactosidase A enzyme, encoded by the GLA gene, leads to glycosphingolipid storage, mainly globotriaosylceramide. globotriaosylceramide 194-215 galactosidase alpha Homo sapiens 96-117 24398019-1 2014 BACKGROUND: Fabry disease is an X-linked inherited metabolic condition where the deficit of the alpha-galactosidase A enzyme, encoded by the GLA gene, leads to glycosphingolipid storage, mainly globotriaosylceramide. globotriaosylceramide 194-215 galactosidase alpha Homo sapiens 141-144 24232002-1 2014 A defect in the gene for the lysosomal enzyme alpha-galactosidase A (Gla) results in globotriaosylceramide (Gb3) accumulation in Fabry disease and leads to premature death from cardiac and cerebrovascular events. globotriaosylceramide 85-106 galactosidase, alpha Mus musculus 46-67 24232002-1 2014 A defect in the gene for the lysosomal enzyme alpha-galactosidase A (Gla) results in globotriaosylceramide (Gb3) accumulation in Fabry disease and leads to premature death from cardiac and cerebrovascular events. globotriaosylceramide 85-106 galactosidase, alpha Mus musculus 69-72 24232002-1 2014 A defect in the gene for the lysosomal enzyme alpha-galactosidase A (Gla) results in globotriaosylceramide (Gb3) accumulation in Fabry disease and leads to premature death from cardiac and cerebrovascular events. globotriaosylceramide 108-111 galactosidase, alpha Mus musculus 46-67 24232002-1 2014 A defect in the gene for the lysosomal enzyme alpha-galactosidase A (Gla) results in globotriaosylceramide (Gb3) accumulation in Fabry disease and leads to premature death from cardiac and cerebrovascular events. globotriaosylceramide 108-111 galactosidase, alpha Mus musculus 69-72 24158513-0 2014 Globotriaosylceramide induces lysosomal degradation of endothelial KCa3.1 in fabry disease. globotriaosylceramide 0-21 potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 Mus musculus 67-73 24158513-1 2014 OBJECTIVE: Globotriaosylceramide (Gb3) induces KCa3.1 downregulation in Fabry disease (FD). globotriaosylceramide 11-32 potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 Mus musculus 47-53 24158513-1 2014 OBJECTIVE: Globotriaosylceramide (Gb3) induces KCa3.1 downregulation in Fabry disease (FD). globotriaosylceramide 34-37 potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 Mus musculus 47-53 23690406-1 2013 The two major forms of Shiga toxin, Stx1 and Stx2, use the glycolipid globotriaosylceramide (Gb3) as their cellular receptor. globotriaosylceramide 70-91 syntaxin 1A Homo sapiens 36-40 23906628-5 2013 In ovarian carcinoma, globotriaosyl ceramide (Gb3), the GSL receptor for the antineoplastic Escherichia coli-derived verotoxin, was increased throughout the tumor. globotriaosylceramide 22-44 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 46-49 23906628-5 2013 In ovarian carcinoma, globotriaosyl ceramide (Gb3), the GSL receptor for the antineoplastic Escherichia coli-derived verotoxin, was increased throughout the tumor. globotriaosylceramide 22-44 cathepsin A Homo sapiens 56-59 24526817-0 2013 Spontaneous Accumulation of Globotriaosylceramide (Gb3) in Proximal Renal Tubules in an ICR Mouse. globotriaosylceramide 28-49 CD1 antigen complex Mus musculus 88-91 24526817-0 2013 Spontaneous Accumulation of Globotriaosylceramide (Gb3) in Proximal Renal Tubules in an ICR Mouse. globotriaosylceramide 51-54 CD1 antigen complex Mus musculus 88-91 23968398-2 2013 In addition to the two biomarkers, globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3), which are routinely used for detection and high-risk screening of Fabry disease patients, novel urinary Gb3-related isoforms/analogues as well as newly defined lyso-Gb3 analogues in plasma and urine from Fabry patients have recently been described by our group. globotriaosylceramide 35-56 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 58-61 24558776-1 2013 Fabry disease (Anderson-Fabry disease) is one of the most common lysosomal storage diseases (after Gaucher disease) caused by deficient activity of the alpha-galactosidase A (alpha-Gal A) enzyme, which leads to progressive accumulation of globotriaosylceramide in various cells, predominantly in endothelium and vascular smooth muscles, with multisystem clinical manifestations. globotriaosylceramide 239-260 galactosidase alpha Homo sapiens 152-173 24558776-1 2013 Fabry disease (Anderson-Fabry disease) is one of the most common lysosomal storage diseases (after Gaucher disease) caused by deficient activity of the alpha-galactosidase A (alpha-Gal A) enzyme, which leads to progressive accumulation of globotriaosylceramide in various cells, predominantly in endothelium and vascular smooth muscles, with multisystem clinical manifestations. globotriaosylceramide 239-260 galactosidase alpha Homo sapiens 175-186 23690406-1 2013 The two major forms of Shiga toxin, Stx1 and Stx2, use the glycolipid globotriaosylceramide (Gb3) as their cellular receptor. globotriaosylceramide 70-91 syntaxin 2 Homo sapiens 45-49 23690406-1 2013 The two major forms of Shiga toxin, Stx1 and Stx2, use the glycolipid globotriaosylceramide (Gb3) as their cellular receptor. globotriaosylceramide 70-91 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 93-96 23702393-6 2013 A trend toward increased sweat volume on QSART testing, and reduced urine globotriaosylceramide concentration were seen with treatment schedule C. Agalsidase alfa was safe and well tolerated with all schedules. globotriaosylceramide 74-95 galactosidase alpha Homo sapiens 147-162 23474038-1 2013 BACKGROUND: Fabry disease (FD) is a genetic disorder resulting from deficiency of the lysosomal enzyme alpha-galactosidase A (alpha-Gal A) which leads to globotriaosylceramide (GL-3) accumulation in multiple tissues. globotriaosylceramide 154-175 galactosidase alpha Homo sapiens 103-124 23385635-2 2013 The deficiency in alpha-GalA activity leads to an intra-lysosomal accumulation of neutral glycosphingolipids, mainly globotriaosylceramide (Gb3), in various organs and systems. globotriaosylceramide 117-138 galactosidase alpha Homo sapiens 18-28 23385635-2 2013 The deficiency in alpha-GalA activity leads to an intra-lysosomal accumulation of neutral glycosphingolipids, mainly globotriaosylceramide (Gb3), in various organs and systems. globotriaosylceramide 117-138 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 140-143 23691056-2 2013 This X-linked defect results in the accumulation of enzyme substrates with terminally alpha-glycosidically bound galactose, mainly the neutral glycosphingolipid Globotriaosylceramide (Gb3) in various tissues, including the kidneys. globotriaosylceramide 161-182 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 184-187 23452955-1 2013 Fabry disease is an X-linked lysosomal disorder (LD) due to deficiency of the enzyme alpha-galactosidase A (alphaGal), which leads to the accumulation of neutral glycosphingolipids, mainly globotriaosylceramide (Gb3). globotriaosylceramide 189-210 galactosidase alpha Homo sapiens 85-106 23474038-1 2013 BACKGROUND: Fabry disease (FD) is a genetic disorder resulting from deficiency of the lysosomal enzyme alpha-galactosidase A (alpha-Gal A) which leads to globotriaosylceramide (GL-3) accumulation in multiple tissues. globotriaosylceramide 154-175 galactosidase alpha Homo sapiens 126-137 22766973-2 2013 Stxs are AB(5) toxins composed of an enzymatically active A subunit and the pentameric B subunit, which preferentially binds to the glycosphingolipid globotriaosylceramide (Gb3Cer/CD77). globotriaosylceramide 150-171 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 180-184 23433711-2 2013 In Fabry disease there is accumulation of mainly globotriaosylceramide due to deficiency of the lysosomal enzyme alpha-galactosidase A. globotriaosylceramide 49-70 galactosidase alpha Homo sapiens 113-134 23734323-2 2013 We proposed globotriaosylceramide (Gb3) as a viable alternative target for antiangiogenic therapies. globotriaosylceramide 12-33 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 35-38 23380967-2 2013 Therefore, Gb(3) in resting or activated CD4(+) T-cells was assessed by flow cytometry and thin layer chromatography of cell extracts. globotriaosylceramide 11-16 CD4 molecule Homo sapiens 41-44 23334311-1 2013 Fabry disease (FD) is an X-linked lysosomal storage disorder caused by accumulation of Gb-3 (globotriaosylceramide) in cellular lysosomes of tissues throughout the body. globotriaosylceramide 93-114 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 87-91 23448451-2 2013 FD causes glycolipids, such as globotriaosylceramide (Gb3), to accumulate in the vascular endothelium of several organs (Fig. globotriaosylceramide 31-52 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 54-57 23176611-1 2012 BACKGROUND: Fabry disease (FD) is a genetic disorder resulting from deficiency of the lysosomal enzyme alpha-galactosidase A (alpha-Gal A), which leads to globotriaosylceramide (GL-3) accumulation in multiple tissues. globotriaosylceramide 155-176 galactosidase alpha Homo sapiens 103-124 23472096-1 2013 Fabry disease (FD) results from mutations in the gene (GLA) that encodes the lysosomal enzyme alpha-galactosidase A (alpha-Gal A), and involves pathological accumulation of globotriaosylceramide (GL-3) and globotriaosylsphingosine (lyso-Gb3). globotriaosylceramide 173-194 galactosidase alpha Homo sapiens 55-58 23472096-1 2013 Fabry disease (FD) results from mutations in the gene (GLA) that encodes the lysosomal enzyme alpha-galactosidase A (alpha-Gal A), and involves pathological accumulation of globotriaosylceramide (GL-3) and globotriaosylsphingosine (lyso-Gb3). globotriaosylceramide 173-194 galactosidase alpha Homo sapiens 94-115 23472096-1 2013 Fabry disease (FD) results from mutations in the gene (GLA) that encodes the lysosomal enzyme alpha-galactosidase A (alpha-Gal A), and involves pathological accumulation of globotriaosylceramide (GL-3) and globotriaosylsphingosine (lyso-Gb3). globotriaosylceramide 173-194 galactosidase alpha Homo sapiens 117-128 23093409-6 2012 Frontal affinity chromatography technology indicated that MytiLec bound specifically to globotriose (Gb3; Galalpha1-4Galbeta1-4Glc), the epitope of globotriaosylceramide. globotriaosylceramide 148-169 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 101-104 23242319-2 2012 Gb(3) is a B cell marker (CD77), but a fraction of activated peripheral blood mononuclear cells (PBMCs) can also express Gb(3). globotriaosylceramide 0-5 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 26-30 23007467-1 2012 Fabry disease is a lysosomal storage disorder (LSD) caused by deficiency of alpha-galactosidase A (alpha-gal A), resulting in deposition of globotriaosylceramide (Gb3; also known as ceramide trihexoside) in the vascular endothelium of many organs. globotriaosylceramide 152-173 galactosidase, alpha Mus musculus 88-109 23007467-1 2012 Fabry disease is a lysosomal storage disorder (LSD) caused by deficiency of alpha-galactosidase A (alpha-gal A), resulting in deposition of globotriaosylceramide (Gb3; also known as ceramide trihexoside) in the vascular endothelium of many organs. globotriaosylceramide 152-173 galactosidase, alpha Mus musculus 111-122 23007467-1 2012 Fabry disease is a lysosomal storage disorder (LSD) caused by deficiency of alpha-galactosidase A (alpha-gal A), resulting in deposition of globotriaosylceramide (Gb3; also known as ceramide trihexoside) in the vascular endothelium of many organs. globotriaosylceramide 187-190 galactosidase, alpha Mus musculus 88-109 23007467-1 2012 Fabry disease is a lysosomal storage disorder (LSD) caused by deficiency of alpha-galactosidase A (alpha-gal A), resulting in deposition of globotriaosylceramide (Gb3; also known as ceramide trihexoside) in the vascular endothelium of many organs. globotriaosylceramide 187-190 galactosidase, alpha Mus musculus 111-122 23176611-1 2012 BACKGROUND: Fabry disease (FD) is a genetic disorder resulting from deficiency of the lysosomal enzyme alpha-galactosidase A (alpha-Gal A), which leads to globotriaosylceramide (GL-3) accumulation in multiple tissues. globotriaosylceramide 155-176 galactosidase alpha Homo sapiens 126-137 23330407-1 2012 Fabry disease (Anderson-Fabry disease) is an X-linked recessive lysosomal storage disorder resulting from deficient activity of lysosomal hydrolase, alpha-galactosidase A (alpha-Gal A), which leads to progressive accumulation of globotriaosylceramide (Gb3) in various cells, predominantly endothelial and vascular smooth muscle cells, with clinical manifestations affecting major organs including the central nervous system. globotriaosylceramide 229-250 galactosidase alpha Homo sapiens 149-170 23058197-1 2012 UNLABELLED: Fabry disease (FD) is a rare X-linked genetic lysosomal storage disease caused by a deficiency of the enzyme alpha-galactosidase A, that produces accumulation of globotriaosylceramide. globotriaosylceramide 174-195 galactosidase alpha Homo sapiens 121-142 26019818-2 2012 Scarce activity of lysosomal alpha-galactosidase A results in progressive accumulation of globotriaosylceramide (Gb3) within lysosomes, believed to trigger a flow of cellular changes that lead to the clinical manifestation of the disease. globotriaosylceramide 90-111 galactosidase alpha Homo sapiens 29-50 26019818-2 2012 Scarce activity of lysosomal alpha-galactosidase A results in progressive accumulation of globotriaosylceramide (Gb3) within lysosomes, believed to trigger a flow of cellular changes that lead to the clinical manifestation of the disease. globotriaosylceramide 90-111 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 113-116 22936806-4 2012 Enhanced ceramide glycosylation and globotriosylceramide (Gb3) correlate well with the numbers of BCSCs in breast cancer cell lines. globotriaosylceramide 36-56 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 58-61 23330407-1 2012 Fabry disease (Anderson-Fabry disease) is an X-linked recessive lysosomal storage disorder resulting from deficient activity of lysosomal hydrolase, alpha-galactosidase A (alpha-Gal A), which leads to progressive accumulation of globotriaosylceramide (Gb3) in various cells, predominantly endothelial and vascular smooth muscle cells, with clinical manifestations affecting major organs including the central nervous system. globotriaosylceramide 229-250 galactosidase alpha Homo sapiens 172-183 22187137-1 2012 Fabry disease (FD) is an X-linked inherited disease due to alpha-galactosidase A (alpha-Gal A) deficiency and characterized by lysosomal storage of globotriaosylceramide (Gb3) and related neutral glycosphingolipids. globotriaosylceramide 148-169 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 171-174 22472949-1 2012 Fabry disease is a lysosomal storage disorder caused by a deficiency of alpha-galactosidase A (alpha-gal A) activity that results in progressive globotriaosylceramide (Gb(3)) deposition. globotriaosylceramide 145-166 galactosidase alpha Homo sapiens 72-93 22472949-1 2012 Fabry disease is a lysosomal storage disorder caused by a deficiency of alpha-galactosidase A (alpha-gal A) activity that results in progressive globotriaosylceramide (Gb(3)) deposition. globotriaosylceramide 145-166 galactosidase alpha Homo sapiens 95-106 22472949-1 2012 Fabry disease is a lysosomal storage disorder caused by a deficiency of alpha-galactosidase A (alpha-gal A) activity that results in progressive globotriaosylceramide (Gb(3)) deposition. globotriaosylceramide 168-174 galactosidase alpha Homo sapiens 72-93 22472949-1 2012 Fabry disease is a lysosomal storage disorder caused by a deficiency of alpha-galactosidase A (alpha-gal A) activity that results in progressive globotriaosylceramide (Gb(3)) deposition. globotriaosylceramide 168-174 galactosidase alpha Homo sapiens 95-106 22425450-1 2012 Fabry disease is a lysosomal storage disease caused by deficient activity of the alpha-Galactosidase A (alpha-Gal A) enzyme, which leads to abnormal accumulation of glycosphingolipids, mainly globotriaosylceramide (Gb3), in the lysosome. globotriaosylceramide 192-213 galactosidase, alpha Mus musculus 81-102 22425450-1 2012 Fabry disease is a lysosomal storage disease caused by deficient activity of the alpha-Galactosidase A (alpha-Gal A) enzyme, which leads to abnormal accumulation of glycosphingolipids, mainly globotriaosylceramide (Gb3), in the lysosome. globotriaosylceramide 192-213 galactosidase, alpha Mus musculus 104-115 22425450-1 2012 Fabry disease is a lysosomal storage disease caused by deficient activity of the alpha-Galactosidase A (alpha-Gal A) enzyme, which leads to abnormal accumulation of glycosphingolipids, mainly globotriaosylceramide (Gb3), in the lysosome. globotriaosylceramide 192-213 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 215-218 22309310-2 2012 Two disease-specific Fabry biomarkers have been identified and quantified in plasma and urine: globotriaosylceramide (Gb(3)) and globotriaosylsphingosine (lyso-Gb(3)). globotriaosylceramide 95-116 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 118-123 22215019-1 2012 Fabry disease is an X-linked lysosomal storage disorder (LSD) caused by mutations in the gene (GLA) that encodes the lysosomal hydrolase alpha-galactosidase A (alpha-Gal A), and is characterized by pathological accumulation of the substrate, globotriaosylceramide (GL-3). globotriaosylceramide 242-263 galactosidase alpha Homo sapiens 95-98 22215019-1 2012 Fabry disease is an X-linked lysosomal storage disorder (LSD) caused by mutations in the gene (GLA) that encodes the lysosomal hydrolase alpha-galactosidase A (alpha-Gal A), and is characterized by pathological accumulation of the substrate, globotriaosylceramide (GL-3). globotriaosylceramide 242-263 galactosidase alpha Homo sapiens 137-158 22215019-1 2012 Fabry disease is an X-linked lysosomal storage disorder (LSD) caused by mutations in the gene (GLA) that encodes the lysosomal hydrolase alpha-galactosidase A (alpha-Gal A), and is characterized by pathological accumulation of the substrate, globotriaosylceramide (GL-3). globotriaosylceramide 242-263 galactosidase alpha Homo sapiens 160-171 22085605-1 2012 Fabry disease is an X-linked inborn error of glycosphingolipid catabolism due to deficient activity of alpha-galactosidase A that leads to accumulation of the enzyme substrates, mainly globotriaosylceramide (Gb3), in body fluids and lysosomes of many cell types. globotriaosylceramide 185-206 galactosidase alpha Homo sapiens 103-124 23766930-1 2012 We have previously demonstrated an association between the accumulation of the glycosphingolipid globotriaosylceramide (Gb3) and the loss of high molecular weight oligomers in the aortas of alpha-galactosidase A-knockout mice, a model of Fabry disease. globotriaosylceramide 97-118 galactosidase, alpha Mus musculus 190-211 22085605-1 2012 Fabry disease is an X-linked inborn error of glycosphingolipid catabolism due to deficient activity of alpha-galactosidase A that leads to accumulation of the enzyme substrates, mainly globotriaosylceramide (Gb3), in body fluids and lysosomes of many cell types. globotriaosylceramide 185-206 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 208-211 22205110-1 2012 Fabry disease (FD) is a rare X-linked lysosomal storage disorder of glycosphingolipids, mostly globotriaosylceramide (Gb3). globotriaosylceramide 95-116 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 118-121 22138589-2 2012 A defect in the alpha-galactosidase gene leads to lysosomal accumulation of the glycolipid globotriaosylceramide (Gb3). globotriaosylceramide 91-112 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 114-117 23208084-6 2012 The link connected the accumulation of glycosphingolipid globotriaosylceramide, characteristic of FD, with the expression of CD74 and macrophage migration inhibitory factor that may play an important role in tumorigenesis regulated by the Von Hippel-Lindau/hypoxia-inducible factor 1alpha pathway. globotriaosylceramide 57-78 CD74 molecule Homo sapiens 125-129 22612023-1 2012 Fabry disease is an X-linked inherited condition with the absence or reduction of alpha-galactosidase A- activity in lysosomes leading to accumulation of globotriaosylceramide and related neutral glycosphingolipids. globotriaosylceramide 154-175 galactosidase alpha Homo sapiens 82-103 23304632-7 2012 Immunohistochemistry and real-time PCR revealed that the expression of globotriaosylceramide (Gb3), the receptor for Stx2, and Gb3 synthase (GalT6) in HASTs was increased by interleukin-1beta (IL-1beta). globotriaosylceramide 71-92 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 94-97 23094092-2 2012 Anti agalsidase ABs negatively influence globotriaosylceramide (Gb3) reduction. globotriaosylceramide 41-62 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 64-67 23304632-7 2012 Immunohistochemistry and real-time PCR revealed that the expression of globotriaosylceramide (Gb3), the receptor for Stx2, and Gb3 synthase (GalT6) in HASTs was increased by interleukin-1beta (IL-1beta). globotriaosylceramide 71-92 syntaxin 2 Homo sapiens 117-121 23304632-7 2012 Immunohistochemistry and real-time PCR revealed that the expression of globotriaosylceramide (Gb3), the receptor for Stx2, and Gb3 synthase (GalT6) in HASTs was increased by interleukin-1beta (IL-1beta). globotriaosylceramide 71-92 interleukin 1 beta Homo sapiens 174-191 23304632-7 2012 Immunohistochemistry and real-time PCR revealed that the expression of globotriaosylceramide (Gb3), the receptor for Stx2, and Gb3 synthase (GalT6) in HASTs was increased by interleukin-1beta (IL-1beta). globotriaosylceramide 71-92 interleukin 1 beta Homo sapiens 193-201 22563919-1 2012 Fabry disease--a genetic disorder characterized by the accumulation of globotriaosylceramide in cell lysosomes resulting from an X-linked deficiency of alpha-galactosidase A activity--presents with multiorgan manifestations, including progressive renal disease. globotriaosylceramide 71-92 galactosidase alpha Homo sapiens 152-173 22241068-4 2012 The oral administration of 1-deoxygalactonojirimycin to transgenic mice expressing human mutant alpha-galactosidase A resulted in significant increases in alpha-galactosidase A activity in various organs, with concomitant reductions in globotriaosylceramide, which contributes to the pathology of Fabry disease. globotriaosylceramide 236-257 galactosidase alpha Homo sapiens 96-117 21896204-1 2011 BACKGROUND: Anderson-Fabry disease (FD) is caused by a deficit of the alpha-galactosidase A enzyme which leads to the accumulation of complex sphingolipids, especially globotriaosylceramide (Gb3), in all the cells of the body, causing the onset of a multi-systemic disease with poor prognosis in adulthood. globotriaosylceramide 168-189 galactosidase alpha Homo sapiens 70-91 22472932-2 2011 Fabry disease is an X-linked hereditary metabolic storage disorder, due to the deficiency in lysosomal alpha-galactosidase A, with the consequent glycosphingolipids accumulation, primarily globotriaosylceramide, at cellular level. globotriaosylceramide 189-210 galactosidase alpha Homo sapiens 103-124 21069478-3 2011 Natural glycosphingolipid, globotriaosylceramide (Gal alpha1-4, Gal beta1-4, Glc beta1-1, ceramide), is also called CD77 and its expression was previously associated with proliferating centroblasts undergoing somatic hypermutation, but it has been demonstrate that globotriaosylceramide is not a reliable marker to discriminate human centroblasts from centrocytes. globotriaosylceramide 27-48 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 Homo sapiens 68-75 21069478-3 2011 Natural glycosphingolipid, globotriaosylceramide (Gal alpha1-4, Gal beta1-4, Glc beta1-1, ceramide), is also called CD77 and its expression was previously associated with proliferating centroblasts undergoing somatic hypermutation, but it has been demonstrate that globotriaosylceramide is not a reliable marker to discriminate human centroblasts from centrocytes. globotriaosylceramide 27-48 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 Homo sapiens 81-88 21069478-3 2011 Natural glycosphingolipid, globotriaosylceramide (Gal alpha1-4, Gal beta1-4, Glc beta1-1, ceramide), is also called CD77 and its expression was previously associated with proliferating centroblasts undergoing somatic hypermutation, but it has been demonstrate that globotriaosylceramide is not a reliable marker to discriminate human centroblasts from centrocytes. globotriaosylceramide 27-48 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 116-120 21069478-3 2011 Natural glycosphingolipid, globotriaosylceramide (Gal alpha1-4, Gal beta1-4, Glc beta1-1, ceramide), is also called CD77 and its expression was previously associated with proliferating centroblasts undergoing somatic hypermutation, but it has been demonstrate that globotriaosylceramide is not a reliable marker to discriminate human centroblasts from centrocytes. globotriaosylceramide 265-286 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 Homo sapiens 68-75 21069478-3 2011 Natural glycosphingolipid, globotriaosylceramide (Gal alpha1-4, Gal beta1-4, Glc beta1-1, ceramide), is also called CD77 and its expression was previously associated with proliferating centroblasts undergoing somatic hypermutation, but it has been demonstrate that globotriaosylceramide is not a reliable marker to discriminate human centroblasts from centrocytes. globotriaosylceramide 265-286 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 Homo sapiens 81-88 21069478-3 2011 Natural glycosphingolipid, globotriaosylceramide (Gal alpha1-4, Gal beta1-4, Glc beta1-1, ceramide), is also called CD77 and its expression was previously associated with proliferating centroblasts undergoing somatic hypermutation, but it has been demonstrate that globotriaosylceramide is not a reliable marker to discriminate human centroblasts from centrocytes. globotriaosylceramide 265-286 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 116-120 21788400-3 2011 We have previously shown that the cellular receptor for Shiga toxin B (STxB), the glycosphingolipid globotriaosylceramide (Gb(3) or CD77) is strongly increased in colorectal adenocarcinoma and their metastases. globotriaosylceramide 100-121 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 132-136 21896204-1 2011 BACKGROUND: Anderson-Fabry disease (FD) is caused by a deficit of the alpha-galactosidase A enzyme which leads to the accumulation of complex sphingolipids, especially globotriaosylceramide (Gb3), in all the cells of the body, causing the onset of a multi-systemic disease with poor prognosis in adulthood. globotriaosylceramide 168-189 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 191-194 21738355-1 2011 Fabry"s disease is an X-linked lysosomal storage disorder caused by abnormalities in the alpha-galactosidase A (GLA) gene, which leads to a GLA deficiency and to the intracellular deposition of globotriaosylceramide (Gb3) within vascular endothelium and other tissues. globotriaosylceramide 194-215 galactosidase alpha Homo sapiens 89-110 21738355-1 2011 Fabry"s disease is an X-linked lysosomal storage disorder caused by abnormalities in the alpha-galactosidase A (GLA) gene, which leads to a GLA deficiency and to the intracellular deposition of globotriaosylceramide (Gb3) within vascular endothelium and other tissues. globotriaosylceramide 194-215 galactosidase alpha Homo sapiens 112-115 21738355-1 2011 Fabry"s disease is an X-linked lysosomal storage disorder caused by abnormalities in the alpha-galactosidase A (GLA) gene, which leads to a GLA deficiency and to the intracellular deposition of globotriaosylceramide (Gb3) within vascular endothelium and other tissues. globotriaosylceramide 194-215 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 217-220 21235448-2 2011 Absent or reduced enzyme activity leads to impaired catabolism of neutral glycosphingolipids, particularly globotriaosylceramide (Gb3), resulting in intracellular deposition of such lipids. globotriaosylceramide 107-128 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 130-133 20131008-2 2011 The systemic accumulation of substrate, mainly globotriaosylceramide (Gb3), results in organ failure. globotriaosylceramide 47-68 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 70-73 21477968-1 2011 BACKGROUND: Fabry disease results from deficiency of alpha-galactosidase A (AGA), causing lysosomal storage of globotriaosylceramide in heart and other tissues. globotriaosylceramide 111-132 galactosidase, alpha Mus musculus 53-74 21328014-1 2011 Fabry disease is a rare X-linked disorder caused by mutations in the alpha-galactosidase gene (GLA), the resultant deficiency of lysosomal alpha-galactosidase enzyme activity leading to systemic accumulation of globotriaosylceramide and other glycosphingolipids. globotriaosylceramide 211-232 galactosidase, alpha Mus musculus 95-98 21675497-1 2011 Fabry disease (FD) is an X-linked lysosomal disorder caused by the deficient activity of the enzyme alpha-galactosidase A, which leads to multisystemic storage of globotriaosylceramide in visceral tissues and vascular endothelium. globotriaosylceramide 163-184 galactosidase alpha Homo sapiens 100-121 21524384-3 2011 We have identified the P(k) blood group antigen (a GSL) globotriaosylceramide (Gb(3)) as a new resistance effector against HIV-1 infection. globotriaosylceramide 56-77 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 79-84 21047542-1 2011 Fabry disease, due to the deficiency of alpha-galactosidase A (alpha-Gal), causes lysosomal accumulation of globotriaosylceramide (Gb3) in multiple tissues and prominently in the vascular endothelium. globotriaosylceramide 108-129 galactosidase, alpha Mus musculus 40-61 21047542-1 2011 Fabry disease, due to the deficiency of alpha-galactosidase A (alpha-Gal), causes lysosomal accumulation of globotriaosylceramide (Gb3) in multiple tissues and prominently in the vascular endothelium. globotriaosylceramide 108-129 galactosidase, alpha Mus musculus 63-72 21047542-1 2011 Fabry disease, due to the deficiency of alpha-galactosidase A (alpha-Gal), causes lysosomal accumulation of globotriaosylceramide (Gb3) in multiple tissues and prominently in the vascular endothelium. globotriaosylceramide 131-134 galactosidase, alpha Mus musculus 40-61 21047542-1 2011 Fabry disease, due to the deficiency of alpha-galactosidase A (alpha-Gal), causes lysosomal accumulation of globotriaosylceramide (Gb3) in multiple tissues and prominently in the vascular endothelium. globotriaosylceramide 131-134 galactosidase, alpha Mus musculus 63-72 20961863-0 2011 Increased globotriaosylceramide levels in a transgenic mouse expressing human alpha1,4-galactosyltransferase and a mouse model for treating Fabry disease. globotriaosylceramide 10-31 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 78-108 20961863-1 2011 Fabry disease is a lysosomal storage disorder caused by an alpha-galactosidase A (alpha-Gal A) deficiency and resulting in the accumulation of glycosphingolipids, predominantly globotriaosylceramide (Gb3). globotriaosylceramide 177-198 galactosidase, alpha Mus musculus 82-93 20961863-1 2011 Fabry disease is a lysosomal storage disorder caused by an alpha-galactosidase A (alpha-Gal A) deficiency and resulting in the accumulation of glycosphingolipids, predominantly globotriaosylceramide (Gb3). globotriaosylceramide 200-203 galactosidase, alpha Mus musculus 59-80 20961863-1 2011 Fabry disease is a lysosomal storage disorder caused by an alpha-galactosidase A (alpha-Gal A) deficiency and resulting in the accumulation of glycosphingolipids, predominantly globotriaosylceramide (Gb3). globotriaosylceramide 200-203 galactosidase, alpha Mus musculus 82-93 20864368-1 2011 BACKGROUND: Fabry disease is caused by a deficiency of alpha-galactosidase A (alpha-Gal A), which results in the accumulation of globotriaosylceramide (GL3) and related glycosphingolipids in different organs. globotriaosylceramide 129-150 galactosidase alpha Homo sapiens 55-76 20846825-1 2011 In Fabry disease a deficiency of alpha-galactosidase A (alpha-gal A) activity leads to accumulation of globotriaosylceramide (Gb3) in various tissues including the heart. globotriaosylceramide 103-124 galactosidase, alpha Mus musculus 33-54 20846825-1 2011 In Fabry disease a deficiency of alpha-galactosidase A (alpha-gal A) activity leads to accumulation of globotriaosylceramide (Gb3) in various tissues including the heart. globotriaosylceramide 103-124 galactosidase, alpha Mus musculus 56-67 20846825-1 2011 In Fabry disease a deficiency of alpha-galactosidase A (alpha-gal A) activity leads to accumulation of globotriaosylceramide (Gb3) in various tissues including the heart. globotriaosylceramide 126-129 galactosidase, alpha Mus musculus 33-54 20846825-1 2011 In Fabry disease a deficiency of alpha-galactosidase A (alpha-gal A) activity leads to accumulation of globotriaosylceramide (Gb3) in various tissues including the heart. globotriaosylceramide 126-129 galactosidase, alpha Mus musculus 56-67 20941593-1 2011 Fabry disease is a multisystem X-linked disorder resulting from alpha-galactosidase A (alpha-GalA) gene mutations leading to the accumulation of globotriaosylceramide mainly in endothelium compromising heart, kidney, and brain. globotriaosylceramide 145-166 galactosidase alpha Homo sapiens 64-85 20941593-1 2011 Fabry disease is a multisystem X-linked disorder resulting from alpha-galactosidase A (alpha-GalA) gene mutations leading to the accumulation of globotriaosylceramide mainly in endothelium compromising heart, kidney, and brain. globotriaosylceramide 145-166 galactosidase alpha Homo sapiens 87-97 23430826-1 2011 Fabry disease is an X-linked glycosphingolipidosis caused by deficient synthesis of the enzyme alpha-galactosidase A, which results in glycosphingolipidosis, predominantly globotriaosylceramide, progressively accumulating in systemic tissue. globotriaosylceramide 172-193 galactosidase alpha Homo sapiens 95-116 21255370-3 2011 Stx binds specifically to the glycosphingolipid globotriaosylceramide (Gb3) at the surface of target cells and is then internalized by endocytosis. globotriaosylceramide 48-69 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2 Homo sapiens 0-3 21255370-3 2011 Stx binds specifically to the glycosphingolipid globotriaosylceramide (Gb3) at the surface of target cells and is then internalized by endocytosis. globotriaosylceramide 48-69 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 71-74 21428036-2 2011 Deficiency of alpha-galactosidase A activity leads to the accumulation of neutral glycosphingolipids, primarily globotriaosylceramide (GL-3) in various tissues, particularly blood vessels, kidneys, myocardium and in ganglions of the peripheral and autonomic nervous system and causes diverse symptoms. globotriaosylceramide 112-133 galactosidase alpha Homo sapiens 14-35 19919901-3 2011 There is an inability to catabolize lipids which results in cellular accumulation of its most abundant substrate, globotriaosylceramide (Gb3), and other neutral glycosphingolipids in vascular endothelium and other tissues throughout the body. globotriaosylceramide 114-135 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 137-140 20864368-1 2011 BACKGROUND: Fabry disease is caused by a deficiency of alpha-galactosidase A (alpha-Gal A), which results in the accumulation of globotriaosylceramide (GL3) and related glycosphingolipids in different organs. globotriaosylceramide 129-150 galactosidase alpha Homo sapiens 78-89 21331308-1 2010 Fabry disease is a rare X-linked lysosomal storage disorder caused by a deficiency in alpha-galactosidase A (GLA), which catalyzes the hydrolysis of terminal alpha-galactosyl groups from glycosphingolipids, such as globotriaosylceramide (Gb3). globotriaosylceramide 215-236 galactosidase alpha Homo sapiens 86-107 21331308-1 2010 Fabry disease is a rare X-linked lysosomal storage disorder caused by a deficiency in alpha-galactosidase A (GLA), which catalyzes the hydrolysis of terminal alpha-galactosyl groups from glycosphingolipids, such as globotriaosylceramide (Gb3). globotriaosylceramide 215-236 galactosidase alpha Homo sapiens 109-112 20716521-3 2010 To evaluate this relationship, Verotoxin binding its receptor GSL, globotriaosyl ceramide (Gb(3)), was analyzed in simple GSL/cholesterol, detergent-resistant membrane vesicles by equilibrium density gradient centrifugation. globotriaosylceramide 67-89 cathepsin A Homo sapiens 62-65 21211678-2 2010 In males, Gb(3) measurement allows to confirm the diagnosis which is based on deficient alpha-galactosidase A (alpha-Gal A) activity in leukocytes. globotriaosylceramide 10-15 galactosidase alpha Homo sapiens 88-109 21211678-2 2010 In males, Gb(3) measurement allows to confirm the diagnosis which is based on deficient alpha-galactosidase A (alpha-Gal A) activity in leukocytes. globotriaosylceramide 10-15 galactosidase alpha Homo sapiens 111-122 21211678-7 2010 Our study shows that urinary Gb(3) (measurement and C24/C18 ratio) allows the diagnosis of 92 % of classical FD heterozygotes, and is often normal in variant FD heterozygotes. globotriaosylceramide 29-34 Bardet-Biedl syndrome 9 Homo sapiens 56-59 21092187-4 2010 Deficient activity of lysosomal alpha-galactosidase A results in progressive accumulation of globotriaosylceramide within lysosomes, believed to trigger a cascade of cellular events. globotriaosylceramide 93-114 galactosidase alpha Homo sapiens 32-53 21088081-1 2010 Anderson-Fabry disease is an X-linked lysosomal storage disorder resulting from a deficiency of the enzyme alpha-galactosidase A (alpha-Gal A) and subsequent cellular storage of the enzyme"s substrate globotriaosylceramide (Gb3) and related glycosphingolipids. globotriaosylceramide 201-222 galactosidase alpha Homo sapiens 107-128 21088081-1 2010 Anderson-Fabry disease is an X-linked lysosomal storage disorder resulting from a deficiency of the enzyme alpha-galactosidase A (alpha-Gal A) and subsequent cellular storage of the enzyme"s substrate globotriaosylceramide (Gb3) and related glycosphingolipids. globotriaosylceramide 201-222 galactosidase alpha Homo sapiens 130-141 21088081-1 2010 Anderson-Fabry disease is an X-linked lysosomal storage disorder resulting from a deficiency of the enzyme alpha-galactosidase A (alpha-Gal A) and subsequent cellular storage of the enzyme"s substrate globotriaosylceramide (Gb3) and related glycosphingolipids. globotriaosylceramide 201-222 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 224-227 20852936-1 2010 Fabry"s disease is an X-linked recessive disorder that results from the deficiency of alpha-galactosidase A and causes the accumulation of globotriaosylceramide (Gb3) in different tissues. globotriaosylceramide 139-160 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 162-165 20837469-1 2010 Globotriaosylceramide (Gb3) is a well known receptor for Shiga toxin (Stx), produced by enterohemorrhagic Escherichia coli and Shigella dysenteriae. globotriaosylceramide 0-21 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 23-26 20644116-4 2010 Stx occurs in 2 variants, Stx1 and Stx2, each of which is composed of 1 catalytically active A subunit that is responsible for cytotoxicity, and 5 identical B subunits that mediate binding to cell-surface globo-triaosylceramide. globotriaosylceramide 205-227 syntaxin 2 Homo sapiens 35-39 20644116-6 2010 This rapid effect requires binding and clustering of globotriaosylceramide, and depends on plasma membrane cholesterol and caveolin-1 but not clathrin. globotriaosylceramide 53-74 caveolin 1 Homo sapiens 123-133 21170881-2 2010 The resulting deficiency in a-GalA activity leads to intra-lysosomal accumulation of neutral glycosphingolipids, mainly globotriaosylceramide (Gb3), in various organ systems. globotriaosylceramide 120-141 galactosidase alpha Homo sapiens 30-34 21170881-2 2010 The resulting deficiency in a-GalA activity leads to intra-lysosomal accumulation of neutral glycosphingolipids, mainly globotriaosylceramide (Gb3), in various organ systems. globotriaosylceramide 120-141 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 143-146 20716521-3 2010 To evaluate this relationship, Verotoxin binding its receptor GSL, globotriaosyl ceramide (Gb(3)), was analyzed in simple GSL/cholesterol, detergent-resistant membrane vesicles by equilibrium density gradient centrifugation. globotriaosylceramide 91-96 cathepsin A Homo sapiens 62-65 20716521-10 2010 We found GalCer and GlcCer bind Gb(3), suggesting GSL-GSL interaction can counter cholesterol masking of Gb(3). globotriaosylceramide 32-37 cathepsin A Homo sapiens 50-53 20716521-10 2010 We found GalCer and GlcCer bind Gb(3), suggesting GSL-GSL interaction can counter cholesterol masking of Gb(3). globotriaosylceramide 32-37 cathepsin A Homo sapiens 54-57 20716521-10 2010 We found GalCer and GlcCer bind Gb(3), suggesting GSL-GSL interaction can counter cholesterol masking of Gb(3). globotriaosylceramide 105-110 cathepsin A Homo sapiens 50-53 20716521-10 2010 We found GalCer and GlcCer bind Gb(3), suggesting GSL-GSL interaction can counter cholesterol masking of Gb(3). globotriaosylceramide 105-110 cathepsin A Homo sapiens 54-57 19515805-1 2009 BACKGROUND: In Fabry disease, storage of globotriaosylceramide (Gb3) in arterial walls is one of the main pathogenetic factors that are thought to underlie the clinical manifestations of the disease. globotriaosylceramide 41-62 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 64-67 20471476-1 2010 Fabry disease is an X-linked lysosomal storage disorder due to deficiency of alpha-Galactosidase A, causing accumulation of globotriaosylceramide and elevated plasma globotriaosylsphingosine (lysoGb3). globotriaosylceramide 124-145 galactosidase alpha Homo sapiens 77-98 19631563-2 2010 Treatment with recombinant enzyme preparations aims to attenuate and reverse accumulation of the major enzyme substrate, globotriaosylceramide (Gb3). globotriaosylceramide 121-142 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 144-147 19948172-1 2010 The glycosphingolipid globotriaosyl ceramide, (Galalpha1-4Galss1-4 glucosyl ceramide-Gb(3)) also known as CD77 and the P(k) blood group antigen, is bound by both verotoxins and by the HIV adhesin, gp120. globotriaosylceramide 22-44 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 106-110 19948172-1 2010 The glycosphingolipid globotriaosyl ceramide, (Galalpha1-4Galss1-4 glucosyl ceramide-Gb(3)) also known as CD77 and the P(k) blood group antigen, is bound by both verotoxins and by the HIV adhesin, gp120. globotriaosylceramide 22-44 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 197-202 19948172-5 2010 Differential binding of verotoxins and gp120 to such Gb(3) isoforms in model and cell membranes indicates a significant role in the eventual pathogenic outcome. globotriaosylceramide 53-58 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 39-44 20092352-5 2010 Stx1 preferred the Pk trisaccharide of its native receptor, globotriaosylceramide (Gb3), while the more potent and clinically relevant variant, Stx2, preferred the Pk trisaccharide with the terminal galactose replaced with N-acetylgalactosamine (NHAc-Pk). globotriaosylceramide 60-81 syntaxin 1A Homo sapiens 0-4 19895884-1 2010 Verotoxin (VT-1) is a cytotoxin, produced by Shigella dysenteriae type 1 or by Shiga toxin-producing Escherichia coli, which binds specifically to globotriaosylceramide (Gb3). globotriaosylceramide 147-168 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 170-173 20228022-1 2010 Fabry disease is an X- linked lysosomal disorder due to deficient activity of the enzyme alpha galactosidase A which leads to multisystemic storage of globotriaosylceramide with neurologic, gastrointestinal, cardiac, renal, skin and ophtalmological involvement. globotriaosylceramide 151-172 galactosidase alpha Homo sapiens 89-110 19242721-2 2009 In affected patients, the enzyme substrate, globotriaosylceramide (Gb3), accumulates in cells of various tissues and organs. globotriaosylceramide 44-65 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 67-70 19859978-1 2009 Fabry disease is an X-linked lysosomal disorder that results from a deficiency of the lysosomal enzyme alpha-galactosidase A leading to accumulation of glycolipids, mainly globotriaosylceramide in the cells from different tissues. globotriaosylceramide 172-193 galactosidase alpha Homo sapiens 103-124 19818152-1 2009 BACKGROUND: In Fabry disease (alpha-galactosidase A deficiency) accumulation of Globotriaosylceramide (Gb3) leads to progressive organ failure and premature death. globotriaosylceramide 80-101 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 103-106 20660166-1 2010 Fabry disease is an X-linked inherited condition due to the absence or reduction of alpha-galactosidase activity in lysosomes, that results in accumulation of globotriaosylceramide (Gb3) and related neutral glycosphingolipids. globotriaosylceramide 159-180 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 182-185 20347160-2 2010 In this work intracerebroventricular administration of Stx2 in rat brains significantly increased the expression of its receptor globotriaosylceramide (Gb(3)) in neuronal populations from striatum, hippocampus and cortex. globotriaosylceramide 129-150 syntaxin 2 Rattus norvegicus 55-59 20347160-2 2010 In this work intracerebroventricular administration of Stx2 in rat brains significantly increased the expression of its receptor globotriaosylceramide (Gb(3)) in neuronal populations from striatum, hippocampus and cortex. globotriaosylceramide 152-158 syntaxin 2 Rattus norvegicus 55-59 20347160-3 2010 Stx2 was immunodetected in neurons that expressed Gb(3) after intracerebroventricular administration of the toxin. globotriaosylceramide 50-55 syntaxin 2 Rattus norvegicus 0-4 20347160-4 2010 Confocal immunofluorescence of microtubule-associated protein 2 showed aberrant dendrites in neurons expressing increased Gb(3). globotriaosylceramide 122-127 microtubule-associated protein 2 Rattus norvegicus 31-63 20347160-8 2010 We thus suggest that Stx2 induces the expression of Gb(3) in neurons and triggers neuronal dysfunctions. globotriaosylceramide 52-57 syntaxin 2 Rattus norvegicus 21-25 19965549-2 2010 Traditionally, globotriaosylceramide (Gb(3)) in urine has been used to evaluate the effect of specific therapy, such as enzyme replacement therapy (ERT). globotriaosylceramide 15-36 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 38-43 20345350-2 2010 This leads to a progressive accumulation of globotriaosylceramide (Gb3) in the lysosomes of different cells and tissues, causing principally ventricular hypertrophy, renal failure and cerebrovascular accidents, reducing lifespan both in hemizygous males and heterozygous females. globotriaosylceramide 44-65 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 67-70 19853240-5 2009 The enzyme cleaved globotriaosylceramide (Gb3) accumulated in cultured fibroblasts from a patient with Fabry disease. globotriaosylceramide 19-40 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 42-45 19674101-1 2009 Abnormal biosynthesis of globotriaosylceramide (Gb3) is known to be associated with Gb3-related diseases, such as Fabry disease. globotriaosylceramide 25-46 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 48-51 19674101-1 2009 Abnormal biosynthesis of globotriaosylceramide (Gb3) is known to be associated with Gb3-related diseases, such as Fabry disease. globotriaosylceramide 25-46 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 84-87 19639234-1 2009 Fabry disease is a lysosomal storage disease caused by a deficiency of alpha-galactosidase A, which results in aberrant glycosphingolipid metabolism and accumulation of globotriaosylceramide (Gb3). globotriaosylceramide 169-190 galactosidase, alpha Mus musculus 71-92 19639234-1 2009 Fabry disease is a lysosomal storage disease caused by a deficiency of alpha-galactosidase A, which results in aberrant glycosphingolipid metabolism and accumulation of globotriaosylceramide (Gb3). globotriaosylceramide 192-195 galactosidase, alpha Mus musculus 71-92 18716315-1 2009 Glycosphingolipid (GSL) fatty acid strictly regulates verotoxin 1 (VT1) and the HIV adhesin, gp120 binding to globotriaosyl ceramide within Gb(3)/cholesterol detergent resistant membrane (DRM) vesicle constructs and in Gb(3) water-air interface monolayers in a similar manner. globotriaosylceramide 110-132 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 93-98 19628671-5 2009 Treatment of knockout mice with a potent inhibitor of glucosylceramide synthase reversed accumulation of globotriaosylceramide but failed to normalize the defect in vasorelaxation. globotriaosylceramide 105-126 UDP-glucose ceramide glucosyltransferase Mus musculus 54-79 18716315-1 2009 Glycosphingolipid (GSL) fatty acid strictly regulates verotoxin 1 (VT1) and the HIV adhesin, gp120 binding to globotriaosyl ceramide within Gb(3)/cholesterol detergent resistant membrane (DRM) vesicle constructs and in Gb(3) water-air interface monolayers in a similar manner. globotriaosylceramide 140-145 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 93-98 18716315-1 2009 Glycosphingolipid (GSL) fatty acid strictly regulates verotoxin 1 (VT1) and the HIV adhesin, gp120 binding to globotriaosyl ceramide within Gb(3)/cholesterol detergent resistant membrane (DRM) vesicle constructs and in Gb(3) water-air interface monolayers in a similar manner. globotriaosylceramide 219-224 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 93-98 19714252-3 2009 We determined the expression of globotriaosylceramide (Gb3Cer/CD77), the Shiga toxin receptor, in human pancreatic and colon adenocarcinomas. globotriaosylceramide 32-53 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 62-66 19495571-1 2009 UNLABELLED: Fabry disease is a rare, X-linked lysosomal storage disease caused by an inborn deficiency of alpha-galactosidase A, which results in the progressive accumulation of globotriaosylceramide and other neutral glycolipids in a range of cells and tissues. globotriaosylceramide 178-199 galactosidase alpha Homo sapiens 106-127 19464216-1 2009 Fabry disease is an X-linked lysosomal storage disorder caused by deficiency of alpha-galactosidase A, resulting in accumulation of the principal substrate, globotriaosylceramide (Gb(3)), in various physiological fluids and tissues in affected patients. globotriaosylceramide 157-178 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 180-185 19444268-4 2009 They also propose that the binding of the HIV-1 glycoprotein gp120 to Gb(3) in renal tubules may play a role in HIV nephropathy. globotriaosylceramide 70-75 Envelope surface glycoprotein gp160, precursor Human immunodeficiency virus 1 61-66 19387866-1 2009 Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the gene encoding alpha-galactosidase A (alpha-Gal A), with consequent accumulation of its major glycosphingolipid substrate, globotriaosylceramide (GL-3). globotriaosylceramide 205-226 galactosidase alpha Homo sapiens 97-118 19387866-1 2009 Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the gene encoding alpha-galactosidase A (alpha-Gal A), with consequent accumulation of its major glycosphingolipid substrate, globotriaosylceramide (GL-3). globotriaosylceramide 205-226 galactosidase alpha Homo sapiens 120-131 19268437-0 2009 An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: utility for Fabry disease diagnosis and treatment monitoring. globotriaosylceramide 50-71 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 73-76 19470247-0 2009 Globotriaosylceramide (Gb3) content in HeLa cells is correlated to Shiga toxin-induced cytotoxicity and Gb3 synthase expression. globotriaosylceramide 0-21 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 104-116 19470247-0 2009 Globotriaosylceramide (Gb3) content in HeLa cells is correlated to Shiga toxin-induced cytotoxicity and Gb3 synthase expression. globotriaosylceramide 23-26 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 104-116 19268437-2 2009 The defect leads to the accumulation of globotriaosylceramide (Gb3). globotriaosylceramide 40-61 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 63-66 19265719-1 2009 PURPOSE: Fabry disease, a genetic deficiency of alpha-galactosidase A, is characterized by pathogenic cellular accumulation of globotriaosylceramide. globotriaosylceramide 127-148 galactosidase alpha Homo sapiens 48-69 19202000-1 2009 The lysosomal storage disorder Fabry disease is characterized by excessive globotriaosylceramide (Gb3) accumulation in major organs such as the heart and kidney. globotriaosylceramide 75-96 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 98-101 19243984-0 2009 Falsely elevated urinary Gb3 (globotriaosylceramide, CTH, GL3). globotriaosylceramide 30-51 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 25-28 19265719-2 2009 During clinical trials, recombinant human alpha-galactosidase A (agalsidase beta; Fabrazyme, Genzyme Corporation, Cambridge, MA), infused intravenously at 1.0 mg/kg every 2 weeks for 6 months, cleared or reduced globotriaosylceramide in renal, cardiac, and dermal microvascular endothelia and other cells, with results sustained for up to 5 years in most patients evaluated. globotriaosylceramide 212-233 galactosidase alpha Homo sapiens 42-63 19169844-1 2009 Fabry disease is a complex, multisystemic and clinically heterogeneous disease with prominent urinary excretion of globotriaosylceramide (Gb(3)), the principal substrate of the deficient enzyme, alpha-galactosidase A. globotriaosylceramide 115-136 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 138-143 19169844-1 2009 Fabry disease is a complex, multisystemic and clinically heterogeneous disease with prominent urinary excretion of globotriaosylceramide (Gb(3)), the principal substrate of the deficient enzyme, alpha-galactosidase A. globotriaosylceramide 115-136 galactosidase alpha Homo sapiens 195-216 19180148-2 2009 Increased membrane globotriaosylceramide (Gb3/CD77) expression was observed; it is suggested that this finding may be potentially useful as a surrogate marker of disease severity. globotriaosylceramide 19-40 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 42-45 19282651-3 2009 Fabry"s disease is an X-linked lysosomal storage disorder caused by a deficiency of the enzyme alpha-galactosidase A, which results in progressive intracellular accumulation of globotriaosylceramide (Gb3) in various organs including the heart. globotriaosylceramide 177-198 galactosidase alpha Homo sapiens 95-116 19282651-3 2009 Fabry"s disease is an X-linked lysosomal storage disorder caused by a deficiency of the enzyme alpha-galactosidase A, which results in progressive intracellular accumulation of globotriaosylceramide (Gb3) in various organs including the heart. globotriaosylceramide 177-198 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 200-203 19013219-3 2009 From the results of immunocytochemical analysis, both HSP70 and HSC70 were constitutively expressed in globotriaosylceramide (Gb3)-expressing Raji cells as well as Gb3-negative K562 cells. globotriaosylceramide 103-124 heat shock protein family A (Hsp70) member 4 Homo sapiens 54-59 19013219-3 2009 From the results of immunocytochemical analysis, both HSP70 and HSC70 were constitutively expressed in globotriaosylceramide (Gb3)-expressing Raji cells as well as Gb3-negative K562 cells. globotriaosylceramide 103-124 heat shock protein family A (Hsp70) member 8 Homo sapiens 64-69 19013219-3 2009 From the results of immunocytochemical analysis, both HSP70 and HSC70 were constitutively expressed in globotriaosylceramide (Gb3)-expressing Raji cells as well as Gb3-negative K562 cells. globotriaosylceramide 103-124 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 126-129 19253940-7 2009 The strategy for the synthesis employed a Gb(3)-MUC5AC thioester cassette as a key building block. globotriaosylceramide 42-47 mucin 5AC, oligomeric mucus/gel-forming Homo sapiens 48-54 19037253-1 2009 Anderson-Fabry disease, an inherited deficiency in the lysosomal enzyme alpha-galactosidase A, is characterized by the progressive accumulation of globotriaosylceramide (Gb3), also known as CD77. globotriaosylceramide 147-168 galactosidase alpha Homo sapiens 72-93 19037253-1 2009 Anderson-Fabry disease, an inherited deficiency in the lysosomal enzyme alpha-galactosidase A, is characterized by the progressive accumulation of globotriaosylceramide (Gb3), also known as CD77. globotriaosylceramide 147-168 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 170-173 19037253-1 2009 Anderson-Fabry disease, an inherited deficiency in the lysosomal enzyme alpha-galactosidase A, is characterized by the progressive accumulation of globotriaosylceramide (Gb3), also known as CD77. globotriaosylceramide 147-168 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 190-194 19180148-2 2009 Increased membrane globotriaosylceramide (Gb3/CD77) expression was observed; it is suggested that this finding may be potentially useful as a surrogate marker of disease severity. globotriaosylceramide 19-40 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 46-50 18451534-1 2008 Silurus asotus lectin (SAL) is a member of the rhamnose-binding lectin (RBL) family, and recognizes globotriaosylceramide (Gb3) on the cell surface of Burkitt"s lymphoma cell lines, such as Raji and Daudi cells. globotriaosylceramide 100-121 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 123-126 19190807-2 2009 Binding of Stx to the glycosphingolipid (GSL) globotriaosylceramide (Gb3Cer/CD77) on endothelial cells followed by receptor-mediated endocytosis is the linchpin in STEC-mediated disease. globotriaosylceramide 46-67 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 76-80 18707907-1 2008 Fabry disease, an X-linked systemic vasculopathy, is caused by a deficiency of alpha-galactosidase A resulting in globotriaosylceramide (Gb(3)) storage in cells. globotriaosylceramide 114-135 galactosidase alpha Homo sapiens 79-100 18707907-1 2008 Fabry disease, an X-linked systemic vasculopathy, is caused by a deficiency of alpha-galactosidase A resulting in globotriaosylceramide (Gb(3)) storage in cells. globotriaosylceramide 137-143 galactosidase alpha Homo sapiens 79-100 18707907-5 2008 Increased Gb(3) also induced expression of intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin. globotriaosylceramide 10-15 intercellular adhesion molecule 1 Homo sapiens 43-76 18707907-5 2008 Increased Gb(3) also induced expression of intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin. globotriaosylceramide 10-15 vascular cell adhesion molecule 1 Homo sapiens 78-111 18707907-5 2008 Increased Gb(3) also induced expression of intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin. globotriaosylceramide 10-15 selectin E Homo sapiens 117-127 18707907-6 2008 Reduction of endogenous Gb(3) by treatment of the cells with an inhibitor of glycosphingolipid synthase or alpha-galactosidase A led to decreased expression of adhesion molecules. globotriaosylceramide 24-29 galactosidase alpha Homo sapiens 107-128 18564063-2 2008 STxB (Shiga toxin B-subunit) is known to bind the glycosphingolipid Gb3 (globotriaosyl ceramide), which is overexpressed by various human tumours. globotriaosylceramide 73-95 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 68-71 18757779-2 2008 Several studies have demonstrated that VT induces endothelial cell (EC) death via the VT receptor globotriaosylceramide (Gb3/CD77) leading to this symptom. globotriaosylceramide 98-119 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 121-124 18757779-2 2008 Several studies have demonstrated that VT induces endothelial cell (EC) death via the VT receptor globotriaosylceramide (Gb3/CD77) leading to this symptom. globotriaosylceramide 98-119 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 125-129 18754742-2 2008 Globotriaosylceramide (Gb(3)), the receptor for Stx2, was localized to neurons of the central nervous system (CNS) of normal mice. globotriaosylceramide 0-21 syntaxin 2 Mus musculus 48-52 18754742-2 2008 Globotriaosylceramide (Gb(3)), the receptor for Stx2, was localized to neurons of the central nervous system (CNS) of normal mice. globotriaosylceramide 23-29 syntaxin 2 Mus musculus 48-52 18565198-2 2008 Defective Gla results in multi-organ accumulation of neutral glycosphingolipids (GSLs), especially in the vascular endothelium, with the major GSL accumulated being globotriaosylceramide (Gb3). globotriaosylceramide 165-186 galactosidase, alpha Mus musculus 10-13 18565198-2 2008 Defective Gla results in multi-organ accumulation of neutral glycosphingolipids (GSLs), especially in the vascular endothelium, with the major GSL accumulated being globotriaosylceramide (Gb3). globotriaosylceramide 188-191 galactosidase, alpha Mus musculus 10-13 18522550-2 2008 In absence of enzyme replacement therapy (ERT), globotriaosylceramide (Gb3) accumulates in tissue, leading to progressive organ damage with severe renal, cardiac and central nervous system complications. globotriaosylceramide 48-69 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 71-74 18339187-2 2008 The subsequent accumulation of globotriaosylceramide (Gb3) in cells and tissues of the body has multisystemic effects and significantly impacts upon quality of life and survival of individuals with this condition. globotriaosylceramide 31-52 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 54-57 18297328-1 2008 UNLABELLED: Fabry disease is an X-linked lysosomal deficiency of alpha-galactosidase A that results in cellular accumulation of galactoconjugates, mainly globotriaosylceramide, particularly in blood vessels. globotriaosylceramide 154-175 galactosidase alpha Homo sapiens 65-86 18219591-0 2008 Naked plasmid DNA-based alpha-galactosidase A gene transfer partially reduces systemic accumulation of globotriaosylceramide in Fabry mice. globotriaosylceramide 103-124 galactosidase, alpha Mus musculus 24-45 18048405-4 2008 Globotriaosylceramide (Gb3) exists as a natural isomer for iGb3, and both isomers are frequently found together in mixtures of glycosphingolipids extracted from mammalian cell membranes. globotriaosylceramide 0-21 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 23-26 18086809-7 2008 Additionally, SB202190 reduced the cellular globotriaosylceramide content under LPS- and TNF-alpha-induced conditions. globotriaosylceramide 44-65 tumor necrosis factor Homo sapiens 89-98 18023222-1 2008 Fabry disease is a complex, multisystemic and clinically heterogeneous disease, in which the urinary excretion of globotriaosylceramide (Gb3), the principal substrate of the deficient enzyme, alpha-galactosidase A, is more prominent than the increased concentrations of the lipid in the plasma of affected hemizygotes and heterozygotes. globotriaosylceramide 114-135 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 137-140 18023222-1 2008 Fabry disease is a complex, multisystemic and clinically heterogeneous disease, in which the urinary excretion of globotriaosylceramide (Gb3), the principal substrate of the deficient enzyme, alpha-galactosidase A, is more prominent than the increased concentrations of the lipid in the plasma of affected hemizygotes and heterozygotes. globotriaosylceramide 114-135 galactosidase alpha Homo sapiens 192-213 18219591-1 2008 Fabry disease is an X-linked recessive inborn metabolic disorder in which a deficiency in lysosomal enzyme alpha-galactosidase A (Gal A) causes the systemic accumulation of globotriaosylceramide (Gb3). globotriaosylceramide 173-194 galactosidase, alpha Mus musculus 107-128 18219591-1 2008 Fabry disease is an X-linked recessive inborn metabolic disorder in which a deficiency in lysosomal enzyme alpha-galactosidase A (Gal A) causes the systemic accumulation of globotriaosylceramide (Gb3). globotriaosylceramide 173-194 galactosidase, alpha Mus musculus 130-135 18219591-1 2008 Fabry disease is an X-linked recessive inborn metabolic disorder in which a deficiency in lysosomal enzyme alpha-galactosidase A (Gal A) causes the systemic accumulation of globotriaosylceramide (Gb3). globotriaosylceramide 196-199 galactosidase, alpha Mus musculus 107-128 18219591-1 2008 Fabry disease is an X-linked recessive inborn metabolic disorder in which a deficiency in lysosomal enzyme alpha-galactosidase A (Gal A) causes the systemic accumulation of globotriaosylceramide (Gb3). globotriaosylceramide 196-199 galactosidase, alpha Mus musculus 130-135 17940933-4 2007 The enzyme deficiency leads to a progressive accumulation of globotriaosylceramide (Gb3) in various tissues and organ systems and is responsible for the large variability of the clinical signs and symptoms of the disease. globotriaosylceramide 61-82 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 84-87 17965340-3 2007 It is demonstrated in this study that Stx2 binds to human neutrophils by a non-classical mechanism that is independent of Gb(3). globotriaosylceramide 122-127 syntaxin 2 Homo sapiens 38-42 17965340-4 2007 In contrast, the investigation revealed that Stx2 binds to murine neutrophils by the classical Gb(3)-dependent mechanism. globotriaosylceramide 95-100 syntaxin 2 Mus musculus 45-49 17849232-1 2007 Fabry disease, or alpha-galactosidase A (alpha-Gal A) deficiency, is a lysosomal storage disorder in which accumulation of globotriaosylceramide (Gb(3)) is thought to be responsible for the development of renal, cardiac and cerebral complications. globotriaosylceramide 123-144 galactosidase alpha Homo sapiens 18-39 17849232-1 2007 Fabry disease, or alpha-galactosidase A (alpha-Gal A) deficiency, is a lysosomal storage disorder in which accumulation of globotriaosylceramide (Gb(3)) is thought to be responsible for the development of renal, cardiac and cerebral complications. globotriaosylceramide 123-144 galactosidase alpha Homo sapiens 41-52 17849232-1 2007 Fabry disease, or alpha-galactosidase A (alpha-Gal A) deficiency, is a lysosomal storage disorder in which accumulation of globotriaosylceramide (Gb(3)) is thought to be responsible for the development of renal, cardiac and cerebral complications. globotriaosylceramide 146-151 galactosidase alpha Homo sapiens 18-39 17849232-1 2007 Fabry disease, or alpha-galactosidase A (alpha-Gal A) deficiency, is a lysosomal storage disorder in which accumulation of globotriaosylceramide (Gb(3)) is thought to be responsible for the development of renal, cardiac and cerebral complications. globotriaosylceramide 146-151 galactosidase alpha Homo sapiens 41-52 18022018-1 2007 Fabry disease, an X-linked recessive glycolipid storage disease, is caused by a deficiency of the lysosomal enzyme alpha-galactosidase A (alpha-Gal A), which cleaves a fatty substance called globotriaosylceramide (GL3). globotriaosylceramide 191-212 galactosidase alpha Homo sapiens 115-136 18022018-1 2007 Fabry disease, an X-linked recessive glycolipid storage disease, is caused by a deficiency of the lysosomal enzyme alpha-galactosidase A (alpha-Gal A), which cleaves a fatty substance called globotriaosylceramide (GL3). globotriaosylceramide 191-212 galactosidase alpha Homo sapiens 138-149 17570073-9 2007 Over the years, we have established a dynamic process, developing techniques or new reagents to detect as many treatable disorders as possible, now evaluating macromolecules associated with lysosomal storage disorders, mainly globotriaosylceramide (Gb3) for Fabry disease. globotriaosylceramide 226-247 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 249-252 17697536-1 2007 Fabry"s disease, a disorder affecting the gene for the lysosomal enzyme alpha-galactosidase A (alpha-GAL A), can cause accumulation of globotriaosylceramide (GL-3) in the vascular endothelial cells. globotriaosylceramide 135-156 galactosidase, alpha Mus musculus 72-93 17535804-0 2007 Caveolin-associated accumulation of globotriaosylceramide in the vascular endothelium of alpha-galactosidase A null mice. globotriaosylceramide 36-57 galactosidase, alpha Mus musculus 89-110 17535804-2 2007 The enzymatic defect results in the deposition of globotriaosylceramide (Gb3) in the vascular endothelium. globotriaosylceramide 50-71 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 73-76 17697536-1 2007 Fabry"s disease, a disorder affecting the gene for the lysosomal enzyme alpha-galactosidase A (alpha-GAL A), can cause accumulation of globotriaosylceramide (GL-3) in the vascular endothelial cells. globotriaosylceramide 135-156 galactosidase, alpha Mus musculus 95-106 17395657-1 2007 BACKGROUND: Fabry disease (FD) is caused by an X-linked deficiency in the activity of alpha-galactosidase A and the resultant accumulation of globotriaosylceramide (Gb3) in multiple tissues. globotriaosylceramide 142-163 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 165-168 17409312-1 2007 Fabry disease, an inherited deficiency of the lysosomal enzyme alpha-galactosidase A, causes progressive intralysosomal accumulation of globotriaosylceramide (GL-3) and premature death from renal, cardiac, and cerebrovascular manifestations. globotriaosylceramide 136-157 galactosidase alpha Homo sapiens 63-84 17160925-2 2006 DEVELOPMENT: Fabry disease is a hereditary deficiency of lisosomal alpha-galactosidase A resulting in accumulation of globotriaosylceramide in vascular endothelium and smooth-muscle cells. globotriaosylceramide 118-139 galactosidase alpha Homo sapiens 67-88 17336267-3 2007 Engagement of Gb(3)/CD77 with SLT-B reduced the amount of CD20 and CXCR4 available, but levels of BCR, MHC Class II, CD21, CD27 and CD54 remained unchanged. globotriaosylceramide 14-19 keratin 20 Homo sapiens 58-62 17336267-3 2007 Engagement of Gb(3)/CD77 with SLT-B reduced the amount of CD20 and CXCR4 available, but levels of BCR, MHC Class II, CD21, CD27 and CD54 remained unchanged. globotriaosylceramide 14-19 C-X-C motif chemokine receptor 4 Homo sapiens 67-72 17336267-3 2007 Engagement of Gb(3)/CD77 with SLT-B reduced the amount of CD20 and CXCR4 available, but levels of BCR, MHC Class II, CD21, CD27 and CD54 remained unchanged. globotriaosylceramide 14-19 CD27 molecule Homo sapiens 123-127 17409683-0 2007 [Regulation of globotriaosylceramide (Gb3)-mediated signal transduction by rhamnose-binding lectin]. globotriaosylceramide 15-36 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 38-41 17409683-1 2007 Silurus asotus (catfish) egg lectin (SAL) has potent affinity to Gal alpha-linked carbohydrate chains of not only glycoproteins but also glycosphingolipids such as globotriaosylceramide (Gb3). globotriaosylceramide 164-185 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 187-190 17171433-1 2007 Fabry disease is an X-linked lysosomal storage disorder of glycosphingolipid catabolism resulting from a deficiency of the enzyme alpha-galactosidase A, and leading to the progressive accumulation of one biomarker, globotriaosylceramide (Gb(3)), predominantly elevated in the urine of these patients. globotriaosylceramide 215-236 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 238-243 17336267-7 2007 Thus, the binding of Gb(3)/CD77 by its cognate ligand transmits information within the lipid bilayer of model lymphoma cells to impact the behaviour of selective proteins, most notably CD20, via a mechanism influenced by the level of cholesterol within the membrane. globotriaosylceramide 21-26 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 27-31 17336267-7 2007 Thus, the binding of Gb(3)/CD77 by its cognate ligand transmits information within the lipid bilayer of model lymphoma cells to impact the behaviour of selective proteins, most notably CD20, via a mechanism influenced by the level of cholesterol within the membrane. globotriaosylceramide 21-26 keratin 20 Homo sapiens 185-189 17371887-1 2007 Fabry disease is an X-linked, hereditary, lysosomal storage disease caused by deficiency of the enzyme alpha-galactosidase A, which results in the accumulation of the neutral glycosphingolipid globotriaosylceramide (Gb3) in the walls of small blood vessels, nerves, dorsal root ganglia, renal glomerular and tubular epithelial cells, and cardiomyocytes. globotriaosylceramide 193-214 galactosidase alpha Homo sapiens 103-124 17371887-1 2007 Fabry disease is an X-linked, hereditary, lysosomal storage disease caused by deficiency of the enzyme alpha-galactosidase A, which results in the accumulation of the neutral glycosphingolipid globotriaosylceramide (Gb3) in the walls of small blood vessels, nerves, dorsal root ganglia, renal glomerular and tubular epithelial cells, and cardiomyocytes. globotriaosylceramide 193-214 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 216-219 17287429-1 2007 Deficiency of lysosomal alpha-galactosidase A (alpha-Gal A) in Fabry disease results in cellular accumulation of globotriaosylceramide (Gl3), often leading to end-stage renal failure. globotriaosylceramide 113-134 galactosidase alpha Homo sapiens 24-45 17287429-1 2007 Deficiency of lysosomal alpha-galactosidase A (alpha-Gal A) in Fabry disease results in cellular accumulation of globotriaosylceramide (Gl3), often leading to end-stage renal failure. globotriaosylceramide 113-134 galactosidase alpha Homo sapiens 47-58 16991089-1 2006 Fabry disease is an X-linked recessive disorder in which affected persons lack alpha-galactosidase A (alpha -GalA), which leads to excess glycosphingolipids in tissues, mainly globotriaosylceramide (Gb3). globotriaosylceramide 176-197 galactosidase alpha Homo sapiens 79-100 16991089-1 2006 Fabry disease is an X-linked recessive disorder in which affected persons lack alpha-galactosidase A (alpha -GalA), which leads to excess glycosphingolipids in tissues, mainly globotriaosylceramide (Gb3). globotriaosylceramide 176-197 galactosidase alpha Homo sapiens 102-113 16991089-1 2006 Fabry disease is an X-linked recessive disorder in which affected persons lack alpha-galactosidase A (alpha -GalA), which leads to excess glycosphingolipids in tissues, mainly globotriaosylceramide (Gb3). globotriaosylceramide 176-197 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 199-202 16898255-1 2006 The neurological manifestations of Fabry disease include both peripheral and central nervous system involvement caused by a deficiency of alpha-galactosidase A and accumulation of alpha-D-galactosyl moieties, particularly globotriosylceramide accumulation (Gb3). globotriaosylceramide 222-242 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 257-260 17043001-2 2006 Lack of enzyme activity results in progressive accumulation of globotriaosylceramide (Gb3) leading to multiorgan dysfunction and early death. globotriaosylceramide 63-84 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 86-89 17073606-1 2006 Fabry disease is caused by a deficiency of a-galactosidase A which leads to the progressive intra-lysosomal accumulation of ceramide trihexoside (CTH), also known as globotriaosylceramide (Gb3), in different cell types and body fluids. globotriaosylceramide 166-187 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 189-192 16970764-1 2006 BACKGROUND: Fabry disease is an X-linked disorder due to a deficiency of alpha-galactosidase A and leads to the accumulation of globotriaosylceramide (Gb3) in various cells. globotriaosylceramide 128-149 galactosidase alpha Homo sapiens 73-94 16970764-1 2006 BACKGROUND: Fabry disease is an X-linked disorder due to a deficiency of alpha-galactosidase A and leads to the accumulation of globotriaosylceramide (Gb3) in various cells. globotriaosylceramide 128-149 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 151-154 16439866-1 2006 OBJECTIVE: To determine the effect of a gp120 binding, non-cytotoxic soluble analogue of the glycosphingolipid (GSL), globotriaosyl ceramide (Gb3) on HIV infection in vitro. globotriaosylceramide 118-140 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 40-45 16713681-5 2006 The peptide bound strongly to Stx-1 and Stx-2, though the binding was inhibited with Gb3Cer. globotriaosylceramide 85-91 syntaxin 1A Homo sapiens 30-35 16713681-5 2006 The peptide bound strongly to Stx-1 and Stx-2, though the binding was inhibited with Gb3Cer. globotriaosylceramide 85-91 syntaxin 2 Homo sapiens 40-45 16595957-1 2006 A two-step binding assay for globotriaosylceramide (Gb3) content was developed by histidine-tagging strategy, which is a well-established method for the purification of recombinant proteins. globotriaosylceramide 29-50 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 52-55 16609685-1 2006 Enzyme replacement therapy (ERT) with recombinant human alpha-galactosidase A (r-halphaGalA) enhances microvascular globotriaosylceramide clearance and improves clinical symptoms in patients with Fabry disease. globotriaosylceramide 116-137 galactosidase alpha Homo sapiens 56-77 16495579-1 2006 We previously developed linear polymers bearing clustered trisaccharides of globotriaosylceramide (Gb3) as orally applicable Shiga toxin (Stx) neutralizers. globotriaosylceramide 76-97 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 99-102 21290687-1 2006 Globotriaosylceramide (Gb3) deposits are found in nearly all cardiac structures, including the myocardium, endocardium, endothelium and conduction cells, and in the autonomic nervous system. globotriaosylceramide 0-21 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 23-26 16601877-1 2006 Fabry disease (McKusick 301500) is an X-linked lysosomal storage disorder secondary to deficient alpha-galactosidase A activity which leads to the widespread accumulation of globotriaosylceramide (Gb(3)) and related glycosphingolipids, especially in vascular smooth-muscle and endothelial cells. globotriaosylceramide 174-195 galactosidase alpha Homo sapiens 97-118 21290697-2 2006 All classic hemizygotes and over 90% of heterozygotes have an elevated level of urinary globotriaosylceramide (Gb3 ). globotriaosylceramide 88-109 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 111-114 16403380-4 2005 Fabry disease is an x-linked recessive disorder in which deficiency of the lysosomal enzyme alpha-galactosidase A leads to progressive accumulation of globotriaosylceramide in vital organs. globotriaosylceramide 151-172 galactosidase alpha Homo sapiens 92-113 16432775-2 2006 In consequence, globotriaosylceramide (Gb3) accumulates in nearly all tissues and body fluids. globotriaosylceramide 16-37 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 39-42 16802573-3 2006 With increasing age globotriaosylceramide (Gb3) progressively accumulates in different cells, tissues and organs throughout the body. globotriaosylceramide 20-41 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 43-46 16287034-2 2006 Globotriaosylceramides (Gb(3)) are biological compounds implicated in Fabry disease, a lysosomal storage disease due to the deficient activity of alpha-D-galactosidase A, which results in an accumulation of Gb(3) in many organs. globotriaosylceramide 0-22 galactosidase alpha Homo sapiens 146-169 16287034-2 2006 Globotriaosylceramides (Gb(3)) are biological compounds implicated in Fabry disease, a lysosomal storage disease due to the deficient activity of alpha-D-galactosidase A, which results in an accumulation of Gb(3) in many organs. globotriaosylceramide 24-29 galactosidase alpha Homo sapiens 146-169 16287034-2 2006 Globotriaosylceramides (Gb(3)) are biological compounds implicated in Fabry disease, a lysosomal storage disease due to the deficient activity of alpha-D-galactosidase A, which results in an accumulation of Gb(3) in many organs. globotriaosylceramide 207-212 galactosidase alpha Homo sapiens 146-169 17236300-1 2006 Anderson Fabry disease (alpha galactosidase A deficiency) is an X-linked recessive lysosomal storage disorder; alpha galactosidase A deficiency results in accumulation of neutral glycosphingolipids, especially globotriaosylceramide (Gb3), in various cell types promoting development of disease with renal, cardiovascular, and cerebrovascular involvement. globotriaosylceramide 210-231 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 233-236 16365318-6 2005 Transfection of Gb(3) synthase, resulting in Gb(3) expression in noncancerous polarized epithelial cells lacking endogenous Gb(3), induced cell invasiveness. globotriaosylceramide 45-50 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 16-30 16148726-1 2005 Fabry disease is a rare X-linked lysosomal storage disorder caused by deficient activity of alpha-galactosidase A (alpha-Gal A) resulting in the storage of glycosphingolipids, especially globotriaosylceramide (Gb3), in cells throughout the body, causing life-threatening renal, cardiac, and cerebrovascular complications in hemizygous males and some heterozygous females. globotriaosylceramide 187-208 galactosidase alpha Homo sapiens 92-113 16148726-1 2005 Fabry disease is a rare X-linked lysosomal storage disorder caused by deficient activity of alpha-galactosidase A (alpha-Gal A) resulting in the storage of glycosphingolipids, especially globotriaosylceramide (Gb3), in cells throughout the body, causing life-threatening renal, cardiac, and cerebrovascular complications in hemizygous males and some heterozygous females. globotriaosylceramide 187-208 galactosidase alpha Homo sapiens 115-126 16148726-1 2005 Fabry disease is a rare X-linked lysosomal storage disorder caused by deficient activity of alpha-galactosidase A (alpha-Gal A) resulting in the storage of glycosphingolipids, especially globotriaosylceramide (Gb3), in cells throughout the body, causing life-threatening renal, cardiac, and cerebrovascular complications in hemizygous males and some heterozygous females. globotriaosylceramide 187-208 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 210-213 15895708-1 2005 UNLABELLED: Fabry disease is a rare, X-linked lysosomal storage disease caused by an inborn deficiency of alpha-galactosidase A, which results in progressive accumulation of globotriaosylceramide in a range of cells and tissues. globotriaosylceramide 174-195 galactosidase alpha Homo sapiens 106-127 16210890-1 2005 BACKGROUND: Fabry disease is a rare X-linked disorder that results from a deficiency in a lysosomal enzyme known as alpha-galactosidase A, with accumulation of globotriaosylceramide (Gl3). globotriaosylceramide 160-181 galactosidase alpha Homo sapiens 116-137 15959771-1 2005 Fabry disease (FD) is an X-linked inborn error of glycosphingolipid (GSL) metabolism, caused by a deficiency of the lysosomal alpha-galactosidase A, which results in high levels in lysosomes and biological fluids of globotriaosylceramide (Gb3) and digalactosylceramide (Ga2), also known as galabiosylceramide. globotriaosylceramide 216-237 galactosidase alpha Homo sapiens 126-147 16165112-3 2005 The populations express high, medium, and low levels of globotriaosylceramide as determined by the binding of the Stx1B reagent. globotriaosylceramide 56-77 syntaxin 1B Homo sapiens 114-119 15744065-1 2005 Rhamnose-binding lectin from catfish (Silurus asotus) eggs (SAL) has the ability to induce externalization of phosphatidylserine (PS), followed by cell shrinkage in globotriaosylceramide (Gb3)-expressing Burkitt"s lymphoma Raji cells. globotriaosylceramide 165-186 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 188-191 15895713-1 2005 AIM: The aim of this study was to determine whether globotriaosylceramide (Gb3) is a useful biomarker in Fabry disease. globotriaosylceramide 52-73 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 75-78 15880667-1 2005 Globotriaosylceramide is a neutral glycolipid containing the trihexoside Gal(alpha1-4)Gal(ss1-4)Glc(ss1-1") covalently bound to N-acylsphingosine. globotriaosylceramide 0-21 adrenoceptor alpha 1D Homo sapiens 77-85 16151903-2 2005 It results from a deficiency of the lysosomal alpha-galactosidase A and leads to progressive accumulation of globotriaosylceramide in the endothelium and tissue cells of various organs. globotriaosylceramide 109-130 galactosidase alpha Homo sapiens 46-67 15320778-2 2004 The disease occurs due to deficient activity of alpha-galactosidase A, leading to progressive accumulation of globotriaosylceramide in multiple organs and tissues. globotriaosylceramide 110-131 galactosidase alpha Homo sapiens 48-69 15702403-1 2005 Anderson-Fabry disease (referred to as Fabry disease) is an X-linked disorder characterized by a deficiency of the lysosomal enzyme alpha-galactosidase A and the subsequent accumulation in various tissues of globotriaosylceramide (Gb(3)), the main substrate of the defective enzyme. globotriaosylceramide 231-236 galactosidase alpha Homo sapiens 132-153 15702403-9 2005 In one patient, after several months of ERT, there was a transient increase in Gb(3) concentrations to baseline (pre-ERT) levels, associated with the presence of antibodies to the recombinant alpha-galactosidase A. globotriaosylceramide 79-84 galactosidase alpha Homo sapiens 192-213 15702404-2 2005 This deficiency leads to the progressive accumulation, in lysosomes of visceral tissues and in body fluids of hemizygotes, of the glycosphingolipids globotriaosylceramide (CTH, Gb(3) or GL-3) and galabiosylceramide (CDH) and to a lesser extent the blood group AB and B related glycolipids. globotriaosylceramide 149-170 V-set and immunoglobulin domain containing 2 Homo sapiens 172-175 14989466-1 2003 AIM: To evaluate the sequelae of the lysosomal storage of globotriaosylceramide (Gb3) in a series of patients with Fabry disease. globotriaosylceramide 58-79 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 81-84 15039308-5 2004 The majority of Gb(3)/CD77(+) cells were activated CD3(+) CD6(+) CD8 alpha(+) T cells, whereas only some CD4(+) T cells and B cells expressed Gb(3)/CD77. globotriaosylceramide 16-21 CD8a molecule Bos taurus 65-74 15102080-2 2004 These disturbances are caused by cellular globotriaosylceramide accumulation in the skin due to deficient lysosomal alpha-galactosidase A activity. globotriaosylceramide 42-63 galactosidase alpha Homo sapiens 116-137 14716680-1 2004 BACKGROUND: Fabry disease is a recessive, X-linked disorder caused by a deficiency of the lysosomal enzyme alpha-galactosidase A, leading to an accumulation of the glycosphingolipid globotriaosylceramide (GL-3) in most tissues of the body. globotriaosylceramide 182-203 galactosidase, alpha Mus musculus 107-128 15458455-1 2004 BACKGROUND: Fabry disease is an X-linked inherited disorder that is caused by excessive lysosomal globotriaosylceramide (CTH) storage due to a deficiency in alpha-galactosidase A (alpha-Gal A). globotriaosylceramide 98-119 galactosidase alpha Homo sapiens 157-178 15458455-1 2004 BACKGROUND: Fabry disease is an X-linked inherited disorder that is caused by excessive lysosomal globotriaosylceramide (CTH) storage due to a deficiency in alpha-galactosidase A (alpha-Gal A). globotriaosylceramide 98-119 galactosidase alpha Homo sapiens 180-191 15458455-1 2004 BACKGROUND: Fabry disease is an X-linked inherited disorder that is caused by excessive lysosomal globotriaosylceramide (CTH) storage due to a deficiency in alpha-galactosidase A (alpha-Gal A). globotriaosylceramide 121-124 galactosidase alpha Homo sapiens 157-178 15458455-1 2004 BACKGROUND: Fabry disease is an X-linked inherited disorder that is caused by excessive lysosomal globotriaosylceramide (CTH) storage due to a deficiency in alpha-galactosidase A (alpha-Gal A). globotriaosylceramide 121-124 galactosidase alpha Homo sapiens 180-191 15288673-5 2004 The main substance accumulated is globotriaosylceramide (Gb3). globotriaosylceramide 34-55 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 57-60 15135109-8 2004 Finally, this method was applied to detect the excess of one of the neutral sphingolipids, namely globotriaosylceramide (Gb3) in the urine of patients affected with Fabry disease. globotriaosylceramide 98-119 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 121-124 15365954-2 2004 The deficiency leads to progressive glycosphingolipid globotriaosylceramide (Gb3) accumulation in fluids and tissues, including vascular endothelium, connective tissue, kidney, heart, brain and peripheral nerves. globotriaosylceramide 54-75 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 77-80 14973368-1 2004 Purified renal globotriaosyl ceramide (Gb3)/cholesterol mixtures sonicated heated in a Triton-containing buffer placed below a discontinuous sucrose gradient form glycosphingolipid (GSL)-containing dense lipid structures at the 30/5% sucrose interface after centrifugation. globotriaosylceramide 15-37 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 39-42 12624185-1 2003 Fabry disease is an X-linked recessive inborn metabolic disorder characterized by systemic and vascular accumulation of globotriaosylceramide (Gb(3)) caused by a deficiency of the lysosomal enzyme alpha-galactosidase A (alpha-gal A). globotriaosylceramide 120-141 galactosidase, alpha Mus musculus 197-218 12624185-1 2003 Fabry disease is an X-linked recessive inborn metabolic disorder characterized by systemic and vascular accumulation of globotriaosylceramide (Gb(3)) caused by a deficiency of the lysosomal enzyme alpha-galactosidase A (alpha-gal A). globotriaosylceramide 120-141 galactosidase, alpha Mus musculus 220-231 12624185-1 2003 Fabry disease is an X-linked recessive inborn metabolic disorder characterized by systemic and vascular accumulation of globotriaosylceramide (Gb(3)) caused by a deficiency of the lysosomal enzyme alpha-galactosidase A (alpha-gal A). globotriaosylceramide 143-148 galactosidase, alpha Mus musculus 197-218 12624185-1 2003 Fabry disease is an X-linked recessive inborn metabolic disorder characterized by systemic and vascular accumulation of globotriaosylceramide (Gb(3)) caused by a deficiency of the lysosomal enzyme alpha-galactosidase A (alpha-gal A). globotriaosylceramide 143-148 galactosidase, alpha Mus musculus 220-231 12580945-2 2003 The potent cytotoxic activity of VTs is important in pathogenicity, resulting in the death of cells expressing receptor Gb3 (globotriaosylceramide). globotriaosylceramide 125-146 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 120-123 12645583-7 2003 Analysis of their structures with glycosphingolipid-specific antibodies and negative secondary ion mass spectrometry identified them as globotriaosylceramide (Gb3) and globotetraosylceramide (Gb4). globotriaosylceramide 136-157 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 159-162 12364551-0 2002 A novel soluble analog of the HIV-1 fusion cofactor, globotriaosylceramide (Gb(3)), eliminates the cholesterol requirement for high affinity gp120/Gb(3) interaction. globotriaosylceramide 53-74 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 76-81 12538729-5 2003 In this model, Gla-/0 mice displayed a progressive age-dependent shortening of the time to occlusive thrombosis after vascular injury that correlated with progressive accumulation of globotriasylceramide (Gb3) in the arterial wall. globotriaosylceramide 205-208 galactosidase, alpha Mus musculus 15-18 12540565-6 2003 Closely following the change in ceramide level was an increase in the expression of globotriaosylceramide (Gb3), the receptor for Stx2. globotriaosylceramide 84-105 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 107-110 12540565-6 2003 Closely following the change in ceramide level was an increase in the expression of globotriaosylceramide (Gb3), the receptor for Stx2. globotriaosylceramide 84-105 syntaxin 2 Homo sapiens 130-134 12413469-0 2002 Self-assembled monolayers of globotriaosylceramide (Gb3) mimics: surface-specific affinity with shiga toxins. globotriaosylceramide 29-50 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 52-55 12232838-3 2002 However, exposure of human brain endothelial cells (HBECs) to tumor necrosis factor (TNF) and/or interleukin (IL)-1 markedly up-regulates Stx receptor (globotriaosylceramide; Gb3) expression and cytotoxicity. globotriaosylceramide 152-173 tumor necrosis factor Homo sapiens 62-83 12232838-3 2002 However, exposure of human brain endothelial cells (HBECs) to tumor necrosis factor (TNF) and/or interleukin (IL)-1 markedly up-regulates Stx receptor (globotriaosylceramide; Gb3) expression and cytotoxicity. globotriaosylceramide 152-173 tumor necrosis factor Homo sapiens 85-88 12232838-3 2002 However, exposure of human brain endothelial cells (HBECs) to tumor necrosis factor (TNF) and/or interleukin (IL)-1 markedly up-regulates Stx receptor (globotriaosylceramide; Gb3) expression and cytotoxicity. globotriaosylceramide 152-173 interleukin 1 alpha Homo sapiens 97-115 12364551-0 2002 A novel soluble analog of the HIV-1 fusion cofactor, globotriaosylceramide (Gb(3)), eliminates the cholesterol requirement for high affinity gp120/Gb(3) interaction. globotriaosylceramide 53-74 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 141-146 12364551-0 2002 A novel soluble analog of the HIV-1 fusion cofactor, globotriaosylceramide (Gb(3)), eliminates the cholesterol requirement for high affinity gp120/Gb(3) interaction. globotriaosylceramide 53-74 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 147-152 12395219-2 2002 The deficiency of alpha-galactosidase A leads to a progressive accumulation of globotriaosylceramide (Gb(3)), the major glycosphingolipid substrate of the enzyme, within vulnerable cells, tissues, and organs, including the cardiovascular system. globotriaosylceramide 79-100 galactosidase alpha Homo sapiens 18-39 12395219-2 2002 The deficiency of alpha-galactosidase A leads to a progressive accumulation of globotriaosylceramide (Gb(3)), the major glycosphingolipid substrate of the enzyme, within vulnerable cells, tissues, and organs, including the cardiovascular system. globotriaosylceramide 102-108 galactosidase alpha Homo sapiens 18-39 11838967-2 2001 Globotriaosyl ceramide (CD77), a marker for germinal center B-cells, is present on Daudi cells but is deficient in the Daudi-derived mutant VT500 cell line. globotriaosylceramide 0-22 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 24-28 12082546-2 2002 Verotoxin 1 (VT1) is an Escherichia coli toxin, which has recently been shown to have anti-neoplastic action by targeting the globotriosylceramide (Gb(3)) glycolipid on tumor cells and tumor neovasculature. globotriaosylceramide 126-146 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 148-153 12053080-1 2002 Anderson-Fabry disease (AFd) is a rare X-linked disorder characterized by deficiency of alpha-galactosidase A that leads to systemic accumulation of neutral glycosphingolipids, predominantly globotriaosylceramide (Gb3), in body fluids and visceral tissues, including the kidney. globotriaosylceramide 191-212 galactosidase alpha Homo sapiens 88-109 12203240-1 2002 A method for measuring globotriaosylceramide (Gb3, or GL3) levels in plasma and urine of humans affected by Anderson-Fabry disease has been developed. globotriaosylceramide 23-44 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 46-49 11908825-1 2001 We determined the binding of verotoxin-1 (VT1) and verotoxin-2 (VT2) against globotriaosylceramide (Gb3) by a monoclonal antibody (mAb)-based enzyme-linked immunosorbent assay (ELISA). globotriaosylceramide 77-98 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 100-103 12191968-1 2002 Cellular injury in post-diarrheal hemolytic-uremic syndrome (D+HUS) is related to shigatoxin (Stx) binding to globotriaosylceramide (Gb3). globotriaosylceramide 110-131 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 133-136 12374217-5 2002 Nonlinear regression analysis of direct binding assay to these Gb3 isoforms confirmed the increased affinity of both toxins for the C22 hydroxylated Gb3. globotriaosylceramide 63-66 Sp7 transcription factor 7 Mus musculus 132-135 12027559-3 2002 Fabry disease is caused by a deficiency of the lysosomal hydrolase alpha-galactosidase A, resulting in the abnormal deposition of the glycosphingolipid globotriaosylceramide (GL-3) in vascular lysosomes. globotriaosylceramide 152-173 galactosidase, alpha Mus musculus 67-88 11890871-1 2002 Anderson-Fabry disease (AFD) is a lysosomal storage disorder (LSD) due to alpha-galactosidase A (alpha-Gal A) deficiency and the resultant accumulation of incompletely metabolised glycosphingolipids (GSLs), primarily globotriosylceramide (Gb(3)), within various tissues. globotriaosylceramide 217-237 galactosidase alpha Homo sapiens 97-108 11890871-1 2002 Anderson-Fabry disease (AFD) is a lysosomal storage disorder (LSD) due to alpha-galactosidase A (alpha-Gal A) deficiency and the resultant accumulation of incompletely metabolised glycosphingolipids (GSLs), primarily globotriosylceramide (Gb(3)), within various tissues. globotriaosylceramide 239-245 galactosidase alpha Homo sapiens 97-108 11726142-3 2001 Attachment of the B subunit of VTs to its receptor, globotriaosylceramide (Gb3), at gut epithelium is the primary step and, consequently, the A subunit of VTs inhibits protein synthesis in the target cell. globotriaosylceramide 52-73 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 75-78 11453701-8 2001 One possibility for this is that the more extensive binding of the Stx to the kidney tissue of the paediatric patient might be due to the higher synthesis and expression of Stx receptors, i.e. Gb(3), in infants and less so in the aged individuals. globotriaosylceramide 193-198 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2 Homo sapiens 67-70 11604159-0 2001 Globotriaosylceramide (Gb(3)/CD77) is synthesized and surface expressed by bovine lymphocytes upon activation in vitro. globotriaosylceramide 0-21 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 29-33 11604159-12 2001 However, stimulation induced an increase of CMH and Gb(3) by a factor of 2.5 and 10, respectively, implicating that bovine lymphocytes regulate surface expression of Gb(3)/CD77 predominantly by quantitative changes in the Gb(3) metabolism. globotriaosylceramide 166-171 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 172-176 11604159-12 2001 However, stimulation induced an increase of CMH and Gb(3) by a factor of 2.5 and 10, respectively, implicating that bovine lymphocytes regulate surface expression of Gb(3)/CD77 predominantly by quantitative changes in the Gb(3) metabolism. globotriaosylceramide 166-171 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 172-176 11604159-13 2001 This report presents Gb(3)/CD77 as the first GSL identified on bovine immune cells and highly recommends this activation dependent antigen as a useful tool to investigate lymphocyte activation within the bovine immune system. globotriaosylceramide 21-26 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 27-31 11571244-1 2001 BACKGROUND: Fabry disease is an X-linked lysosomal deficiency of alpha-galactosidase A that results in cellular accumulation of galacto-conjugates such as globotriosylceramide, particularly in blood vessels. globotriaosylceramide 155-175 galactosidase alpha Homo sapiens 65-86 11453701-8 2001 One possibility for this is that the more extensive binding of the Stx to the kidney tissue of the paediatric patient might be due to the higher synthesis and expression of Stx receptors, i.e. Gb(3), in infants and less so in the aged individuals. globotriaosylceramide 193-198 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2 Homo sapiens 173-176 11439963-8 2001 Patients in the recombinant alpha-galactosidase A group also had decreased microvascular endothelial deposits of globotriaosylceramide in the skin (P<0.001) and heart (P<0.001). globotriaosylceramide 113-134 galactosidase alpha Homo sapiens 28-49 11439963-10 2001 After six months of open-label therapy, all patients in the former placebo group and 98 percent of patients in the former recombinant alpha-galactosidase A group who had biopsies had clearance of microvascular endothelial deposits of globotriaosylceramide. globotriaosylceramide 234-255 galactosidase alpha Homo sapiens 134-155 11439963-13 2001 CONCLUSIONS: Recombinant alpha-galactosidase A replacement therapy cleared microvascular endothelial deposits of globotriaosylceramide from the kidneys, heart, and skin in patients with Fabry"s disease, reversing the pathogenesis of the chief clinical manifestations of this disease. globotriaosylceramide 113-134 galactosidase alpha Homo sapiens 25-46 11369233-3 2001 SLT-1 binds to the glycolipid globotriaosylceramide [3, 4], which acts as a shuttle, allowing the toxin to be imported and routed near ribosomes. globotriaosylceramide 30-51 unconventional SNARE in the ER 1 Homo sapiens 0-5 11437603-1 2001 A new single-step purification method for Shiga toxin (Stx) was developed using receptor-mediated affinity chromatography, in which Gb3Cer (globotriaosylceramide) was conjugated to octyl Sepharose CL-4B as a carrier. globotriaosylceramide 140-161 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 132-135 11418306-1 2001 The ribosome-inactivating protein, Shiga-like toxin-1 (SLT-1, SLT-I, Verotoxin 1, VT1) targets cells that express the glycolipid globotriaosylceramide (CD77) on their surface. globotriaosylceramide 129-150 unconventional SNARE in the ER 1 Homo sapiens 35-53 11418306-1 2001 The ribosome-inactivating protein, Shiga-like toxin-1 (SLT-1, SLT-I, Verotoxin 1, VT1) targets cells that express the glycolipid globotriaosylceramide (CD77) on their surface. globotriaosylceramide 129-150 unconventional SNARE in the ER 1 Homo sapiens 55-60 11418306-1 2001 The ribosome-inactivating protein, Shiga-like toxin-1 (SLT-1, SLT-I, Verotoxin 1, VT1) targets cells that express the glycolipid globotriaosylceramide (CD77) on their surface. globotriaosylceramide 129-150 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 152-156 11264150-6 2001 Exogenously added GlcCer and the homologous Glc-containing globotriaosylceramide (Gb3Cer), but not galactosylceramide, dose-dependently prolonged clotting times of normal plasma in the presence, but not absence, of APC:protein S, which suggests that GlcCer or Gb3Cer can enhance protein C pathway anticoagulant activity. globotriaosylceramide 59-80 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 82-85 11158156-1 2001 The relationship between differential susceptibility to hemolytic-uremic syndrome (HUS) and levels of globotriaosylceramide (Gb3) in serum was studied in patients infected with verotoxin-producing Escherichia coli (VTEC). globotriaosylceramide 102-123 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 125-128 11249924-0 2001 Quantified increases of cholesterol, total lipid and globotriaosylceramide in filipin-positive Niemann-Pick type C fibroblasts. globotriaosylceramide 53-74 protein interacting with PRKCA 1 Homo sapiens 103-107 11249924-7 2001 Another increase found in the NPC cells was that of a minor lipid fraction, globotriaosylceramide (Gb3, known as a cell signalling glycolipid). globotriaosylceramide 76-97 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 99-102 11201791-6 2000 Using this approach, we identified globotriaosylceramide (Gb3) and ganglioside GM3 as the main lymphocyte GSL recognized by gp120. globotriaosylceramide 35-56 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 58-61 11758681-2 2001 This leads to systemic accumulation of the glycosphingolipid globotriaosylceramide (Gb3) in all body tissues and organs, including the kidney. globotriaosylceramide 61-82 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 84-87 11063874-0 2000 Globotriaosyl ceramide (CD77/Gb3) in the glycolipid-enriched membrane domain participates in B-cell receptor-mediated apoptosis by regulating lyn kinase activity in human B cells. globotriaosylceramide 0-22 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 24-28 11063874-0 2000 Globotriaosyl ceramide (CD77/Gb3) in the glycolipid-enriched membrane domain participates in B-cell receptor-mediated apoptosis by regulating lyn kinase activity in human B cells. globotriaosylceramide 0-22 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 29-32 11063874-0 2000 Globotriaosyl ceramide (CD77/Gb3) in the glycolipid-enriched membrane domain participates in B-cell receptor-mediated apoptosis by regulating lyn kinase activity in human B cells. globotriaosylceramide 0-22 LYN proto-oncogene, Src family tyrosine kinase Homo sapiens 142-145 10801274-1 2000 Human intestinal cells lack globotriaosylceramide (Gb(3)), the receptor for Shiga toxin-1 (Stx1) and Shiga toxin-2 (Stx2). globotriaosylceramide 51-56 syntaxin 1A Homo sapiens 91-95 10801274-4 2000 Stx1 (12.5 ng/ml) induced apoptosis in both HEp-2 (21.9 +/- 7.9% vs. 0.8 +/- 0.3%, P = 0.01) and Caco-2 (10.1 +/- 1.2% vs. 3.1 +/- 0.4%, P = 0.006) cells but not in Gb(3)-deficient T84 cells. globotriaosylceramide 165-170 syntaxin 1A Homo sapiens 0-4 10840053-2 2000 A deficiency in the lysosomal hydrolase alpha-galactosidase A (alpha-gal A; EC ) leads to impaired catabolism of alpha-galactosyl-terminal lipids such as globotriaosylceramide (Gb3). globotriaosylceramide 154-175 galactosidase, alpha Mus musculus 40-61 10840053-2 2000 A deficiency in the lysosomal hydrolase alpha-galactosidase A (alpha-gal A; EC ) leads to impaired catabolism of alpha-galactosyl-terminal lipids such as globotriaosylceramide (Gb3). globotriaosylceramide 154-175 galactosidase, alpha Mus musculus 63-74 10840053-2 2000 A deficiency in the lysosomal hydrolase alpha-galactosidase A (alpha-gal A; EC ) leads to impaired catabolism of alpha-galactosyl-terminal lipids such as globotriaosylceramide (Gb3). globotriaosylceramide 177-180 galactosidase, alpha Mus musculus 40-61 10840053-2 2000 A deficiency in the lysosomal hydrolase alpha-galactosidase A (alpha-gal A; EC ) leads to impaired catabolism of alpha-galactosyl-terminal lipids such as globotriaosylceramide (Gb3). globotriaosylceramide 177-180 galactosidase, alpha Mus musculus 63-74 10841515-4 2000 A concentration-dependent decrement in renal and hepatic globotriaosylceramide levels was observed in alpha-Gal A(-) males treated for 4 weeks with D-t-EtDO-P4. globotriaosylceramide 57-78 galactosidase, alpha Mus musculus 102-113 10841515-5 2000 When 8-week-old alpha-Gal A(-) males were treated for 8 weeks with 10 mg/kg twice daily, renal globotriaosylceramide fell to below starting levels, consistent with an alpha-galactosidase A-independent salvage pathway for globotriaosylceramide degradation. globotriaosylceramide 95-116 galactosidase, alpha Mus musculus 16-27 11201791-6 2000 Using this approach, we identified globotriaosylceramide (Gb3) and ganglioside GM3 as the main lymphocyte GSL recognized by gp120. globotriaosylceramide 35-56 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 124-129 10652021-9 2000 CONCLUSIONS: These findings suggest that selective glucosylceramide synthase inhibitors are highly effective in the depletion of globotriaosylceramide from Fabry cell lines. globotriaosylceramide 129-150 UDP-glucose ceramide glucosyltransferase Homo sapiens 51-76 10575015-0 1999 Activation of Src family kinase yes induced by Shiga toxin binding to globotriaosyl ceramide (Gb3/CD77) in low density, detergent-insoluble microdomains. globotriaosylceramide 70-92 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 94-97 10567921-8 2000 Unlike VT1 cytotoxicity, IFN-alpha-induced Stat1 nuclear translocation was not inhibited when RME was prevented, suggesting that the accessory function of Gb(3) occurs at the plasma membrane. globotriaosylceramide 155-160 signal transducer and activator of transcription 1 Homo sapiens 43-48 10567921-10 2000 In both systems, long chain fatty acid-containing Gb(3) isoforms, which are less effective to mediate VT1 cytotoxicity, were found to correlate with higher IFN-alpha-mediated antiviral activity. globotriaosylceramide 50-55 interferon alpha 2 Homo sapiens 156-165 10567921-11 2000 Inhibition of Gb(3) synthesis in toto prevented IFN-alpha antiviral activity in all cells. globotriaosylceramide 14-19 interferon alpha 2 Homo sapiens 48-57 10567921-12 2000 We propose that the long chain Gb(3) fatty isoforms preferentially remain in the plasma membrane, and by associating with IFNAR1, mediate IFN-alpha antiviral signaling, whereas short chain Gb(3) fatty acid isoforms are preferentially internalized to mediate VT1 cytotoxicity and IFNAR1-dependent IFN-alpha growth inhibition. globotriaosylceramide 31-36 interferon alpha 2 Homo sapiens 138-147 10658586-3 1999 Neoglycopeptides generated were tested for the inhibition of verotoxin binding to globotriosylceramide (Gb3) using ELISA. globotriaosylceramide 82-102 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 104-107 10692420-0 2000 Retroviral transfection of Madin-Darby canine kidney cells with human MDR1 results in a major increase in globotriaosylceramide and 10(5)- to 10(6)-fold increased cell sensitivity to verocytotoxin. globotriaosylceramide 106-127 ATP binding cassette subfamily B member 1 Homo sapiens 70-74 10692420-4 2000 P-gp (but not MRP) inhibitors, e.g. ketoconazole or cyclosporin A (CsA) prevented the increased Gb(3) and VT sensitivity, concomitant with increased vinblastine sensitivity. globotriaosylceramide 96-101 PGP Canis lupus familiaris 0-4 10618424-9 2000 After the single dose of alpha-gal A, nine of the 10 patients had significantly reduced Gb(3) levels both in the liver and shed renal tubular epithelial cells in the urine sediment. globotriaosylceramide 88-93 galactosidase alpha Homo sapiens 25-36 10567921-0 2000 Functional significance of globotriaosyl ceramide in interferon-alpha(2)/type 1 interferon receptor-mediated antiviral activity. globotriaosylceramide 27-49 interferon alpha 2 Homo sapiens 53-99 10567921-3 2000 Gb(3)-deficient variant cells selected for VT resistance are cross-resistant to interferon-alpha (IFN-alpha)-mediated antiproliferative activity. globotriaosylceramide 0-5 interferon alpha 2 Homo sapiens 98-107 10567921-5 2000 The crucial role of Gb(3) for the signal transduction of IFN-alpha-mediated antiviral activity is now reported. globotriaosylceramide 20-25 interferon alpha 2 Homo sapiens 57-66 10567921-6 2000 IFN-alpha-mediated antiviral activity, nuclear translocation of activated Stat1, and increased expression of PKR were defective in Gb(3)-deficient vero mutant cells, although the surface expression of IFNAR1 was unaltered. globotriaosylceramide 131-136 interferon alpha-2 Chlorocebus sabaeus 0-9 10567921-6 2000 IFN-alpha-mediated antiviral activity, nuclear translocation of activated Stat1, and increased expression of PKR were defective in Gb(3)-deficient vero mutant cells, although the surface expression of IFNAR1 was unaltered. globotriaosylceramide 131-136 eukaryotic translation initiation factor 2 alpha kinase 2 Homo sapiens 109-112 10567921-8 2000 Unlike VT1 cytotoxicity, IFN-alpha-induced Stat1 nuclear translocation was not inhibited when RME was prevented, suggesting that the accessory function of Gb(3) occurs at the plasma membrane. globotriaosylceramide 155-160 interferon alpha 2 Homo sapiens 25-34 11133022-0 1999 Globotriaosyl ceramide modulates interferon-alpha-induced growth inhibition and CD19 expression in Burkitt"s lymphoma cells. globotriaosylceramide 0-22 CD19 molecule Homo sapiens 80-84 11133022-1 1999 Previous studies have indicated that globotriaosyl ceramide (Gb3 or CD77) plays a role in alpha-interferon signal transduction and CD19-mediated homotypic adhesion in B cell lines derived from Burkitt"s lymphoma. globotriaosylceramide 37-59 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 61-64 11133022-1 1999 Previous studies have indicated that globotriaosyl ceramide (Gb3 or CD77) plays a role in alpha-interferon signal transduction and CD19-mediated homotypic adhesion in B cell lines derived from Burkitt"s lymphoma. globotriaosylceramide 37-59 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 68-72 11133022-1 1999 Previous studies have indicated that globotriaosyl ceramide (Gb3 or CD77) plays a role in alpha-interferon signal transduction and CD19-mediated homotypic adhesion in B cell lines derived from Burkitt"s lymphoma. globotriaosylceramide 37-59 CD19 molecule Homo sapiens 131-135 10575015-0 1999 Activation of Src family kinase yes induced by Shiga toxin binding to globotriaosyl ceramide (Gb3/CD77) in low density, detergent-insoluble microdomains. globotriaosylceramide 70-92 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 98-102 10575015-1 1999 Shiga toxin (Stx) is an enterotoxin produced by Shigella dysenteriae serotype 1 and enterohemorrhagic Escherichia coli, which binds specifically to globotriaosylceramide, Gb3, on the cell surface and causes cell death. globotriaosylceramide 148-169 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 171-174 10515895-1 1999 The ribosome-inactivating protein, Shiga-like toxin-1 (SLT-1), targets cells that express the glycolipid globotriaosylceramide (CD77) on their surface. globotriaosylceramide 105-126 unconventional SNARE in the ER 1 Homo sapiens 35-53 10515895-1 1999 The ribosome-inactivating protein, Shiga-like toxin-1 (SLT-1), targets cells that express the glycolipid globotriaosylceramide (CD77) on their surface. globotriaosylceramide 105-126 unconventional SNARE in the ER 1 Homo sapiens 55-60 10515895-1 1999 The ribosome-inactivating protein, Shiga-like toxin-1 (SLT-1), targets cells that express the glycolipid globotriaosylceramide (CD77) on their surface. globotriaosylceramide 105-126 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 128-132 10233996-3 1999 We identified globotriaosylceramide (Gb3) and ganglioside GM3 as the main glycosphingolipids recognized by gp120. globotriaosylceramide 14-35 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 37-40 10589997-0 1999 Role of glycosphingolipids in HIV-1 entry: requirement of globotriosylceramide (Gb3) in CD4/CXCR4-dependent fusion. globotriaosylceramide 58-78 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 80-83 10589997-0 1999 Role of glycosphingolipids in HIV-1 entry: requirement of globotriosylceramide (Gb3) in CD4/CXCR4-dependent fusion. globotriaosylceramide 58-78 CD4 molecule Homo sapiens 88-91 10589997-0 1999 Role of glycosphingolipids in HIV-1 entry: requirement of globotriosylceramide (Gb3) in CD4/CXCR4-dependent fusion. globotriaosylceramide 58-78 C-X-C motif chemokine receptor 4 Homo sapiens 92-97 10540335-0 1999 The extrafollicular-to-follicular transition of human B lymphocytes: induction of functional globotriaosylceramide (CD77) on high threshold occupancy of CD40. globotriaosylceramide 93-114 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 116-120 10540335-0 1999 The extrafollicular-to-follicular transition of human B lymphocytes: induction of functional globotriaosylceramide (CD77) on high threshold occupancy of CD40. globotriaosylceramide 93-114 CD40 molecule Homo sapiens 153-157 10540335-1 1999 Amongst lymphocytes, expression of CD77 (globotriaosylceramide, Gb3) is exclusive to B cells of the germinal center (GC). globotriaosylceramide 41-62 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 35-39 10479149-6 1999 TNF-alpha and IL-1beta treatment was associated with the increased HBMEC expression of the toxin-binding glycolipid globotriaosylceramide. globotriaosylceramide 116-137 tumor necrosis factor Homo sapiens 0-9 10479149-6 1999 TNF-alpha and IL-1beta treatment was associated with the increased HBMEC expression of the toxin-binding glycolipid globotriaosylceramide. globotriaosylceramide 116-137 interleukin 1 beta Homo sapiens 14-22 10233996-3 1999 We identified globotriaosylceramide (Gb3) and ganglioside GM3 as the main glycosphingolipids recognized by gp120. globotriaosylceramide 14-35 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 107-112 10198223-1 1999 The globotriaosylceramide (Gb3) verotoxin (VT) interaction is one of several examples of glycolipid receptors where the ceramide (or lipid) free oligosaccharides fail to show the expected binding parameters. globotriaosylceramide 4-25 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 27-30 9988695-5 1999 Whereas [3H]globotriaosylceramide ([3H]Gb3) comprised 1.9% of the total [3H]SLs and [3H]GSLs synthesized in control cells, it comprised 16. globotriaosylceramide 12-33 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 39-42 9826718-0 1998 The neutral glycosphingolipid globotriaosylceramide promotes fusion mediated by a CD4-dependent CXCR4-utilizing HIV type 1 envelope glycoprotein. globotriaosylceramide 30-51 CD4 molecule Homo sapiens 82-85 9826718-0 1998 The neutral glycosphingolipid globotriaosylceramide promotes fusion mediated by a CD4-dependent CXCR4-utilizing HIV type 1 envelope glycoprotein. globotriaosylceramide 30-51 C-X-C motif chemokine receptor 4 Homo sapiens 96-101 9507533-1 1997 The presence of cell surface receptor glycolipid, globotriaosylceramide (Gb3), is essential to confer susceptibility to the E. coli-derived verotoxin (VT). globotriaosylceramide 50-71 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 73-76 9712788-3 1998 By HPTLC, Shiga toxin was shown to bind globotriaosylceramide (Gb3) and a minor platelet glycolipid with an Rf of 0.03, band 0.03. globotriaosylceramide 40-61 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 63-66 9648915-1 1998 A region of the N-terminal extracellular domain of the B-cell restricted cell differentiation antigen, CD19, has high amino acid sequence similarity to the receptor binding subunit B of verotoxin 1 (VT), an Escherichia coli elaborated cytotoxin, which specifically binds to the cell surface glycolipid, globotriaosylceramide, also known as the germinal center (GC) B-cell differentiation antigen, CD77. globotriaosylceramide 303-324 CD19 molecule Homo sapiens 103-107 9485303-3 1998 The B-pentamer binds to a specific glycolipid, globotriaosylceramide (Gb3), on the surface of target cells and thereby plays a crucial role in the entry of the toxin. globotriaosylceramide 47-68 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 70-73 9485304-1 1998 The wild-type binding pentamer of Shiga-like toxin IIe (SLT-IIe) binds both the globotriaosylceramide (Gb3) and globotetraosylceramide (Gb4) cell surface glycolipids, whereas the double mutant GT3 (Q65E/K67Q) exhibits a marked preference for Gb3 [Tyrrell, G. J., et al. globotriaosylceramide 80-101 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 103-106 9821866-0 1998 Globotriaosyl ceramide (Gb3) expression in human tumour cells: intracellular trafficking defines a new retrograde transport pathway from the cell surface to the nucleus, which correlates with sensitivity to verotoxin. globotriaosylceramide 0-22 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 24-27 9803963-3 1998 Compared with PBMC from seronegative donors, the GSL metabolism in PBMC from HIV-1-infected individuals was characterized by an increased synthesis of two GSL: the B-lymphocyte differentiation antigen globotriaosylceramide (Gb3, also referred to as CD77), and the monosialoganglioside GM3, a marker of T-lymphocytes and macrophages. globotriaosylceramide 201-222 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 224-227 9402090-3 1997 The functional receptor for these closely related toxins appears to be a glycosphingolipid, globotriaosylceramide (Gb3). globotriaosylceramide 92-113 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 115-118 9214299-3 1997 Protons of the exocyclic hydroxymethyl group on the terminal Gal residue of globotriaosylceramide (Gb3) were replaced with deuterium. globotriaosylceramide 76-97 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 99-102 9083293-11 1997 Thin layer chromatography of extracted glycolipids from the GMVEC showed binding of VT-1 to globotriaosylceramide (Gb3), known to be the functional receptor for VT. globotriaosylceramide 92-113 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 115-118 7599789-0 1995 Expression of the glycolipid globotriaosylceramide (Gb3) in testicular carcinoma in situ. globotriaosylceramide 29-50 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 52-55 8827457-3 1996 To explore the functional significance of the change, we examined the role of neutral glycosphingolipids as receptors for the murine pulmonary surfactant protein, SP-A, and found that SP-A bound to LacCer, Gg3Cer, and Gg1Cer, but not to Gb3Cer, Gb4Cer, IV3GalNAc alpha-Gb4Cer, sulfatide, or several gangliosides. globotriaosylceramide 237-243 surfactant associated protein A1 Mus musculus 184-188 7577818-1 1995 Possible binding sites for the glycolipid globotriaosylceramide (Gal alpha 1-->4Gal beta 1-->4Glc beta 1-->1 Cer; Gb3) on the B-subunits of verotoxin-1 (VT1) were explored using binding data for specifically mutated verotoxins and by computational docking of favoured conformers of Gb3 with the crystal structure of VT1. globotriaosylceramide 42-63 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 123-126 7577818-1 1995 Possible binding sites for the glycolipid globotriaosylceramide (Gal alpha 1-->4Gal beta 1-->4Glc beta 1-->1 Cer; Gb3) on the B-subunits of verotoxin-1 (VT1) were explored using binding data for specifically mutated verotoxins and by computational docking of favoured conformers of Gb3 with the crystal structure of VT1. globotriaosylceramide 42-63 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 291-294 7530504-8 1995 To examine the role of the two recently cloned TNF-receptors (TNFR-p75 and TNFR-p55) in the TNF alpha-induced increase in GbOse3cer in human endothelial cells, cells were incubated with TNF alpha, the TNFR-p55 selective R32W-S86T-TNF alpha-mutant, or the TNFR-p75 selective D143N-A145R-TNF alpha-mutant. globotriaosylceramide 122-131 tumor necrosis factor receptor superfamily, member 1a Mus musculus 62-66 7530504-8 1995 To examine the role of the two recently cloned TNF-receptors (TNFR-p75 and TNFR-p55) in the TNF alpha-induced increase in GbOse3cer in human endothelial cells, cells were incubated with TNF alpha, the TNFR-p55 selective R32W-S86T-TNF alpha-mutant, or the TNFR-p75 selective D143N-A145R-TNF alpha-mutant. globotriaosylceramide 122-131 tumor necrosis factor receptor superfamily, member 1a Mus musculus 75-79 7530504-8 1995 To examine the role of the two recently cloned TNF-receptors (TNFR-p75 and TNFR-p55) in the TNF alpha-induced increase in GbOse3cer in human endothelial cells, cells were incubated with TNF alpha, the TNFR-p55 selective R32W-S86T-TNF alpha-mutant, or the TNFR-p75 selective D143N-A145R-TNF alpha-mutant. globotriaosylceramide 122-131 tumor necrosis factor Homo sapiens 92-101 7530504-8 1995 To examine the role of the two recently cloned TNF-receptors (TNFR-p75 and TNFR-p55) in the TNF alpha-induced increase in GbOse3cer in human endothelial cells, cells were incubated with TNF alpha, the TNFR-p55 selective R32W-S86T-TNF alpha-mutant, or the TNFR-p75 selective D143N-A145R-TNF alpha-mutant. globotriaosylceramide 122-131 TNF receptor superfamily member 1A Homo sapiens 75-79 7530504-8 1995 To examine the role of the two recently cloned TNF-receptors (TNFR-p75 and TNFR-p55) in the TNF alpha-induced increase in GbOse3cer in human endothelial cells, cells were incubated with TNF alpha, the TNFR-p55 selective R32W-S86T-TNF alpha-mutant, or the TNFR-p75 selective D143N-A145R-TNF alpha-mutant. globotriaosylceramide 122-131 TNF receptor superfamily member 1A Homo sapiens 75-79 8902189-2 1996 We have previously reported light microscopic pleiomorphic changes in cells suggestive of altered plasma membranes, an increase in globotriaosylceramide (Gb3), reflected by an increase in Gb3 on the surface of the plasma membrane, and a decrease in the rate and amount of ganglioside synthesized. globotriaosylceramide 131-152 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 154-157 8807854-1 1996 BACKGROUND: The Escherichia coli verotoxins (VTs) can initiate human vascular disease via the specific recognition of globotriaosyl-ceramide (Gb3) on target endothelial cells. globotriaosylceramide 118-140 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 142-145 7657808-0 1995 Maturational regulation of globotriaosylceramide, the Shiga-like toxin 1 receptor, in cultured human gut epithelial cells. globotriaosylceramide 27-48 unconventional SNARE in the ER 1 Homo sapiens 54-72 7868240-0 1995 Globotriaosylceramide, Gb3, is an alternative functional receptor for Shiga-like toxin 2e. globotriaosylceramide 0-21 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 23-26 7599789-3 1995 In this study, the expression of the globo-series core-structure, globotriaosylceramide (Gb3) was investigated in the preinvasive stage of testicular germ cell tumours, carcinoma in situ (CIS). globotriaosylceramide 66-87 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 89-92 7516406-0 1994 CD19 has a potential CD77 (globotriaosyl ceramide)-binding site with sequence similarity to verotoxin B-subunits: implications of molecular mimicry for B cell adhesion and enterohemorrhagic Escherichia coli pathogenesis. globotriaosylceramide 27-49 CD19 molecule Homo sapiens 0-4 7516406-0 1994 CD19 has a potential CD77 (globotriaosyl ceramide)-binding site with sequence similarity to verotoxin B-subunits: implications of molecular mimicry for B cell adhesion and enterohemorrhagic Escherichia coli pathogenesis. globotriaosylceramide 27-49 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 21-25 7516406-1 1994 The glycosphingolipid globotriaosyl ceramide (CD77) and other globo-series glycolipids containing terminal galactose (Gal)alpha 1-4Gal residues function as receptors for the verotoxin (Shiga-like toxin) family of Escherichia coli-elaborated toxins. globotriaosylceramide 22-44 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 46-50 8157640-11 1994 C20:0 and C22:1 containing Gb3 had the greatest capacity to bind VT1. globotriaosylceramide 27-30 Sp7 transcription factor 7 Mus musculus 10-13 1333300-8 1992 Glycolipid extracts of TNF-alpha-treated cells tested on thin-layer chromatography demonstrated an increase of globotriaosylceramide (GbOse3cer), a functional receptor for VT-1, which suggests that preincubation of human endothelial cells with TNF-alpha leads to an increase in GbOse3cer synthesis in these cells. globotriaosylceramide 111-132 tumor necrosis factor Homo sapiens 23-32 8158025-2 1994 Shiga toxin recognizes a galactose-alpha 1-->4-galactose terminal glycolipid, globotriaosylceramide (Gb3), in sensitive mammalian cells and is translocated by endocytosis to the cytoplasm, where it blocks protein synthesis. globotriaosylceramide 81-102 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 104-107 8250238-1 1993 Galactosyltransferase is required for the addition of galactose to lactosylceramide (galactose beta 1-4 glucose beta 1-1 ceramide), resulting in the synthesis of globotriaosylceramide (Gb3). globotriaosylceramide 162-183 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 185-188 8250811-10 1993 An increase of globotriaosylceramide (Gb3) was observed, suggesting that that preincubation of endothelial cells with TNF alpha leads to an increase in Gb3 synthesis in these cells. globotriaosylceramide 15-36 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 38-41 8250811-10 1993 An increase of globotriaosylceramide (Gb3) was observed, suggesting that that preincubation of endothelial cells with TNF alpha leads to an increase in Gb3 synthesis in these cells. globotriaosylceramide 15-36 tumor necrosis factor Homo sapiens 118-127 8250811-10 1993 An increase of globotriaosylceramide (Gb3) was observed, suggesting that that preincubation of endothelial cells with TNF alpha leads to an increase in Gb3 synthesis in these cells. globotriaosylceramide 15-36 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 152-155 1333300-8 1992 Glycolipid extracts of TNF-alpha-treated cells tested on thin-layer chromatography demonstrated an increase of globotriaosylceramide (GbOse3cer), a functional receptor for VT-1, which suggests that preincubation of human endothelial cells with TNF-alpha leads to an increase in GbOse3cer synthesis in these cells. globotriaosylceramide 134-143 tumor necrosis factor Homo sapiens 23-32 1333300-8 1992 Glycolipid extracts of TNF-alpha-treated cells tested on thin-layer chromatography demonstrated an increase of globotriaosylceramide (GbOse3cer), a functional receptor for VT-1, which suggests that preincubation of human endothelial cells with TNF-alpha leads to an increase in GbOse3cer synthesis in these cells. globotriaosylceramide 134-143 tumor necrosis factor Homo sapiens 244-253 1333300-8 1992 Glycolipid extracts of TNF-alpha-treated cells tested on thin-layer chromatography demonstrated an increase of globotriaosylceramide (GbOse3cer), a functional receptor for VT-1, which suggests that preincubation of human endothelial cells with TNF-alpha leads to an increase in GbOse3cer synthesis in these cells. globotriaosylceramide 278-287 tumor necrosis factor Homo sapiens 23-32 1491612-6 1992 Globotriaosylceramide (Gb3) is found at 50 nM and 73 nM for the NFA and HFA species, respectively, while globoside (Gb4) is found at 45 nM and 46 nM for the NFA and HFA species. globotriaosylceramide 0-21 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 23-26 1305422-4 1992 Binding of these two antibodies to the GM3-lactam-BSA conjugate was inhibited by soluble glycosides of GM2-, GM3-, and GM4-lactam and by GM3- and GM4-lactam, respectively, but not by Gb3 or asialo-GM1 and GM2-saccharides. globotriaosylceramide 183-186 granulocyte macrophage antigen 3 Mus musculus 39-42 1305422-4 1992 Binding of these two antibodies to the GM3-lactam-BSA conjugate was inhibited by soluble glycosides of GM2-, GM3-, and GM4-lactam and by GM3- and GM4-lactam, respectively, but not by Gb3 or asialo-GM1 and GM2-saccharides. globotriaosylceramide 183-186 granulocyte macrophage antigen 3 Mus musculus 109-112 1305422-4 1992 Binding of these two antibodies to the GM3-lactam-BSA conjugate was inhibited by soluble glycosides of GM2-, GM3-, and GM4-lactam and by GM3- and GM4-lactam, respectively, but not by Gb3 or asialo-GM1 and GM2-saccharides. globotriaosylceramide 183-186 granulocyte macrophage antigen 3 Mus musculus 109-112 1305422-4 1992 Binding of these two antibodies to the GM3-lactam-BSA conjugate was inhibited by soluble glycosides of GM2-, GM3-, and GM4-lactam and by GM3- and GM4-lactam, respectively, but not by Gb3 or asialo-GM1 and GM2-saccharides. globotriaosylceramide 183-186 T cell receptor alpha variable 6-3 Mus musculus 146-149 2078521-1 1990 The neutral glycosphingolipid (GSL) globotriaosylceramide (Gb3) of the globo-series was recently defined as the CD77 antigen. globotriaosylceramide 36-57 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 59-62 1527419-3 1992 Globotriaosylceramide (Gb3), a glycolipid known to bind to both Shiga toxin and Shiga-like toxins, was found to occur in human milk with an average concentration of 73 nM (77 micrograms/L) for Gb3 containing hydroxylated fatty acids and 50 nM (53 micrograms/L) for Gb3 containing nonhydroxylated fatty acids. globotriaosylceramide 0-21 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 23-26 1527419-3 1992 Globotriaosylceramide (Gb3), a glycolipid known to bind to both Shiga toxin and Shiga-like toxins, was found to occur in human milk with an average concentration of 73 nM (77 micrograms/L) for Gb3 containing hydroxylated fatty acids and 50 nM (53 micrograms/L) for Gb3 containing nonhydroxylated fatty acids. globotriaosylceramide 0-21 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 193-196 1527419-3 1992 Globotriaosylceramide (Gb3), a glycolipid known to bind to both Shiga toxin and Shiga-like toxins, was found to occur in human milk with an average concentration of 73 nM (77 micrograms/L) for Gb3 containing hydroxylated fatty acids and 50 nM (53 micrograms/L) for Gb3 containing nonhydroxylated fatty acids. globotriaosylceramide 0-21 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 193-196 1537890-2 1992 Verotoxin (VT) binds to globotriaosylceramide (Gal alpha 1-4Gal beta 1-4GlcCer Gb3) in susceptible cells. globotriaosylceramide 24-45 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 79-82 1310610-1 1992 Globotriaosylceramide [(Gal alpha 1-4Gal beta 1-4Glc-ceramide (Gb3)] was separated from human kidney, and the fatty acid composition was determined. globotriaosylceramide 0-21 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 63-66 1709864-1 1991 We have previously reported that a neutral glycolipid (globotriosylceramide; Gb3) was specifically expressed on Burkitt"s lymphoma cells and on a subset of germinal center tonsillar B lymphocytes. globotriaosylceramide 55-75 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 77-80 2162261-1 1990 Globotriaosylceramide, the natural substrate of alpha-galactosidase A (the enzyme deficient in Fabry"s disease) was prepared from human kidney by repeated medium pressure chromatography on Lichroprep Si 60 (E. Merck) before and after peracetylation. globotriaosylceramide 0-21 galactosidase alpha Homo sapiens 48-69 1314564-2 1992 Previous studies have implicated the glycolipid receptor for the Escherichia coli-derived verotoxin, globotriaosylceramide (Gb3; Gal alpha 1-4Gal beta 1-4Glc-ceramide), in the mechanism of alpha 2 interferon signal transduction. globotriaosylceramide 101-122 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 124-127 1649877-8 1991 The relative resistance of EC to Shiga toxin and Shiga-like toxins may be due to reduced toxin binding, as low levels of globotriaosylceramide (Gb3), the toxin-specific receptor, were found in EC membranes. globotriaosylceramide 121-142 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 144-147 1910293-3 1991 Both of these cell lines contain significant levels of the verotoxin binding glycolipid globotriosylceramide (Gb3) (1 nmol/10(7) cells and 3 nmol/10(6) cells, respectively). globotriaosylceramide 88-108 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 110-113 2200824-5 1990 By contrast, permeabilized mouse IL-3-dependent bone marrow culture-derived mast cells (BMMC) and mast cells recovered after 21 days of coculture of BMMC with mouse 3T3 fibroblasts expressed lactosylceramide, globotriosylceramide, globotetraosylceramide, ganglioside GM1, and ganglioside GM3, but not globopentaosylceramide intracellularly as determined by immunofluorescence. globotriaosylceramide 209-229 interleukin 3 Mus musculus 33-37 2320574-3 1990 Saposin B, previously known as SAP-1 and sulfatide activator, stimulates the hydrolysis of a wide variety of substrates including cerebroside sulfate, GM1 ganglioside, and globotriaosylceramide by arylsulfatase A, acid beta-galactosidase, and alpha-galactosidase, respectively. globotriaosylceramide 172-193 prosaposin Homo sapiens 31-36 2157788-4 1990 Gas-liquid chromatography revealed that globotriaosylceramide (Gb3) was markedly increased in the heart (32.4 times higher than control) and increased to a lesser extent in the liver and kidney (3.74 and 6.79 times, respectively). globotriaosylceramide 40-61 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 63-66 2078521-1 1990 The neutral glycosphingolipid (GSL) globotriaosylceramide (Gb3) of the globo-series was recently defined as the CD77 antigen. globotriaosylceramide 36-57 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 112-116 2298824-10 1990 Analysis of the glycosphingolipid (GSL) composition of m5S/1M cells showed that globotriaosylceramide (Gb3Cer), which is known to be a Burkitt lymphoma-associated antigen, is specifically expressed in the EGF-treated cells. globotriaosylceramide 80-101 epidermal growth factor Mus musculus 205-208 2298824-10 1990 Analysis of the glycosphingolipid (GSL) composition of m5S/1M cells showed that globotriaosylceramide (Gb3Cer), which is known to be a Burkitt lymphoma-associated antigen, is specifically expressed in the EGF-treated cells. globotriaosylceramide 103-109 epidermal growth factor Mus musculus 205-208 34796992-1 2022 Fabry disease (FD), which is a lysosomal storage disease resulting from a deficiency of alpha-galactosidase A, leads to the accumulation of globotriaosylceramide in various tissues and multiorgan impairment. globotriaosylceramide 140-161 galactosidase alpha Homo sapiens 88-109 33768330-2 2021 The intracellular deposition globotriaosylceramide (Gb3) is just the first step of the mechanism. globotriaosylceramide 29-50 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 52-55 11741960-3 2002 Thus, certain neutral glycosphingolipids (e.g. GlcCer, LacCer, and Gb(3)Cer) can enhance anticoagulant activity of APC/protein S by mechanisms that are distinctly different from those of phospholipids alone. globotriaosylceramide 67-75 APC regulator of WNT signaling pathway Homo sapiens 115-118 32612933-5 2020 After starting ERT serial urine globotriaosylceramide (Gb3) measurements showed an upward trend from 333 to 2260 mug/mmol creatinine for patient 1 and 1165 to 2260 mug/mmol creatinine for patient 2. globotriaosylceramide 32-53 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 55-58 34885938-2 2021 As a result, the main glycosphingolipid substrates, globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3), accumulate in plasma, urine, and tissues. globotriaosylceramide 52-73 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 75-78 34917096-2 2021 Progressive cellular accumulation of the AGAL substrate globotriaosylceramide (Gb3) leads to endothelial dysfunction. globotriaosylceramide 56-77 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 79-82 34704396-1 2021 AIMS: Fabry disease (FD) is an X-linked genetic disease caused by mutations in the GLA gene that leads to deficient activity of lysosomal enzymes, accumulation of globotriaosylceramide in multi-organ systems, and variant clinical manifestations. globotriaosylceramide 163-184 galactosidase alpha Homo sapiens 83-86 34748189-2 2021 The lysosomal accumulation of the substrates globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3) results in progressive renal failure, cardiomyopathy associated with cardiac arrhythmia, and recurrent strokes, significantly limiting life expectancy in affected patients. globotriaosylceramide 45-66 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 68-71 34803097-1 2021 Fabry disease is a rare X-linked lysosomal storage disorder caused by mutations in the alpha-galactosidase A (GLA) gene that results in deficiency of the enzyme GLA and leads to the accumulation of globotriaosylceramide (GL-3) in cells. globotriaosylceramide 198-219 galactosidase, alpha Mus musculus 87-108 34803097-1 2021 Fabry disease is a rare X-linked lysosomal storage disorder caused by mutations in the alpha-galactosidase A (GLA) gene that results in deficiency of the enzyme GLA and leads to the accumulation of globotriaosylceramide (GL-3) in cells. globotriaosylceramide 198-219 galactosidase, alpha Mus musculus 110-113 34541380-6 2021 FD myelinated axons exhibited lipid accumulations that were determined to be the FD-associated lipid globotriaosylceramide (Gb3), and to a lesser extent lysosomes. globotriaosylceramide 101-122 alpha 1,4-galactosyltransferase (P blood group) Rattus norvegicus 124-127 34631425-1 2021 In Fabry disease, accumulation of glycolipids, predominantly globotriaosylceramide (Gb3), affects the kidneys, and nephropathy is one of the important disorders that influence the disease severity and prognosis of patients. globotriaosylceramide 61-82 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 84-87 34411438-2 2021 We discovered increased levels of globotriaosylceramide (Gb3) in cellular and murine models of CLN3 and CLN7 diseases and used fluorescent-conjugated bacterial toxins to label Gb3 to develop a cell-based high content imaging (HCI) screening assay for the repurposing of FDA-approved compounds able to reduce this accumulation within BD cells. globotriaosylceramide 34-55 ceroid lipofuscinosis, neuronal 3, juvenile (Batten, Spielmeyer-Vogt disease) Mus musculus 95-99 34576250-2 2021 Lysosomal accumulation of globotriaosylceramide (Gb3) is the element characterizing Fabry disease due to a hereditary deficiency alpha-galactosidase A (GLA) enzyme. globotriaosylceramide 26-47 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 49-52 34422789-5 2021 This FC in vitro model recapitulated several clinical FC features, including cardiomyocyte hypertrophy and lysosomal globotriaosylceramide (Gb3) deposition. globotriaosylceramide 117-138 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 140-143 34300196-2 2021 Deficiency or reduced activity of alpha-galactosidase A (GLA) is leading to progressive intracellular accumulation of globotriaosylceramide (GL3) in various organs, including the heart, kidney and nerve system. globotriaosylceramide 118-139 galactosidase alpha Homo sapiens 57-60 34440358-0 2021 MiRNA Let-7a and Let-7d Are Induced by Globotriaosylceramide via NF-kB Activation in Fabry Disease. globotriaosylceramide 39-60 microRNA let-7d Homo sapiens 17-23 34300196-2 2021 Deficiency or reduced activity of alpha-galactosidase A (GLA) is leading to progressive intracellular accumulation of globotriaosylceramide (GL3) in various organs, including the heart, kidney and nerve system. globotriaosylceramide 118-139 galactosidase alpha Homo sapiens 34-55 34073185-1 2021 The B subunit pentamer verotoxin (VT aka Shiga toxin-Stx) binding to its cellular glycosphingolipid (GSL) receptor, globotriaosyl ceramide (Gb3) mediates internalization and the subsequent receptor mediated retrograde intracellular traffic of the AB5 subunit holotoxin to the endoplasmic reticulum. globotriaosylceramide 116-138 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2 Homo sapiens 53-56 34155339-2 2022 The glycolipid globotriaosylceramide (Gb3) is the main receptor for Shiga toxin (Stx) in kidney target cells. globotriaosylceramide 15-36 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 38-41 34204583-2 2021 The absence of the enzyme or its activity results in the accumulation of glycosphingolipids, mainly globotriaosylceramide (Gb3), in different tissues, leading to a wide range of clinical manifestations. globotriaosylceramide 100-121 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 123-126 34073185-1 2021 The B subunit pentamer verotoxin (VT aka Shiga toxin-Stx) binding to its cellular glycosphingolipid (GSL) receptor, globotriaosyl ceramide (Gb3) mediates internalization and the subsequent receptor mediated retrograde intracellular traffic of the AB5 subunit holotoxin to the endoplasmic reticulum. globotriaosylceramide 116-138 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 140-143 34284652-1 2021 Fabry disease (FD) is a progressive, X-linked inherited disorder of glycosphingolipid metabolism due to deficient or absent lysosomal alpha-galactosidase A (alpha-Gal A) activity which results in progressive accumulation of globotriaosylceramide (Gb3) and related metabolites. globotriaosylceramide 224-245 galactosidase alpha Homo sapiens 134-155 34284652-1 2021 Fabry disease (FD) is a progressive, X-linked inherited disorder of glycosphingolipid metabolism due to deficient or absent lysosomal alpha-galactosidase A (alpha-Gal A) activity which results in progressive accumulation of globotriaosylceramide (Gb3) and related metabolites. globotriaosylceramide 224-245 galactosidase alpha Homo sapiens 157-168 34284652-1 2021 Fabry disease (FD) is a progressive, X-linked inherited disorder of glycosphingolipid metabolism due to deficient or absent lysosomal alpha-galactosidase A (alpha-Gal A) activity which results in progressive accumulation of globotriaosylceramide (Gb3) and related metabolites. globotriaosylceramide 224-245 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 247-250 35512362-1 2022 AIMS: Fabry disease (FD) is an X-linked lysosomal storage disorder caused by a deficiency of the lysosomal enzyme alpha-galactosidase A (GLA/AGAL), resulting in the lysosomal accumulation of globotriaosylceramide (Gb3). globotriaosylceramide 191-212 galactosidase alpha Homo sapiens 114-135 34609404-1 2021 Fabry disease represents an X-linked inherited disorder resulting in the accumulation of globotriaosylceramide (Gb3). globotriaosylceramide 89-110 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 112-115 35512362-1 2022 AIMS: Fabry disease (FD) is an X-linked lysosomal storage disorder caused by a deficiency of the lysosomal enzyme alpha-galactosidase A (GLA/AGAL), resulting in the lysosomal accumulation of globotriaosylceramide (Gb3). globotriaosylceramide 191-212 galactosidase alpha Homo sapiens 137-140 35512362-1 2022 AIMS: Fabry disease (FD) is an X-linked lysosomal storage disorder caused by a deficiency of the lysosomal enzyme alpha-galactosidase A (GLA/AGAL), resulting in the lysosomal accumulation of globotriaosylceramide (Gb3). globotriaosylceramide 191-212 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 214-217 35242579-1 2022 Background: Fabry disease (FD) is a lysosomal storage disorder resulting in systemic accumulation of globotriaosylceramide (Gb3) causing multi-organ dysfunction. globotriaosylceramide 101-122 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 124-127 35246967-1 2022 BACKGROUND: Fabry disease (FD) is caused by a defect in alpha-galactosidase A gene (GLA) which leads to a progressive accumulation of neutral shingolipids, mainly globotriaosylceramide and its metabolites in several organs. globotriaosylceramide 163-184 galactosidase alpha Homo sapiens 56-77 35246967-1 2022 BACKGROUND: Fabry disease (FD) is caused by a defect in alpha-galactosidase A gene (GLA) which leads to a progressive accumulation of neutral shingolipids, mainly globotriaosylceramide and its metabolites in several organs. globotriaosylceramide 163-184 galactosidase alpha Homo sapiens 84-87 35059891-9 2022 The a-galactosidase A enzyme activity was normal at 6.03 mumol/mL/h (normal 2.40-17.65 mumol/mL/h), and low expression of globotriaosylceramide (Gb3) was detected in the renal tissue of this patient. globotriaosylceramide 122-143 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 145-148 2644022-7 1989 The holotoxins bind to cells, via their B subunits, to a specific receptor which is probably the glycolipid, globotriosyl ceramide (Gb3). globotriaosylceramide 109-130 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 132-135 35163813-2 2022 Reduced activity or deficiency of alpha-galactosidase A (AGAL) leads to escalating storage of intracellular globotriaosylceramide (GL-3) in numerous organs, including the kidneys, heart and nerve system. globotriaosylceramide 108-129 galactosidase alpha Homo sapiens 34-55 3514610-3 1986 PA1 cells contain globotriaosylceramide, sialosylgangliotriaosylceramide, sialylated and nonsialylated lacto-N-neotetraosylceramide, and the following glycolipids with a blood group type 1 sequence: (formula; see text) The two former glycolipids, lacto-N-tetraosylceramide and sialosyllacto-N-tetraosylceramide, reacted with monoclonal antibodies, K21 and K4, respectively. globotriaosylceramide 18-39 PAXIP1 associated glutamate rich protein 1 Homo sapiens 0-3 3827882-0 1986 A triple-binding-domain model explains the specificity of the interaction of a sphingolipid activator protein (SAP-1) with sulphatide, GM1-ganglioside and globotriaosylceramide. globotriaosylceramide 155-176 prosaposin Homo sapiens 111-116 3566745-1 1987 The deliberate transfer of globotriaosylceramide (Gb3) expression in mouse lymphoma L5178 cells was achieved by transfection with a cosmid DNA library prepared from human Burkitt lymphoma Ramos cells in which Gb3 was highly expressed. globotriaosylceramide 27-48 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 50-53 3566745-1 1987 The deliberate transfer of globotriaosylceramide (Gb3) expression in mouse lymphoma L5178 cells was achieved by transfection with a cosmid DNA library prepared from human Burkitt lymphoma Ramos cells in which Gb3 was highly expressed. globotriaosylceramide 27-48 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 209-212 33753109-3 2021 Generally, the B-subunit of Shiga toxin (STXB) receptor, globotriaosylceramide (Gb3), is expressed in high amounts on a number of human tumors cancer cells. globotriaosylceramide 57-78 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 80-83 3519828-3 1986 A glycolipid that specifically binds shigella toxin was isolated from both HeLa cells and rabbit jejunal mucosa and identified as globotriaosylceramide (Gb3) by its identical mobility on HPTLC to authentic erythrocyte Gb3. globotriaosylceramide 130-151 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 153-156 3519828-3 1986 A glycolipid that specifically binds shigella toxin was isolated from both HeLa cells and rabbit jejunal mucosa and identified as globotriaosylceramide (Gb3) by its identical mobility on HPTLC to authentic erythrocyte Gb3. globotriaosylceramide 130-151 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 218-221 3081038-2 1986 SAP-1 or sulfatide/GM1 ganglioside activator protein has previously been demonstrated to stimulate the enzymatic hydrolysis of sulfatide, GM1 ganglioside and globotriaosylceramide. globotriaosylceramide 158-179 prosaposin Homo sapiens 0-5 33928440-1 2022 The accumulation of globotriaosylceramide (Gb-3) in multiple organs, such as the heart, kidney, and nervous system, due to mutations in the galactosidase alpha (GLA) gene, represents the key point of Fabry disease (FD). globotriaosylceramide 20-41 galactosidase alpha Homo sapiens 140-159 33928440-1 2022 The accumulation of globotriaosylceramide (Gb-3) in multiple organs, such as the heart, kidney, and nervous system, due to mutations in the galactosidase alpha (GLA) gene, represents the key point of Fabry disease (FD). globotriaosylceramide 20-41 galactosidase alpha Homo sapiens 161-164 33915609-1 2021 OBJECTIVES: Fabry disease (FD) is an X-linked lysosomal storage disorder, resulting from a deficiency of the enzyme alpha-galactosidase A, responsible for breaking down glycolipids such as globotriaosylceramide and its deacylated derivative, globotriaosylsphingosine (LysoGb3). globotriaosylceramide 189-210 galactosidase alpha Homo sapiens 116-137